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GENERAL ASPECTS OF ANGIOGENESIS 
I.1 BIOLOGICAL FEATURES OF ANGIOGENESIS 
ngiogenesis is a complex biological phenomenon that results in the generation of new blood 
vessels starting from the pre-existing vasculature network. Since this event is related to both 
physiological and pathological processes, a variety of proteins are involved in angiogenesis 
regulation by different mechanisms in order to keep pro- and anti-angiogenic responses balanced.1 In 
physiological conditions, the hierarchy of mature vasculature is structurally well-defined and organized 
to provide efficiently the oxygen and nutrients supply required to support cell growth and survival. On 
the other hand, a tumor-related angiogenic event is characterized by abnormal spread and diffusion of 
unarranged, undifferentiated vessels that are not capable of sustaining cancer cells progression and 
development.2 Hence, the tumor mass requires a continual neovascularization, augmenting the 
recruitment of new vessels. In this framework, compounds able to interfere with tumor angiogenesis 
represent a powerful tool in chemotherapy, thus their individuation and investigation became more and 
more important. 
In the last decade, the use of anti-angiogenic agents demonstrated to restrain cancer growth and diffusion 
by limiting the initiation of capillary network: tumor cells are not able to exploit the pre-existent 
vasculature for nutrients and oxygen supply, with a consistent delay in cancer progression and 
metastasis.3 Moreover, the clearance of chemotherapeutics by tumor mass is prevented and the overall 
efficacy of the drug is improved. Disorder is the main feature of tumor vasculature, which is composed 
by a large number of vessel subtypes lacking in organization, structure and function. The first 
consequence is an ineffective vascularization of the tumor mass, leading to a decrease of oxygen 
pressure and pH: these metabolic stress conditions up-regulate specific antigens to maintain and support 
a pro-angiogenic state, stimulating a continuous formation of new blood vessels.4 The transition from a 
quiescent to an aggressive state was named “angiogenic switch” by Hanahan and Folkman in 1996 and 
it results in a rapid tumor 
growth, progression and 
metastasis (FIGURE 1).5 
However, another feature 
contributes to tumor mass 
transition from a dormant to 
an aggressive state: 
oncogenic mutations.3 
Activated oncogenes are 
capable of increasing cell 
proliferation and survival 
by escaping cell death and 
apoptosis. This process is 
defined tumorigenesis and 
allows the development of 
large tumor masses that can 
 
FIGURE 1. A small tumor mass is able to receive oxygen and nutrients supply by 
diffusion from the pre-existing vasculature. Once the angiogenic switch occurred, the 
up-regulation of specific angiogenic factors by cancer cells drives the formation of new 
blood vessels to feed more extensively the tumor, which starts expanding and shredding 
into metastasis.  
A 
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eventually be lethal for the patient. Both tumorigenesis and angiogenesis are basic requirements for 
cancer progression: oncogenic transfection in tumor mass triggers angiogenic events by up-regulating 
vascular endothelial growth factors (VEGFs) expression; on the other hand, endothelial cell proliferation 
is necessary for sustaining neoplastic growth by supplying nutrients and oxygen. In conclusion, the anti-
angiogenic strategy in cancer treatment relies on the ability of certain angiogenesis inhibitors to prevent 
and modulate new blood vessel formation, aiming at converting cancer into a chronic, steady disease. 
I.2 ANGIOGENESIS INHIBITORS 
The biological activity of anti-angiogenic agents relies on two main mechanisms of action: I) 
sequestration of certain soluble proteins; II) disruption or inhibition of protein-protein interactions. In 
the first case, the anti-angiogenic agent interacts selectively with a specific pro-angiogenic factor, 
provoking its aggregation or avoiding its interaction with the target receptor. This interference can result 
in a positive overall anti-cancer effect, characterized by tumor restriction, or in a negative response, with 
cancer cells consequently over-expressing the sequestered lacking protein. The inhibitors of a specific 
receptor can interact either with the extracellular or with the intracellular domains. Depending on the 
target cell membrane receptor, from small molecules to engineered proteins were developed and 
validated as anti-angiogenic agents.3 A number of endogenous angiogenesis inhibitors are present in the 
blood flow and tissues environment: most of them belong to the collagen protein family. Tumstatin and 
endostatin are two well-known examples of collagen-related peptide fragments able to block and down-
regulate the angiogenic process.6 Apart from these natural inhibitors, a variety of synthetic agents have 
been prepared, some of which reached the market. Bevacizumab (Avastin®) was the first monoclonal 
antibody to be approved by the FDA for the treatment of colon cancer. It is a humanized anti-VEGF 
antibody that directly targets the VEGF-A protein: the binding of bevacizumab to VEGF-A prevents the 
latter from interacting with VEGF receptors (VEGFRs), thus impeding the spread of the angiogenesis 
signaling. Erlotinib (Tarceva®, 1 in FIGURE 2) is a small molecule drug able to inhibit the tyrosine 
kinase portion of epidermal growth factor receptor (EGFR), but also to block the expression of some 
angiogenic proteins, such as VEGF, basic fibroblast growth factor (bFGF) and transforming growth 
factor-α (TGF-α). Approved by the FDA, 1 is used in lung cancer treatment and the anti-tumor activity 
of bevacizumab is augmented when co-administered with erlotinib.7 Caplostatin is a non-toxic HPMA 
(N-(2-hydroxypropyl)methacrylamide) copolymer decorated with the synthetic fumagillin analogue 
TNP-470 (3, FIGURE 2). The biological activity of caplostatin arises from fragment 3, which was 
demonstrated to inhibit the endothelial proliferation in vitro. Upon conjugation to the HMPA moiety 
and the formation of caplostatin, the major neurotoxic side effects of 3 were suppressed, maintaining 
the wide anti-tumor activity shown by the parental compound fumagillin (2, FIGURE 2).8 
 
FIGURE 2. Structures of erlotinib (1), fumagillin (2) and its derivative TNP-470 (3). 
Clinical trials on anti-angiogenic agents validated the angiogenesis blockade as promising strategy to 
fight cancer progression and to understand better the biological mechanisms underlying the overall 
phenomena that cause the formation of new vasculature. The anti-tumor activity spectrum of the drugs 
reported in the literature can be expanded by co-administering different anti-angiogenic agents aiming 
at circumventing drug resistance, a common feature developed by aggressive cancer cells. However, 
against this kind of tumors angiogenesis inhibition can generate only a fleeting effect, because cancer 
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cells can adopt a variety of adaptive mechanisms to overcome the anti-angiogenic treatment.9 Resistant 
tumors have two main weapons they can exploit when facing the therapy: I) activation and/or up-
regulation of diverse angiogenic pathways; II) increase in pericyte composition of the new blood vessels. 
In the first case, when the activity of a certain protein is inhibited, tumor cells still have a number of 
other antigens on which they rely on to stimulate angiogenic processes. On the other hand, a higher 
pericyte density around the tumor microvasculature can protect the newly formed capillary network 
against anti-angiogenic therapy, thus becoming crucial for the correct establishment and maturation of 
the just sprouted vessels. A coherent solution may be found in impeding pericyte interaction with 
angiogenic proteins within the tumor environment. 
Thanks to the continuous research advances, scientists are gathering more and more information about 
angiogenesis and the biological aspects driving tumors towards the angiogenic switch. Although the 
clinical application of anti-angiogenic agents decreased with respect to the initial usage, a number of 
these inhibitors have been developed and reported in the literature: likely, further improvements of this 
strategy will allow first to restrain effectively, then to cure cancer and other diseases related to 
angiogenesis.
  
 
 
PART I. TARGETING INTEGRINS 
In the first part of my Thesis, I will describe the integrin receptor family. 
After a brief biological introduction, the attention will be focused on the RGD recognition motif, giving 
a general overview of some of the integrin ligands reported in the literature and concluding with the 
specific class of peptidomimetics containing a 2,5-diketopiperazine (DKP) scaffold, developed in our 
research group. 
Next, the isoDGR sequence will be discussed, with cyclopeptides and cyclo[DKP-isoDGR] compounds 
as examples of the limited number of integrin binders containing the isoDGR sequence described so far. 
The last topic concerns the exploitation of RGD ligands in cancer therapy, where peptides and 
peptidomimetics targeting integrins are employed as carriers to deliver relevant payloads at the tumor 
site, taking advantage of integrin over-expression on the surface of cancer cells. 
Part of the work described in this Chapter was published in the following article: 
 Panzeri, S.; Zanella, S.; Arosio, D.; Vahdati, L.; Dal Corso, A.; Pignataro, L.; Paolillo, M.; 
Schinelli, S.; Belvisi, L.; Gennari, C.; Piarulli, U. Chem. Eur. J. 2015, 21, 6265. 
 
1 INTEGRIN RECEPTORS AND LIGANDS 
1.1 INTEGRIN RECEPTOR FAMILY 
n the last twenty years, different cell adhesion 
molecules (CAMs) have been discovered and 
studied in order to elucidate their role in cell life 
and survival.10 This wide class of molecules is 
composed by diverse protein families, which are 
responsible for physiological integrity, morphology and 
division of cells, but may also become involved in the 
pathological development of diseases and 
malfunctions. In particular, CAMs fulfill a central role 
in cell-to-cell and cell-extra-cellular matrix (ECM) 
relationships: many disorders can arise when the correct 
operation of these essential mechanisms fails, thus even 
leading to cancer, thrombosis, arthritis and diabetes.11 
Four protein classes compose the cell adhesion 
molecules: integrins, cadherins, selectins and 
immunoglobulins (FIGURE 3). 
Integrins are a family of transmembrane glycoproteins, 
which consists of two subunits, namely α and β. 18 α-
subunits and 10 β-subunits pair together in a non-
covalent manner, forming 24 specific heterodimers 
(FIGURE 4 and FIGURE 5) that act in some essential 
events of the cell biology, i.e. cell proliferation, migration, survival, and intracellular signal 
transduction.12 Particular growth factors, such as immunoglobulins and cytokines, are known to interact 
with integrin receptors and trigger signaling pathways by activating receptor tyrosine kinases (RTKs).13 
The interaction with extracellular ligands provokes first the formation of receptor clustering, then a 
conformational rearrangement in integrin subunits, resulting in the modulation of ligand affinity.14 
  
FIGURE 4. The integrin family. Adapted from ref. 12a. FIGURE 5. Integrin receptor representation. Adapted from ref. 12b. 
 
FIGURE 3. Cell Adhesion molecules families: 
immunoglobulins (a), cadherins (b), selectins (c), and 
integrins (d). 
I 
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Endogenous ligands presenting the tripeptide sequence arginine-glycine-aspartic acid (Arg-Gly-Asp, or 
RGD, FIGURE 6) can interact with a number of integrin receptors (e.g. αVβ3, αVβ5, α5β1),15 which are 
strictly related to cancer development, metastasis and tumor angiogenesis. Hence, integrin receptors can 
be exploited as target in cancer therapy. For this reason, different research groups designed and 
synthesized a variety of peptides and peptidomimetics displaying the RGD recognition motif to target 
and bind these specific integrins. In this frame, the attention will be focused on αVβ3 receptor. 
1.2 INTEGRIN αVβ3 AS TARGET RECEPTOR 
Among all the integrin receptors, αVβ3 is one of the most involved in angiogenesis, and participates to 
the subtle regulation mechanism underlying the angiogenic processes. Different interleukines and 
growth factors, which are over-expressed in tumor masses, are able to trigger the expression of this 
receptor in endothelial cells.16 Therefore, the population of integrin αVβ3 on the membrane of cancer 
cells is very abundant with respect to healthy tissues, resulting in a continuous stimulation of 
angiogenesis.17 The way integrin αVβ3 stimulates angiogenesis derives from its ability to interact with 
matrix metalloproteinase-2 (MMP-2) that degrades the collagen matrix, therefore allowing the 
reorganization of the ECM in order to form new blood vessels.18 In cancer cells, the coordinated 
regulation system able to stop angiogenic signaling fails. A small tumor mass can grow up very quickly 
by enabling pro-angiogenic events related to integrin receptors with the so called “angiogenic switch”, 
thus becoming a highly aggressive tumor, capable of spreading and 
shredding by metastasis. For this reason, many efforts have been devoted 
to discover and elucidate the rationale for the interaction of extra-cellular 
matrix proteins with cells. One of the most important contributions to 
this field is represented by the work of Ruoslahti and Pierschbacher, 
which in 1984 discovered the molecular basis of the ECM proteins 
recognition.19 In particular, they demonstrated that fibronectin, an 
endogenous ligand for many integrins, was recognized by its target 
receptors thanks to the tripeptide sequence Arg-Gly-Asp (RGD, FIGURE 
6). 
1.3 RGD INTEGRIN LIGANDS 
Since the discovery of Ruoslahti, a number of different peptide and peptidomimetic libraries have been 
developed and, among them, a few were found to bind integrin αVβ3 with high affinity. Diverse strategies 
were adopted aiming at displaying the RGD motif in a proper conformation. The first approach was the 
inclusion of this sequence in cyclic structures, resulting in a higher rigidity of the peptide backbone and 
limiting the flexibility of flanking residues. Among the RGD-based binders reported in the literature, 
the research group of Professor Kessler developed the potent integrin 
ligand Cilengitide (4, FIGURE 7).20 Xiong and co-workers managed to 
isolate the co-crystal of integrin αVβ3 complexed with Cilengitide and 
studied the key interactions by X-ray analysis (FIGURE 8):21 while 
interacting with the receptor binding site, the RGD recognition motif 
turned out to adopt an extended conformation in which the Cβ atoms 
of arginine and aspartic acid residues are distant about 9 Å. This 
requirement proved to be a fundamental requirement in order to 
achieve the ligand-protein interaction, in particular the so-called 
“electrostatic clamp”. 
 
FIGURE 6. The Arg-Gly-Asp 
(RGD) recognition motif. 
 
FIGURE 7. The potent integrin ligand 
Cilengitide (4). 
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FIGURE 8. Co-crystal of integrin αVβ3 complexed with Cilengitide (4). Adapted from ref. 21. 
The formation of this electrostatic interaction is essential and relies on the establishment of two bridge 
salts: one between the arginine side chain and negatively charged residues in the α subunit; the other 
involving the β-carboxylate moiety of aspartic and the Mn2+ divalent metal cation of the metal ion-
dependent adhesion site (MIDAS) region in the β subunit.20b Different types of integrin ligands 
satisfying these fundamental requirements were developed as anti-angiogenic agents and showed high 
affinity for the target receptor.22 
As shown in FIGURE 9, various strategies were adopted to present the RGD binding motif in a suitable 
conformation for the interaction with the integrin receptor. The common feature of ligands 5-14 is the 
inclusion of the RGD tripeptide sequence within a cyclic structure, in order to limit the backbone 
flexibility, with the aim of arranging the arginine and the aspartic side chains in a similar way to that of 
Cilengitide.23 
 
FIGURE 9. Selected examples of integrin ligands (5-14) and relative integrin affinity, expressed as IC50 value. See ref. 23.  
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Even though a variety of ligands targeting αVβ3 and αVβ5 integrin managed to enter clinical trials due to 
their potent activity against tumor angiogenesis, this approach in cancer treatment was unsuccessful. As 
a matter of fact, although Cilengitide is non-toxic and tolerated, its anti-angiogenic activity – and thus 
its anti-cancer efficacy – has become controversial. Indeed, in contrast with the initially reported results, 
in specific experimental conditions, Cilengitide was shown to act as an angiogenesis agonist.24 Though 
the use of αVβ3 integrin ligands as anti-angiogenic agents was put into question, a different strategy 
emerged, consisting in their use as tumor targeting agents. Following the latter approach, different RGD-
based small molecules have been used as carriers to deliver selectively both chemotherapeutics25 and 
imaging agents26, exploiting the over-expression of integrin αVβ3 on the membrane of tumor cells. 
In 2009-2012 our research group described a new class of cyclic integrin ligands in which a 2,5-
diketopiperazine (DKP1-DKP7, FIGURE 10 on the left) scaffold constrained the RGD sequence.27 Apart 
from the decreased flexibility of the peptide backbone, the DKP portion avoids metabolic cleavage of 
amide bonds in α-amino peptides, due to the increased constrain and conformational rigidity of the 
backbone. Moreover, the structure itself of the DKP ring can actively participate to the ligand-receptor 
interaction, owing to the presence of hydrogen bond donors and acceptors, such as amide protons and 
carbonyl groups, respectively. In this frame, a better matching with the biological target can be achieved 
by introducing diversity in the DKP ring at four positions. By varying the configuration at C3 and C6 
and the substitution at N1 and N4, a small library of DKP scaffolds was synthesized (DKP1-DKP7, 
FIGURE 10 on the left) and used to prepare cyclo[DKP-RGD] peptidomimetics bearing the RGD 
recognition motif (15-21, FIGURE 10 on the right).27a  
In vitro binding assays on the isolated αVβ3 and αVβ5 integrin receptors qualified the synthesized 
peptidomimetics 16-21 as low nanomolar binders for αVβ3 (TABLE 1). In contrast to Cilengitide (4 in 
FIGURE 7) reported as reference compound, these ligands showed a higher αVβ3/αVβ5 selectivity for 
integrin. Compounds 16-21 were investigated by means of NMR and MC/SD simulations, in order to 
elucidate their conformational preferences: the ligands possessing the best affinity for the αVβ3 receptor 
were distinguished by a defined, extended arrangement of the RGD tripeptide due to the presence of 
intramolecular hydrogen bond patterns locking the structure and limiting the backbone flexibility. 
Further in vitro biological investigations were performed on cyclo[DKP3-RGD] (17): the tested 
compound efficiently inhibited angiogenesis in human umbilical vein endothelial cells (HUVECs).28 
Moreover, 17 exerted a potent biological activity either under basal conditions or in the presence of 
different effectors29 (FIGURE 11): this effect was ascribed to the disruption of endothelial cell-ECM 
attachment upon the interaction of cyclo[DKP3-RGD] with integrin receptors. On the other hand, 
compound 17 did not affect other cellular aspects, e.g. cell viability and proliferation.  
 
FIGURE 10. DKP1-DKP7 scaffold library and the corresponding cyclo[DKP-RGD] peptidomimetics (15-21).27a 
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TABLE 1. Evaluation of the binding affinity of compounds 15-21 on isolated receptor. 
Compound Structure 
IC50 (nM)[a] 
αVβ3 αVβ5 
15 cyclo[DKP1-RGD] 3898 ± 418 >104 
16 cyclo[DKP2-RGD] 3.2 ± 2.7 114 ± 99 
17 cyclo[DKP3-RGD] 4.5 ± 1.1 149 ± 25 
18 cyclo[DKP4-RGD] 7.6 ± 4.3 216 ± 5 
19 cyclo[DKP5-RGD] 12.2 ± 5.0 131 ± 29 
20 cyclo[DKP6-RGD] 2.1 ± 0.6 79 ± 3 
21 cyclo[DKP7-RGD] 0.2 ± 0.09 109 ± 15 
4 Cilengitide 0.6 ± 0.1[b] 11.7 ± 1.5[b] 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of 
biotinylated vitronectin binding. Screening assays were performed by incubating the immobilized 
integrins αVβ3 and αVβ5 with increasing concentrations (10
-12 – 10-5 M) of the RGD ligands in the 
presence of biotinylated vitronectin (1 mg/mL), and measuring the concentration of bound 
vitronectin in the presence of the competitive ligands (see ref. 27). [b] Calculated as the concentration 
of compound required for 50% inhibition of biotinylated vitronectin binding (see ref. 20). 
 
 
FIGURE 11. Representative phase contrast photomicrographs of HUVE cells plated on Matrigel in basal conditions or in the 
presence of VEGF, EGF, IGF-I, and bFGF or IL-8, without and with cyclo[DKP3-RGD] (17) at different concentrations. 
Adapted from ref. 28. 
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1.4 ISODGR INTEGRIN LIGANDS 
In 2006, Dr. Corti and colleagues identified a new integrin binding motif while investigating the 
interaction of fibronectin with integrin receptors.30 The asparagine residue in the asparagine-glycine-
arginine (Asn-Gly-Arg, or NGR, FIGURE 12) sequence of fibronectin was observed to undergo 
spontaneous post-translational modifications with the formation of an isoaspartate portion, thus 
converting the original NGR tripeptide into the new isoaspartate-glycine-arginine (isoAsp-Gly-Arg, or 
isoDGR, FIGURE 12). The reason why this transformation occurs lies in tissue aging and the β-amino 
acid product isoAsp is not provoking a loss of function in fibronectin, a usual consequence of such 
modifications. Actually, the conversion of NGR into isoDGR enabled a stronger interaction with the 
integrin target receptor, resulting in an overall gain of protein function. 
 
FIGURE 12. Post-translational modification converting the NGR portion into its derivative isoDGR. 
In this frame, biochemical studies highlighted that the NGR portion in the FN-I5 region of fibronectin 
is involved in the deamidation of Asn263 to Asp and isoAsp: the conversion of the amide side chain of 
asparagine into the carboxylic acid fragment in aspartate or isoaspartate is responsible for the increased 
endothelial cell adhesion. This reaction occurs at physiological pH and consists in the loss of a molecule 
of ammonia leading to a succinimide intermediate, whose hydrolysis restores the carboxylic moiety in 
the side chain and forms both the DGR and isoDGR motifs (FIGURE 13). 
 
FIGURE 13. The deamidation reaction responsible for the transformation of NGR into isoDGR and DGR motifs in fibronectin. 
At this stage, the question about which between the isoDGR and the DGR tripeptides was the one 
responsible for the activation of the integrin receptor arose. Affinity assays on a library of cyclic peptides 
proved that among the isoDGR (isoAsp-Gly-Arg), isodGR (D-isoAsp-Gly-Arg) and DGR (Asp-Gly-
Arg) motifs only the first one is able to bind the αVβ3 receptor with sub-micromolar affinity.30b Provided 
these findings, the group of Corti focused its attention on the molecular requirements for the interaction 
with the integrin receptor and compared two cyclopeptides containing the isoDGR or the RGD 
sequences, namely isoDGR-2C and RGD-2C (22 and 23 respectively in FIGURE 14). 
12 PART I – 1 INTEGRIN RECEPTORS AND LIGANDS  
 
 
FIGURE 14. The two cyclopeptides 22 and 23 investigated by Corti and colleagues. 
As consequence of the backbone structure, the isoDGR binding motif occupies the interaction site of 
αVβ3 integrin adopting a reversed orientation, but still presenting the arginine and the aspartate side 
chains with a suitable distance to establish the same polar interactions shown in RGD binders (FIGURE 
15).31 
  
FIGURE 15. Representation of isoDGR-2C (22, on the left) and RGD-2C (23, on the right) interacting the αVβ3 binding pocket. 
The α subunit is colored in pink, the β subunit in cyan. Adapted from ref. 31. 
Following NMR experiments were in agreement with the docking studies and the two tested compounds 
22 and 23 showed comparable IC50 values in affinity binding assays on isolated αVβ3 receptor, thus 
reinforcing the idea of a possible competition for the same binding site. Based on these findings, many 
efforts have been devoted to the synthesis of potent isoDGR-based 
ligands. Keeping in mind the structural features of the strong binder 
Cilengitide (4, FIGURE 7), in 2010 Professor Kessler and co-workers 
prepared a library of cyclic pentapeptides containing the isoDGR 
motif.32 However, these ligands displayed from moderate to low 
affinities for the isolated αVβ3 integrin, with the best binder 
cyclo[GisoDGRphg] (24 in FIGURE 16) having IC50 = (89 ± 19) nM. 
The major difference between RGD and isoDGR recognition motifs 
was reported in 2012, when the research group of Dr. Musco 
demonstrated the ability of some isoDGR-containing compounds to 
inhibit αVβ3 integrin activation by interacting with the binding site in 
the inactive form, thus qualifying them as true integrin antagonists.33 The inhibition of this 
conformational change is crucial for stopping the integrin intracellular signaling, therefore preventing 
the pathological events related to tumor exploitation of integrin receptors. For this reason, the 
development of potent isoDGR binders became very attractive, with the possibility to exploit them as 
lone-standing anti-angiogenic agents or as carrier to effect active drug targeting to tumor site. 
In 2013, our research group employed the well-established DKP scaffold system in the synthesis of two 
constrained peptidomimetic ligands containing the isoDGR motif (25-26, FIGURE 17).34 The in vitro 
 
 
FIGURE 16. Structure of the integrin 
ligand cyclo[GisoDGRphg] (24). 
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TABLE 2. Evaluation of the binding affinity of compounds 25-26 on isolated receptor. 
Compound Structure 
IC50 (nM)[a] 
αVβ3 αVβ5 
16 cyclo[DKP2-RGD] 3.2 ± 2.7 114 ± 99 
17 cyclo[DKP3-RGD] 4.5 ± 1.1 149 ± 25 
25 cyclo[DKP2-isoDGR] 46.7 ± 18.2 220 ± 84 
26 cyclo[DKP3-isoDGR] 9.2 ± 1.1 312 ± 21 
4 Cilengitide 0.6 ± 0.1[b] 11.7 ± 1.5[b] 
24 cyclo[GisoDGRphg] 89 ± 19[c] n.d. 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of 
biotinylated vitronectin binding. Screening assays were performed by incubating the 
immobilized integrins αVβ3 and αVβ5 with increasing concentrations (10
-12 – 10-5 M) of the RGD 
or isoDGR ligands in the presence of biotinylated vitronectin (1 mg/mL), and measuring the 
concentration of bound vitronectin in the presence of the competitive ligands (see ref. 27). [b] 
Calculated as the concentration of compound required for 50% inhibition of biotinylated 
vitronectin binding (see ref. 20). [c] Determined by a solid phase binding assay using supported 
vitronectin, soluble αVβ3 integrin, specific primary and secondary antibodies (see ref. 32). 
 
 
FIGURE 17. The cyclo[DKP-
isoDGR] peptidomimetics 25-
26 reported by our research 
group. 
evaluation of 25 and 26 in binding assays on purified integrin αVβ3 (TABLE 2) qualified cyclo[DKP3-
isoDGR] 26 as the most potent isoDGR-based peptidomimetic reported so far in the literature. NMR 
and Monte Carlo/Stochastic Dynamics (MC/SD) studies revealed a higher conformational flexibility in 
compound 25, compared to 26: due to a lower rigidity, cyclo[DKP2-isoDGR] (25) showed a lesser 
affinity for αVβ3 integrin in comparison with cyclo[DKP3-isoDGR] (26). Although 26 is able to adopt 
two different conformations, in both of them the isoDGR sequence is arranged in such an extended 
conformation that is appropriate for interacting with the target receptor (FIGURE 18, on the left). In 
addition, docking studies on the representative conformations from MC/SD calculations resulted in top-
ranked poses of cyclo[DKP3-isoDGR] within the αVβ3 receptor binding site, while considering the 
integrin-Cilengitide co-crystal complex as model (FIGURE 18, on the right). 
  
FIGURE 18. MC/SD simulations (on the left) and docking studies (on the right) on the isoDGR peptidomimetic 26. Adapted 
from ref. 34. 
1.5 RGD LIGANDS IN CANCER THERAPY 
A variety of radiolabeled agents containing RGD-based ligands was synthesized and validated in cancer 
imaging at the clinical level.35 On the other hand, small molecules containing this tripeptide sequence 
are still under investigation and far from therapeutic treatments. As mentioned before, the over-
expression of integrin αVβ3 by cancer cells can be exploited for the selective delivery of therapeutics by 
RGD-decorated prodrugs. Integrin receptors are used to exploit different internalization-recycling cycles 
upon interaction with their ligands: these processes are mediated by such proteins as caveolin and 
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clathrin, capable of triggering receptor folding and inclusion into vesicles that are delivered to 
endosomes.36 In the case of integrin αVβ3, two pathways are available: I) protein degradation by specific 
enzymes in endosomes or lysosomes, II) restoration to the cell membrane. Consequences of these events 
encompass cell migration/diffusion and activation of other receptor families by cross-talk mechanisms.37 
Among the cytotoxic agents used in chemotherapy, paclitaxel (PTX, 27, FIGURE 19) is one of the most 
widely employed in the construction of RGD-containing small molecule-drug conjugates (SMDCs). 
Paclitaxel is usually derivatized at the 2’-hydroxy group, which is essential for the biological activity of 
the drug, by formation of an ester bond: this strategy increased the efficacy of paclitaxel in in vivo tests.38 
 
FIGURE 19. The anti-cancer agent paclitaxel (27) and the prodrug 28 developed by Ryppa and co-workers. 
However, such PTX esters showed poor stability even in phosphate buffer and the premature release of 
the drug was observed, limiting the overall applicability of this kind of SMDC. As representative 
example of such paclitaxel conjugates, in 2009 Ryppa and co-workers synthesized prodrug 28 (FIGURE 
19), a divalent RGD compound designed to improve the affinity towards the target receptor by exploiting 
the multi-presentation of the recognition sequence, and studied its anti-proliferative activity on 
HUVECs.39 The short half-life of 28 (ca. 2 h in phosphate buffer solution at 37 °C) compromised the 
assay even after less than 1 h, frustrating the targeting ability issued by the integrin binding portions. 
Having in hands peptidomimetics able to target integrin αVβ3 with high affinity (16-21, FIGURE 10, 
TABLE 1), in 2012 our research group reported the synthesis and the biological evaluation of 
cyclo[DKP3-RGD]-PTX conjugate 29 (FIGURE 20).40 Paclitaxel was linked to the cyclo[DKP3-RGD]-
CH2NH2 targeting moiety (30, FIGURE 20) through a succinate fragment and, despite the increased steric 
hindrance on the cyclo[DKP-RGD] portion, conjugate 29 retained a low nanomolar affinity and a very 
high selectivity for the target αVβ3 integrin [IC50 (αVβ3) = (5.2 ± 2.3) nM and IC50 (αVβ5) = (219 ± 124) 
nM]. In vivo tests on conjugate 29 in nude mice xenografted with IGROV-1/Pt1 cancer cells (namely, a 
cell line over-expressing the αVβ3 receptor) showed a better efficacy of the conjugate with respect to the 
free cytotoxic agent. Indeed, due to the active integrin targeting, the anti-tumor activity of 29 was 
superior despite the lower dose administered to the animal (FIGURE 21). Similarly to compound 28, the 
drawback of this approach was the poor stability of the ester bond connecting the drug to the RGD 
peptidomimetic. As a matter of fact, even though prodrug 29 proved to be stable in physiological 
solution for at least 7 days, the release of paclitaxel took place both in human and in murine plasma, 
with half-lives of 143 min and 165 min respectively (FIGURE 21). 
These in vivo experiments on 29 pointed out the benefit of using cyclo[DKP-RGD] integrin binders as 
targeting agent in site-directed anti-cancer conjugates and, at the same time, confirmed that the linker 
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FIGURE 20. The chemical structures of cyclo[DKP3-RGD]-PTX conjugate 29 and of cyclo[DKP3-RGD]-CH2NH2 30 
integrin ligand. 
 
 
FIGURE 21. A) Stability of conjugate 29 (1.28 mM) in physiological solution; B) stability of 29 in murine plasma; C) 
biological evaluation of 29 in vivo compared to paclitaxel (PTX) on IGROV-1/Pt1 ovarian carcinoma. Adapted from ref. 
40. 
system represents a very critical point for the efficacy of the prodrug and its essential role in the selective 
release of the cytotoxic payload within the tumor site. This observation prompted the investigation and 
the research of different systems to link the portions of the conjugate. Generally, a small molecule-drug 
conjugate can be divided into at least three portions: the ligand, the drug, and the linker, as depicted in 
FIGURE 22.41 Additional parts, such as spacers, can be added to improve the pharmacokinetic properties 
of the SMDC: the main role of these fragments is to increase the solubility and the stability in aqueous 
medium, as well as to enhance the drug release under specific conditions. 
 
FIGURE 22. General representation of a small molecule-drug conjugate. Adapted from ref. 41. 
16 PART I – 1 INTEGRIN RECEPTORS AND LIGANDS  
 
In the literature, several examples of linker moieties, capable of being cleaved under specific conditions, 
have been developed. In particular, the most common strategies employed in this class of smart prodrugs 
consists in: 
 hydrolysis of certain amide, oxime and hydrazone functional groups; 
 enzymatic cleavage of a specific amide bond in substrate peptide sequences; 
 reduction of disulfide bonds. 
The general mode of action of internalizing small molecule-drug conjugates is shown in FIGURE 23.42 
Upon interaction with the target receptor, a series of events takes place and the formation of a vesicle 
including the ligand-receptor complex occurs. The fusion of this vesicle with early endosomes can allow 
the release of the payload from pH-dependent linker systems. Otherwise, the conjugate survives and 
gets in touch with proteases in lysosomes, where ester and specific amide bonds are hydrolyzed, thus 
releasing the drug. Passive diffusion drives the cytotoxic agent outside the corpuscle (i.e. endosome or 
lysosome) and the vesicle recycling restores the receptor on the cell surface. 
 
FIGURE 23. General mechanism of action of internalizing SMDCs. Adapted from ref. 42. 
Thus, the logical development of compound 29 was the synthesis of conjugates in which the integrin 
ligand and the payload were connected through a peptide linker, eventually cleaved in the presence of 
some specific proteases located in endosomes and lysosomes inside the cell. For this reason, taking 
inspiration from the work published by Scheeren and co-workers,43 our research group synthesized the 
conjugate cyclo[DKP3-RGD]-Val-Ala-PTX (31, FIGURE 24).25a The structure of prodrug 31 resembles 
the schematic representation shown in FIGURE 22 and it is possible to recognize the integrin ligand 
(cyclo[DKP3-RGD]), the cytotoxic agent (paclitaxel), the peptide linker (valine-alanine, Val-Ala) and 
two different spacers. 
Conjugate 31 showed a high affinity for the purified αVβ3 receptor (TABLE 3) and a marked selectivity 
for the integrin over-expressing cell line CCRF-CEM αVβ3 with respect to the isogenic cell line CCRF-
CEM non-expressing the target receptor (TABLE 4). The related conjugate cyclo[DKP3-RGD]-
uncleavable-PTX 32 was designed to be unable to release the drug, and thus used as negative control in 
anti-proliferative assays. The free drug itself showed a pronounced selectivity against CCRF-CEM αVβ3 
cells: the S value of the compound 31 was corrected taking into account the different biological activity 
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FIGURE 24. Structures of conjugates 31 and 32. 
 
TABLE 3. Evaluation of the binding affinity of compounds 31 and 32 on isolated receptor. 
Compound Structure 
IC50 (nM)[a] 
αVβ3 αVβ5 
31 cyclo[DKP3-RGD]-Val-Ala-PTX 13.3 ± 3.6 924 ± 290 
32 cyclo[DKP3-RGD]-uncleavable-PTX 10.8 ± 1.7 1050 ± 270 
17 cyclo[DKP3-RGD] 4.5 ± 1.1 149 ± 25 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of biotinylated 
vitronectin binding as estimated by GraphPad Prism software. All values are the arithmetic mean the standard 
deviation (SD) of triplicate determinations. 
 
TABLE 4. Evaluation of anti-tumor activity of compounds 31 and 32 in vitro. 
Compound Structure 
IC50 (nM)[a] 
S[b] TI[c] CCRF-CEM 
(αVβ3 –) 
CCRF-CEM αVβ3 
(αVβ3 +) 
27 Paclitaxel 155 ± 55 21 ± 2 7.4 1 
31 cyclo[DKP3-RGD]-Val-Ala-PTX 5153 ± 977 77 ± 20 66.9 9.0 
32 cyclo[DKP3-RGD]-uncleavable-PTX > 10000 > 10000 n.d. n.d. 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of cell viability in culture, based on 
quantitation of the ATP present as estimated by CellTiter-GLO; cells were treated for 6 h in U-bottomed 96-well plates, then washed and 
incubated for 138 h in compound-free medium in 96-well flat-bottomed plates. [b] Selectivity (S): IC50 (αVβ3 –)/IC50 (αVβ3 +). [c] Targeting 
index (TI): selectivity/selectivity observed with free paclitaxel. 
of paclitaxel on the two cell lines and the corresponding Targeting Index (TI) was calculated. This new 
parameter allowed the direct evaluation of the tumor-targeting ability of 31 in vitro. 
As previously shown in FIGURE 23, the mechanism of action of conjugates 31 and 32 relies on the 
interaction with integrin αVβ3 and on the subsequent internalization by vesicles. After reaching the 
lysosomal corpuscles, specific proteases, such as cathepsin B, process the substrate dipeptide Val-Ala 
and hydrolyze the C-terminus of the dipeptide sequence in 31 (FIGURE 25). A fast electron cascade takes 
place in the aromatic aniline ring, with the release of CO2 and the formation of the stable free amine that 
will slowly cyclize releasing the free paclitaxel 27 inside the tumor cell. 
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FIGURE 25. Proteolysis of conjugate 31 leading to the release of free paclitaxel 27. 
The uncleavable conjugate 32 is not susceptible to enzymatic hydrolysis, lacking any substrate peptide 
sequence: once entered the cell, the paclitaxel payload cannot be released and thus no biological activity 
against the tumor cell line is observed (see TABLE 4). 
Since the literature on SMDC targeting integrin αVβ3 still lacks a lead compound, prodrug 31 and its 
biological studies represent a valuable reference in this field. Moreover, the targeting index (TI) of 9.0 
– yet not outstanding in absolute terms – demonstrates the feasibility of combining an RGD-
peptidomimetic and paclitaxel using the Val-Ala dipeptide as linker strategy. In view of these promising 
results, we decided to expand the library of cyclo[DKP-isoDGR] and to develop an isoDGR-based 
ligand suitable for the preparation of small molecule-drug conjugates, with the aim of comparing the 
targeting efficacy of the isoDGR motif with respect to the RGD sequence. 
1.6 CHEMICAL TOOLS AS NEGATIVE CONTROL IN BIOLOGICAL 
INVESTIGATIONS 
In order to evaluate the ability of any synthesized compound to target cancer cells, in vitro assays such 
as those mentioned above (TABLE 4) require two cell lines that differ in the expression of integrin 
receptors on the surface of cell membrane (see CCRF-CEM and CCRF-CEM αVβ3 in TABLE 4). We 
decided to use two isogenic cell lines differing only in the level of integrin αVβ3 expression. In this 
particular case, the native non-expressing cell line CCRF-CEM was manipulated by transfection with a 
DNA vector to prepare a subclone expressing integrin αVβ3. Quite unexpectedly, the CCRF-CEM αVβ3 
subclone showed a slightly higher sensitivity to paclitaxel with respect to the parental CCRF-CEM: this 
is the reason why we introduced the targeting index and standardized the S value of prodrug 31, taking 
into account the intrinsic selectivity shown by the cytotoxic agent itself. 
The research of appropriate cell lines could not be trivial and the conditions used to grow and to store 
the cell cultures could affect the integrin expression on the cell surface. Therefore, the biological system 
has to be monitored regularly, confirming that no mutation occurred over time. A possible simplification 
of this scenario can be the use of a single cell line in in vitro assays and performing parallel experiments 
in the presence of a negative control. In principle, a compound unable to interact with the receptor should 
work as well as an integrin non-expressing cell line (such as parental CCRF-CEM) when investigating 
the targeting ability of integrin ligands. 
In 1994, Engel and co-workers published an interesting article, in which a variety of linear and cyclic 
penta- and hexapeptides was examined as integrin ligands.44 Among the compounds synthesized and 
studied, selected cyclopeptides 33-38 are shown in FIGURE 26. An amino acid residue with non-natural 
configuration was introduced systematically along the backbone to evaluate the influence on the overall 
conformation and, therefore, on the biological activity of the compound. 
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FIGURE 26. Selected cyclopeptides 33-38 bearing either the RGD or the RAD motif. Residues in lowercase are D-amino 
acids. 
The ability of compounds 33-38 to inhibit the binding of vitronectin to both soluble and immobilized 
integrin αVβ3 was evaluated in vitro (TABLE 5). Cyclo[RGDfV] 36, namely Bachem, was found to be a 
potent integrin ligand and its further optimization led to Cilengitide (4, FIGURE 7) by N-methylation of 
the valine residue.20 Replacement of glycine with alanine resulted in weaker integrin binders: in 
particular, in comparison with the corresponding RGD peptide 35, 38 showed a two orders of magnitude 
loss of affinity towards the target receptor. Similarly, 37 was the worst ligand among those synthesized 
and reported by the authors. 
TABLE 5. Evaluation of the inhibitory activity of compounds 33-38 on isolated αVβ3. 
Compound Structure 
IC50 (μM) 
soluble αVβ3 immobilized αVβ3 
33 cyclo[rGDFV] 72 ± 10.7 25 ± 4 
34 cyclo[RGdFV] 152 ± 3.5 18.1 ± 14.8 
35 cyclo[RGDfV] 0.049 ± 0.019 0.050 ± 0.024 
36 cyclo[RGDFv] 11.3 ± 1.2 0.4 ± 0.1 
37 cyclo[RaDFV] >>240 >>240 
38 cyclo[RADfV] 4.1 ± 1.0 8.9 ± 5.0 
In the literature, compounds displaying the Arg-Ala-Asp sequence were found to be unable to bind the 
integrin receptor, and therefore replacement of the RGD motif with the RAD derivative has been 
exploited as negative control both in drug targeting and in tumor imaging.45 
Based on these results, we concluded that the inclusion of RAD or RaD sequence into a DKP 
peptidomimetic may afford a weak ligand for integrin αVβ3, to be exploited in anti-proliferative assays 
as negative control. The first step would be the preparation of cyclo[DKP-RAD] and/or cyclo[DKP-
RaD] to test in in vitro binding assay on isolated receptor, as previously done with both RGD and 
isoDGR compounds. Then, the motif showing the highest IC50 value will be used to synthesize a suitable 
derivative for conjugation, aiming at preparing prodrugs related to those presenting the RGD recognition 
motif as targeting moiety. 
2 SYNTHESIS OF INTEGRIN LIGANDS 
2.1 CYCLO[DKP-ISODGR] LIGANDS 
2.1.1 SYNTHESIS OF CYCLO[DKP-ISODGR] PEPTIDOMIMETICS 
ompounds 25 and 26 (FIGURE 17, see 
PARAGRAPH I – 1.4) were the first 
two isoDGR integrin ligands 
reported by our research group.34 However, 
the library of cyclo[DKP-RGD] 
peptidomimetics consisted of seven members, 
with six of them presenting a low nanomolar 
affinity for integrin αVβ3 (TABLE 1, 
PARAGRAPH I – 1.3). Following a similar 
strategy to that reported for the synthesis of 25 
and 26, two more cyclo[DKP-isoDGR] 
compounds, namely cyclo[DKP5-isoDGR] 
and cyclo[DKP7-isoDGR] (39 and 40, 
respectively, in FIGURE 27) have been 
synthesized.46 The new compounds 39 and 40 were synthesized starting from DKP scaffolds 41 and 42, 
suitable for solid-phase peptide synthesis (SPPS). The retrosynthetic analysis of 39 and 40 is 
straightforward (SCHEME 1): macrocycle opening leads to linear compound A, which is readily 
accessible by solid phase synthesis using SASRIN resin, protected amino acids and azido acid scaffolds 
41-42, obtained by known compounds 43-44 (see SCHEME 3). 
 
SCHEME 1. Retrosynthesis of compounds 39-40. 
We selected acid-labile tBu and Mtr (Mtr = 4-Methoxy-2,3,6-trimethylbenzenesulphonyl) groups to 
protect the isoAsp (PG1) and Arg (PG2) side chains respectively, and carboxybenzyl-carbamate (Cbz) 
for the α-amino functionality of arginine (PG3). Fluorenylmethyloxycarbonyl (Fmoc) was used for the 
base-labile PGs (PG4 and PG5). The synthesis of compounds 39-40 is shown in SCHEME 2 and started 
from connecting the glycine and the isoaspartate residues to the solid support. The carboxylic acid 
 
 
FIGURE 27. The library of cyclo[DKP-isoDGR] peptidomimetics 
and the DKP scaffold used in the synthesis of 33 and 34. 
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moiety was activated using condensing agents, such as N,N’-diisopropylcarbodiimide (DIC) and 1-
hydroxy-7-azabenzotriazole (HOAt) in N,N-dimethylformamide (DMF). Subsequent treatment with a 
2% solution of piperidine and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) removed the Fmoc protecting 
group and liberated the amine moiety to couple in the next step (steps a-e). At this stage, a Staudinger 
reduction of the supported azide was carried out in the presence of PMe3 (step f): the reaction completion 
was checked by subjecting few beads to the Kaiser test. The resulting free –NH2 functionality was 
reacted with Cbz-Arg(Mtr)-OH (step g) and the linear compound was cleaved from the resin using 1% 
trifluoroacetic acid (TFA) solution in dichloromethane (step h). The very mild conditions for the 
cleavage reaction allowed to selectively obtain the free carboxylic acids 45-46 without deprotecting the 
isoaspartate side chain (bearing a tBu ester moiety). Hydrogenolysis at room temperature on 45 and 46 
(step i), catalyzed by 10% Pd/C, afforded the amino acids 47 and 48 that led to the cyclized protected 
compounds 49-50, upon macrocyclization with HATU, HOAt and diisopropylethylamine in high 
dilution conditions (step j). At last, Mtr and tBu ester 
protecting groups were removed in TFA using 
thioanisole, 1,2-ethanedithiol (EDT) and anisole as 
scavengers: the final peptidomimetics 39-40 were 
obtained as TFA salts after reverse-phase HPLC 
purification and freeze-drying from water. The 
preparation of DKP azido acids 41-42 necessary for the 
SPPS was carried out in two steps by further modification 
of the corresponding precursors 43-44, already reported 
for the synthesis of isoDGR ligands 25-26 (SCHEME 3). 
The alkylation at the second nitrogen atom in the DKP 
ring of 43-44 was performed using benzyl bromide with 
potassium hexamethyldisilazide (KHMDS) as base at 
low temperature. The dibenzylated compounds 53-54 
were treated with a catalytic amount of [Pd(PPh3)4] in the 
 
SCHEME 2. Reagents and conditions: a) Fmoc-Gly-OH, DIC, DMAP (cat.), DMF; b) 2% piperidine and 2% DBU in DMF; 
c) Fmoc-Asp(OH)-OtBu, DIC, HOAt, DMF; d) 2% piperidine and 2% DBU in DMF; e) 41-42, DIC, HOAt, DMF; f) PMe3, 
dioxane/water 4:1, 20 min × 3 times; g) Cbz-Arg(Mtr)-OH, DIC, HOAt, DMF; h) 1% TFA in CH2Cl2, r.t., 5 min × 10 times, 
71-81%; i) H2, 10% Pd/C, THF/H2O 1:1, 98%-quant.; j) HATU, HOAt, iPr2NEt, DMF (1.4 mM), 32%; k) 
TFA/thioanisole/EDT/anisole 90:5:3:2, 25-37%. 
 
SCHEME 3. Preparation of scaffolds 41-42. 
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presence of N-methylaniline to remove the allyl ester and to obtain the desired azido acids 41-42. The 
choice of protecting groups and of the solid support is a key aspect of the synthesis. SASRIN resin was 
chosen because of such mild cleavage conditions (1% TFA in CH2Cl2) compatible with the presence of 
acid-labile protecting groups. Protection of the α-amino group of arginine with Cbz, (sensitive to 
catalytic hydrogenation) allowed for isolation and purification of the free carboxylic acid, after the 
cleavage from the beads, in order to continue the synthesis with a pure intermediate. Moreover, since 
the SPPS protocol relies on a large excess of reagents (up to 3-5 eq in comparison to the 1 eq of the 
resin), a Kaiser test should be performed after each coupling and Fmoc-removal steps, repeating the last 
operation whenever the test result was unsatisfactory. 
2.1.2 BIOLOGICAL EVALUATION OF CYCLO[DKP-ISODGR] PEPTIDOMIMETICS 39-40 
2.1.2.1 BINDING ASSAYS ON ISOLATED RECEPTOR 
In collaboration with Dr. Daniela Arosio (CNR-ISTM, Milan), the new peptidomimetics 39 and 40 were 
tested in vitro to assess their affinity for isolated integrin receptors αVβ3 and αVβ5: the experimental IC50 
values are presented in TABLE 6, where compounds 4, 17, 25 and 26 (entries 1-4) are reported as 
references. 
TABLE 6. Evaluation of the binding affinity of compounds 39-40 on isolated receptor. 
Entry Compound Structure 
IC50 (nM)[a] 
αVβ3 αVβ5 
1 4 Cilengitide 0.6 ± 0.1[b] 11.7 ± 1.5[b] 
2 17 cyclo[DKP3-RGD] 4.5 ± 1.1 149 ± 25 
3 25 cyclo[DKP2-isoDGR] 46.7 ± 18.2 220 ± 84 
4 26 cyclo[DKP3-isoDGR] 9.2 ± 1.1 312 ± 21 
5 39 cyclo[DKP5-isoDGR] 490 ± 77 9100 ± 800 
6 40 cyclo[DKP7-isoDGR] 255 ± 140 5100 ± 400 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of 
biotinylated vitronectin binding. Screening assays were performed by incubating the immobilized 
integrins αVβ3 and αVβ5 with increasing concentrations (10
-12 – 10-5 M) of the RGD or isoDGR ligands 
in the presence of biotinylated vitronectin (1 mg/mL), and measuring the concentration of bound 
vitronectin in the presence of the competitive ligands, see ref. 46. [b] Calculated as the concentration 
of compound required for 50% inhibition of biotinylated vitronectin binding, see ref. 20. 
The isoDGR-based peptidomimetics (entries 3-6) showed a range of affinity for target integrin receptor 
from low nanomolar to submicromolar concentrations: the data reported in TABLE 6 pointed out how 
the conformational behaviour of cyclo[DKP-isoDGR] compounds is strictly dependent on the structure 
of the diketopiperazine scaffold. This trend is peculiar of this class of peptidomimetics, since it was not 
observed with the corresponding RGD ligands (see TABLE 1, PARAGRAPH I – 1.3). In comparison with 
the already reported ligands 25-26, the newly synthesized cyclo[DKP5-isoDGR] 39 and cyclo[DKP7-
isoDGR] 40 showed lower integrin affinities. 
2.1.2.2 INHIBITION OF INTEGRIN-MEDIATED SIGNALING 
Among the peptidomimetics synthesized in our group, cyclo[DKP3-isoDGR] 26 represents the most 
potent isoDGR integrin binder and, for this reason, in collaboration with Dr. Mayra Paolillo (Università 
degli Studi di Pavia, Pavia), 26 was further investigated in vitro, together with the RGD ligand 
cyclo[DKP3-RGD] 17. In this way, a direct comparison between 17 and 26, containing the same DKP3 
scaffold and possessing similar IC50 values on isolated αVβ3 receptor, was established by evaluating their 
effects on different cellular functions of U373 glioblastoma cells. 
The focal adhesion kinase (FAK) is a tyrosine kinase located in the cytoplasm and plays an essential 
role in cell motility, survival, and proliferation exploiting a variety of mechanisms. FAK exerts its 
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biological ativity by associating with membrane receptors and with specific protein complexes in the 
nucleus. Cell binding to ECM proteins triggers the formation of integrin clusters that, in turn, promotes 
the activation of FAK: this phenomenon is essential for tumor growth, progression and metastasis, and 
leads to the association of FAK with Src (FIGURE 28).47 This complex is responsible for the subsequent 
signalling cascade of Akt, an intracellular kinase related to cell survival and strictly regulated by integrin 
receptors. 
For these reasons, both FAK and Akt were considered as appropriate integrin-dependent effectors in 
order to evaluate the acivity of cyclo[DKP3-RGD] (17) and cyclo[DKP3-isoDGR] (26) on the integrin 
transduction pathway. Notably, compounds 17 and 26 were found able to prevent the phosphorylation 
of FAK and Akt, displaying inhibitory effects on cell infiltration processes mediated by integrin 
receptors (FIGURE 29): these experimental data qualify 17 and 26 as integrin antagonists. 
After 24 hours the decrease in phosphorylated protein content was clearly evident in comparison with 
the control experiment. Concerning cyclo[DKP3-RGD], these results are coherent with the remarkable 
anti-angiogenic activity already observed when treating HUVE cells with 17 in the presence of 
angiogenesis promoters.28 As far as we know about isoDGR motif and related ligands, cyclo[DKP3-
isoDGR] 26 represents the first compound in this field that was investigated and assessed as inhibitor of 
FAK/Akt signalling and of integrin-mediated infiltration processes. 
2.2 ISODGR-BASED SMDCS 
In view of the very interesting biological results mentioned in the previous paragraph, we decided to 
explore further the field isoDGR peptidomimetics and to continue the comparison between RGD and 
isoDGR recognition motifs. In PARAGRAPH I – 1.5, it has been already shown how RGD compounds 
can effect drug turgeting to tumors. In particular, the SMDC cyclo[DKP3-RGD]-Val-Ala-PTX (31) was 
 
FIGURE 28. Integrin interactions with ECM recruite focal adhesion proteins, e.g. talin, FAK., and trigger FAK activation and 
FAK-Src complex formation. Adapted from ref. 47b. 
  
FIGURE 29. Inhibition of FAK and Akt phosphorylation upon treatment with 17 or 26 (+) for 8 and 24 hours. Adapted from 
ref. 46. 
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shown to be able to deliver selectively (S = 66.9 and TI = 9.0 in TABLE 4) the cytotoxic agent paclitaxel, 
discriminating two cell lines expressing integrin αVβ3 at different levels. Prompted by these encouraging 
results, we planned to synthesize an isoDGR analog of 31, namely cyclo[DKP3-isoDGR]-Val-Ala-PTX 
(55, FIGURE 30), and to investigate its biological activity. 
 
FIGURE 30. Structure of cyclo[DKP3-isoDGR]-Val-Ala-PTX 55 and of cyclo[DKP3-isoDGR]-CH2NH2 peptidomimetic 56. 
2.2.1 SYNTHESIS CYCLO[DKP-ISODGR]-CH2NH2 PEPTIDOMIMETIC 56 
In order to conjugate paclitaxel (or any other molecular entity) to cyclo[DKP-isoDGR] ligand, we had 
to synthesize a peptidomimetic containing the isoDGR sequence and a proper handle, namely 
cyclo[DKP3-isoDGR]-CH2NH2 (56, FIGURE 30). Contrary to compounds 25-26 and 39-40, we 
envisaged a new synthetic plan, exploiting a solution-phase approach to limit the wastefulness of 
valuable compounds (e.g. the DKP scaffold) and to pave the way for a future scale up. For this reason, 
we revised the retrosynthetic analysis of 56 (SCHEME 4). Compound 56 derives from intermediate A by 
removing protecting groups 1, 4 and 5 (PG1, PG4 and PG5) and opening the macrocycle. In turn, A can 
be obtained following two different strategies, the retrosynthetic plans A and B shown in SCHEME 4. 
The pathways are straightforward and differ only in the disconnection sequence (dipeptide first, in plan 
A, or arginine first, in plan B). In any case, the precursors are the same and consist of glycinate ester, 
α,α-diprotected aspartate and an already published DKP scaffold (used as either Boc- or azide-protected 
amine). While reversing the retrosynthetic analyses to the corresponding synthetic schemes (SCHEME 
5), the use of three classes of orthogonal protecting groups was required. In particular, acid-labile 
protecting groups are in green (PG1 = tBu ester, PG4 = PG5 = Mtr), hydrogenation-labile groups in 
orange (PG2 = benzyl ester, PG3 = Cbz) and base-labile groups in cyan (PG6 = Fmoc). 
 
SCHEME 4. Retrosynthetic analysis of cyclo[DKP3-isoDGR]-CH2NH2 peptidomimetic (56). Protecting groups in different 
colors are orthogonal. 
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The synthesis of isoDGR peptidomimetic 56 started with the preparation of amine 62 by simple coupling 
reaction of Fmoc-Asp(OH)-OAllyl 59 and glycine benzyl ester 60 (step c) and Fmoc-deprotection of 
the corresponding dipeptide 61 (step d) in the presence of piperidine in DMF. Interestingly, compound 
62 was easily purified by flash chromatography (FC) on silica gel after workup of the reaction mixture 
with ethyl acetate/sat. aq. NaHCO3. As matter of fact, the crude amine compound was tested in coupling 
reaction with Fmoc-Phe-OH as model carboxylic acid, without obtaining the desired amide product 
(results not shown). With 62 in our hands, we first investigated the feasibility of synthetic plan A and 
managed to obtain azide 63: the allyl ester in 57 (synthesized according to the previously reported 
procedure)40 was cleaved (step a) and the resulting carboxylic acid 58 was coupled with amine 62 (step 
b). However, the Staudinger reduction on 63 (step e) led to a complex mixture, in which the presence of 
the desired amine 64 was not detected by mass spectrometry analysis (results not shown). Catalytic 
hydrogenation on 63 was not considered as an alternative, as it would have removed the benzyl ester 
moiety on glycine residue. Hence, we decided to focus on the different synthetic plan B. The starting 
material 68, as well as 57, is an intermediate of cyclo[DKP3-RGD]-CH2NH2 (30) and is obtained from 
57 by one pot reduction and Boc-protection using PMe3 and 2-(Boc-oxyimino)-2-phenylacetonitrile 
(Boc-ON) in tetrahydrofuran (THF). The transformation of 57 into 68 was achieved in very good yields 
(76-88%).40 This strategy was preferred to the direct Staudinger reduction on azide 57 because of the 
easy purification of protected compound 68 by flash chromatography and the quantitative yield of a 
reliable reaction such as the subsequent Boc-deprotection. Indeed, treating 68 with TFA in 
dichloromethane (step j) afforded the corresponding free amine 69 as trifluoroacetate salt that reacted 
with Cbz-Arg(Mtr)-OH (step k) forming compound 70 in 94% yield after two steps. A catalytic amount 
 
SCHEME 5. Synthesis of peptidomimetic 56. Reagents and conditions. Synthetic plan A: a) [Pd(PPh3)4], N-Methylaniline, 
CH2Cl2, 0 °C, 1 h, 84%; b) 62, HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 67%; c) HATU, HOAt, iPr2NEt, DMF, 
0 °C to r.t., overnight, 86%; d) piperidine, DMF, 2 h, r.t., 67%; e) PMe3 in toluene, H2O, THF, 5 h; f) Cbz-Arg(Mtr)-OH, 
HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight; g) H2, 10% Pd/C, THF/H2O 1:1, overnight, r.t.; h) HATU, HOAt, 
iPr2NEt, DMF/CH2Cl21:1 (1.4 mM), 0 °C to r.t., overnight; i) TFA/TMSBr/thioanisole/EDT/phenol 70:14:10:5:1, 2 h, r.t. 
Synthetic plan B: j) TFA, CH2Cl2, r.t., 2 h; k) Cbz-Arg(Mtr)-OH, HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 94% 
over 2 steps; l) [Pd(PPh3)4], N-Methylaniline, CH2Cl2, 0 °C, 1 h, 88%; m) 62, HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., 
overnight, 95%; n) H2, 10% Pd/C, THF/H2O 1:1, overnight, r.t., 95%; o) HATU, HOAt, iPr2NEt, DMF/CH2Cl2 1:1 (1.4 
mM), 0 °C to r.t., overnight, 79%; p) TFA/TMSBr/thioanisole/EDT/phenol 70:14:10:5:1, 2 h, r.t., 47%. 
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of [Pd(PPh3)4] in the presence of an amine nucleophile, i.e. N-methylaniline, effected the allyl ester 
removal on 70 (step l), leaving the Cbz-protecting group on the α-amino functionality of arginine 
untouched and affording carboxylic acid 71. The subsequent amide coupling with dipeptide 62 (step m) 
furnished the linear, protected compound 65 in high yields (95%). Palladium-catalyzed hydrogenation 
of 65 in THF/H2O (step n) removed simultaneously both the carboxybenzyl-carbamate and the benzyl 
ester from arginine and glycine residues, respectively. The resulting linear amino acid 66 was treated 
with HATU, HOAt and iPr2NEt under high dilution conditions (1.4 mM in 1:1 DMF/CH2Cl2, step o) to 
favor the intramolecular macrocyclization. The final deprotection of 67 (step p) was carried out in TFA 
with trimethylsilylbromide (TMSBr), thioanisole, EDT and phenol as scavengers. The trifluoroacetate 
salt of the desired cyclic peptidomimetic 56 was obtained in modest yields (47%), after reverse-phase 
HPLC and freeze-drying from water. To the best of our knowledge, cyclo[DKP3-isoDGR]-CH2NH2 (56) 
is the first isoDGR peptidomimetic entirely synthesized in solution-phase. 
2.2.2 SYNTHESIS CYCLO[DKP-ISODGR]-VAL-ALA-PTX PRODRUG 55 
The next step was the conjugation of compound 56 to paclitaxel (PTX, 27) through a smart linker system 
able to release the cytotoxic agent selectively at the tumor site. As depicted in FIGURE 30, we planned 
the synthesis of cyclo[DKP3-isoDGR]-Val-Ala-PTX 55 to establish a comparison with the 
corresponding RGD prodrug cyclo[DKP3-RGD]-Val-Ala-PTX (31, FIGURE 24, PARAGRAPH I – 1.5). 
Thus, we exploited the same retrosynthesis used for 31: SCHEME 6 shows how 55 can be obtained 
starting from peptidomimetic 56, peptide linker A and paclitaxel (27). 
 
SCHEME 6. Retrosynthetic analysis of cyclo[DKP3-isoDGR]-Val-Ala-PTX prodrug (55). 
The retrosynthesis of linker A is shown in SCHEME 7. The carboxylic acid A derives from glutaric 
anhydride and intermediate B, after removing protecting group 2 (PG2) at the valine nitrogen atom. In 
turn, B can be cut at the carbamate level, revealing the benzyl alcohol derivative C and the mono-
protected diamine D. Retro-amide coupling on C affords 4-aminobenzyl alcohol and dipeptide E, which 
is obtained starting from L-alanine and nitrogen-protected L-valine.  
The retrosynthetic approach shown in SCHEME 7 was applied to the synthesis of peptide linker 72 
(compound A with PG1 = Boc, SCHEME 8).25a We chose Boc and Fmoc as protecting groups 1 and 2, 
respectively. Fmoc-valine 73 was activated with N,N’-dicyclohexylcarbodiimide (DCC) and N-
hydroxysuccinimide  (NHS)  in  THF,  affording  the  corresponding  activated  ester  (step a1)  that  was 
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reacted with L-alanine in the presence of sodium hydrogencarbonate as base in THF/H2O (step a2). In 
this way, dipeptide 74 was obtained in modest yields (47%): subsequent optimization of the reaction 
conditions, which consisted in longer reaction time, allowed the isolation of the desired product in higher 
yields (results not shown). The next coupling was effected pre-activating the carboxylic acid 74 with 2-
ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) in dichloromethane/methanol: the activated 
ester formed in situ was directly reacted with 4-aminobenzyl alcohol affording compound 75 in 65% 
yield (step b). Carbonate 76 was prepared by reacting benzyl alcohol 75 with 4-
nitrophenylchloroformate in the presence of a base (step c). The reaction between 76 and N-(Boc)-N,N’-
dimethylethylenediamine (78), which was synthesized according to previously reported procedures (step 
f),48 smoothly gave the protected carbamate 79 (step d). Conversion of 79 into the corresponding amine 
upon treatment with piperidine (step e1) and the subsequent opening of glutaric anhydride furnished the 
desired peptide linker 72 (step e2). 
The next step was the coupling reaction of 56 with 72 (SCHEME 9). The carboxylic acid of the linker 
was first activated as N-hydroxysuccinimidyl ester (80, step a), then reacted with the isoDGR 
peptidomimetic using a procedure well-established in our group (step b). The conjugation was 
performed in phosphate buffer solution (PBS) and acetonitrile controlling the acidity of the reaction 
medium: pH was set around 7.5 by addition of aliquots of sodium hydroxide over the reaction time. 
Indeed, in acidic conditions, the benzyl amine 56 is protonated and cannot act as nucleophile towards 
 
 
SCHEME 7. Retrosynthetic analysis of peptide linker A. 
 
SCHEME 8. Synthesis of peptide linker 72. Reagents and conditions. a) 1. DCC, NHS, THF, r.t.; 2. L-alanine, NaHCO3, 
THF/H2O (1:1), r.t., 1 h, 47%; b) 4-aminobenzyl alcohol, EEDQ, CH2Cl2/MeOH (2:1), r.t., overnight, 65%; c) 4-
nitrophenylchloroformate, pyridine, THF, r.t., 4 h, 88%, d) 78, iPr2NEt, THF, r.t., overnight, 91%; e) 1. piperidine, DMF, 0 
°C to r.t., 2 h; 2. glutaric anhydride, DMAP, iPr2NEt, DMF, 0 °C to r.t., overnight, 77%; f) Boc2O, CH2Cl2, 0 °C to r.t., 
overnight, 91%. The synthesis was performed according to ref. 25a. 
28 PART I – 2 SYNTHESIS OF INTEGRIN LIGANDS  
 
 
SCHEME 9. Synthesis of isoDGR derivative 82. Reagents and conditions. a) NHS, EDC·HCl, DMF, 0 °C to r.t., overnight; 
b) 56, PBS/CH3CN, pH 7.5, 0 °C to r.t., overnight; c) TFA, CH2Cl2, r.t., 1 h, 55% over three steps. 
the electrophile 80. However, in basic conditions, the hydrolysis of the activated ester 80 becomes 
competitive, leading to the starting material 72 as dead end. The reaction mixture was concentrated 
under high vacuum, then the residue was dissolved in the minimum amount of acetonitrile and 
precipitated with diethyl ether: the solid precipitate was collected and identified as 72. The crude 
compound 81 was directly deprotected from Boc-carbamate, affording the free amine 82 as 
trifluoroacetate salt after reverse-phase HPLC and freeze-drying from water.The last fragment to 
synthesize before starting the assembly of the final conjugate 55 was a suitable activated derivative of 
paclitaxel. In particular, the cytotoxic agent had to be made reactive only at the 2’-position. Indeed, the 
three hydroxy groups at the positions 1, 7 and 2’ are different in terms of reactivity, considering, first of 
all, that the alcohol functionality at position 1 is tertiary and thus less reactive (SCHEME 10). Both the –
OH functions at positions 7 and 2’ are secondary, but the methyl group on the quaternary C8 hinders the 
hydroxy group on the adjacent C7. For this reason, a careful control of reaction conditions can result in 
a regioselective functionalization of the 2’-hydroxy moiety. To carry out the conjugation of 82 to 
paclitaxel, 27 was reacted with 4-nitrophenylchloroformate in the presence of pyridine in CH2Cl2 at low 
temperature, affording carbonate 83 (SCHEME 10). 
 
SCHEME 10. Synthesis of paclitaxel derivative 83. Reagents and conditions. a) 4-nitrophenylchloroformate, pyridine, 
CH2Cl2, -50 °C to -20 °C, 4 h, 84% based on recovered starting material. The synthesis was performed according to ref. 
25a. 
The activation reaction was checked by thin-layer chromatography (TLC), monitoring the formation of 
the product: since we did not manage to achieve full conversion of paclitaxel into the desired carbonate, 
we tried to perform the reaction at -20 °C for times longer than 4 hours. However, already after 2 hours, 
a third spot appeared on the TLC: this compound was less polar and bearing a larger chromophore 
system, since it had a higher retention factor (Rf) and it was more UV visible. These observations 
suggested the formation of byproduct 83’, deriving from the double activation of paclitaxel on both 2’- 
and 7-position. This hypothesis was coherent with the fact that, when treated with ceric ammonium 
molibdate solution, this compound was stained to a smaller extent with respect to the spot of the desired 
product 83 (i.e. more hydroxyl groups were available in 83). A simple flash chromatography on silica 
gel allowed the isolation of the byproduct 83’ (identified by MS, data not shown), the desired product 
83, and the unreacted starting material 27, which was subsequently recycled to prepare a new batch of 
activated paclitaxel. The final conjugation step of 82 to paclitaxel derivative 83 was performed in DMF 
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SCHEME 11. Synthesis of conjugate 55. Reagents and conditions. a) 83, iPr2NEt, DMF, 0 °C to r.t., overnight, 52%. 
with diisopropylethylamine as base to deprotonate the trifluoroacetate salt (SCHEME 11, step a). Over 
the time, the reaction mixture changed from colorless and transparent to bright yellow due to the release 
of 4-nitrophenol, an evidence that reaction was taking place. The work-up was straightforward and 
consisted in solvent evaporation, dissolution of the crude residue with water/acetonitrile and 
centrifugation to remove the precipitate: the supernatant was purified using reverse-phase HPLC. The 
desired conjugate 55 was identified by MS analysis, isolated and freeze-dried from water as 
trifluoroacetate salt. It is worth to mention that 55 represents the first isoDGR peptidomimetic-drug 
conjugate, especially because of the aforementioned difficulty in synthesizing isoDGR-containing 
ligands possessing low IC50 values towards integrin receptors. 
2.2.3 BIOLOGICAL EVALUATION OF CYCLO[DKP-ISODGR]-VAL-ALA-PTX PRODRUG 55 
2.2.3.1 BINDING ASSAYS ON ISOLATED RECEPTOR 
As preliminary evaluation of the activity of conjugate 55, in vitro binding assays on purified integrin 
αVβ3 (TABLE 7) were run in house by Dr. Arosio. The simple ligands cyclo[DKP3-RGD] 17 and 
cyclo[DKP3-isoDGR] 26, as well as the RGD conjugate analog 31 are reported as reference compounds. 
Despite the increased hindrance around the isoDGR portion, cyclo[DKP-isoDGR]-Val-Ala-PTX 55 
maintained a remarkable ability to target the integrin receptor, comparable to those both of the parental 
isoDGR ligand (entry 2) and of the related RGD-conjugate (entry 3). 
TABLE 7. Evaluation of the binding affinity of compound 55 on isolated receptor. 
Entry Compound Structure 
IC50 (nM)[a] 
αVβ3 αVβ5 
1 17 cyclo[DKP3-RGD] 4.5 ± 1.1 149 ± 25 
2 26 cyclo[DKP3-isoDGR] 9.2 ± 1.1 312 ± 21 
3 31 cyclo[DKP3-RGD]-Val-Ala-PTX 13.3 ± 3.6[b] 924 ± 290[b] 
4 55 cyclo[DKP3-isoDGR]-Val-Ala-PTX 11.0 ± 0.2 n.d. 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of biotinylated vitronectin 
binding. Screening assays were performed by incubating the immobilized integrins αVβ3 and αVβ5 with increasing 
concentrations (10-12 – 10-5 M) of the RGD or isoDGR ligands in the presence of biotinylated vitronectin (1 mg/mL), and 
measuring the concentration of bound vitronectin in the presence of the competitive ligands. [b] See ref. 25a. 
This experimental evidence stimulated us to investigate further the biological activity of the newly 
synthesized prodrug and, in particular, to determine its ability to deliver selectively the payload to cancer 
30 PART I – 2 SYNTHESIS OF INTEGRIN LIGANDS  
 
cells. For this reason, in collaboration with Nerviano Medical Science (NMS, Nerviano) we subjected 
55 to a number of different in vitro tests: in the next paragraph, preliminary results of anti-proliferation 
analysis are reported, while lysosome extract digestion and stability assays are currently ongoing. These 
biological characterizations will allow to establish a direct comparison between the RGD and the 
isoDGR ability to target tumors, adding further data to those shown in PARAGRAPH I – 2.1.2. 
2.2.3.2 ANTI-PROLIFERATIVE ASSAYS 
In collaboration with Dr. Fabio Gasparri (Nerviano Medical Sciences s.r.l., Nerviano), the targeting 
ability of the newly synthesized cyclo[DKP3-isoDGR]-Val-Ala-PTX conjugate (55) was assessed by in 
vitro anti-proliferative assays. In order to carry out this test, U87 human glioblastoma cells were first 
selected as integrin αVβ3-expressing cell line, then used to generate the corresponding clone U87 β3-KO, 
in which the expression of the gene encoding for the β3 integrin subunit was deleted using CRISPR-
Cas9 gene editing technology.49 Immunofluorescence studies on this set of cell lines are shown in 
FIGURE 31 and demonstrated the complete knock-out of β3 integrins in U87 β3-KO. Moreover, the 
presence of integrin αVβ5 was checked, confirming that the CRISP-Cas9 technique selectively silenced 
only the target β3 gene, without affecting the expression of other αV integrins. 
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FIGURE 31. Immunofluorescence experiments on U87 and U87 β3-KO cells to assess the different αVβ3 integrin 
expression. 
With this cellular model in our hands, we proceeded evaluating the biological activity of prodrug 55. 
Cells were incubated with increasing doses of cyclo[DKP3-isoDGR]-Val-Ala-PTX for 144 h (TABLE 
8), before measuring the cell viability in the culture. Parallel experiments were performed following the 
same protocol and testing either the reference compound cyclo[DKP3-RGD]-Val-Ala-PTX (31) or the 
free drug paclitaxel (27). As previously observed (see TABLE 4, ref. 25a), paclitaxel itself showed a 
remarkable intrinsic selectivity towards, in this case, the non αVβ3-expressing clone U87 β3-KO: for this 
reason, the S values of both the tested conjugates 31 and 55 were normalized and the experimental TI 
were obtained. Unexpectedly, the reference prodrug 31 proved not to work properly with the current 
biological system (TI = 0.3), but, on the other hand, compound 55 was able to target the parental U87 
cell line (αVβ3 +) ca. 26 times more efficiently (TI = 8.0) than 31. 
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TABLE 8. Evaluation of anti-proliferative activity of compound 55 in vitro. 
Compound Structure 
IC50 (nM)[a] 
S[b] TI[c] 
U87 β3-KO (αVβ3 –) U87 (αVβ3 +) 
27 Paclitaxel 2.5 ± 0.3 39.5 ± 7.1 0.06 1 
31 cyclo[DKP3-RGD]-Val-Ala-PTX 184.9 ± 176.3 9416.3 ± 655.6 0.02 0.3 
55 cyclo[DKP3-isoDGR]-Val-Ala-PTX 409.5 ± 68.4 861.7 ± 215.2 0.48 8.0 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of cell viability in culture, based on 
quantitation of the ATP present as estimated by CellTiter-GLO; cells were treated for 144 h in U-bottomed 96-well plates. [b] Selectivity 
(S): IC50 (αVβ3 –)/IC50 (αVβ3 +). [c] Targeting index (TI): selectivity/selectivity observed with free paclitaxel. 
These results can be rationalized taking into account that the CRISPR-Cas9 gene editing manipulation 
left untouched a variety of integrin receptors (e.g. αVβ5, αVβ5, α5β1) able to interact with both 31 and 55. 
However, due to the different structural properties of the RGD and isoDGR recognition sequences, 
ligands based on either the former or the latter motif interact with other integrins displaying different 
binding affinity, which could eventually explain the difference in biological activity of 31 and 55 against 
the U87/U87 β3-KO cellular model. These preliminary results emphasize the central role of the 
biological system chosen to test and compare the synthesized compounds. The very different activity 
shown by cyclo[DKP3-RGD]-Val-Ala-PTX (31) first on CCRF-CEM (TABLE 4), then on U87 (TABLE 
8) further prompted us to prepare a chemical tool as negative control in biological investigations (see 
PARAGRAPH I – 1.6 and PARAGRAPH I – 2.4). 
2.3 CYCLIC ISODGR PEPTIDES 
2.3.1 SYNTHESIS OF CYCLO[GISODGRF] 84 
In the frame of isoDGR integrin ligands, I collaborated with Cristina Paissoni, a PhD student in 
Industrial Chemistry (R10582) working under the supervision of Dr. Giovanna Musco (Ospedale San 
Raffaele, Milano) and Prof. Laura Belvisi (Università degli Studi di Milano, Milano). Cristina worked 
on the development of computational methods to design new potent integrin ligands containing the 
isoDGR motif or related sequences. During my PhD, I 
synthesized the compound cyclo[GisodGRf] (84, FIGURE 
32), one of the most promising cyclic peptides resulting 
from theoretical calculations, to validate with experimental 
results the in silico method developed by Cristina. 
Compound 84 is a cyclic peptide readily accessible by 
solid-phase peptide synthesis using suitably protected 
amino acid building blocks (SCHEME 12). From a 
retrosynthetic point of view, macrocycle opening of 84 can 
be effected at each of the five amide bonds, but only the two choices depicted in SCHEME 12 will lead 
to primary, linear carboxylic acids, namely A and B. During the intramolecular cyclization, these 
intermediates (A and B) will not suffer from epimerization and should be more reactive in comparison 
with the other α-substituted amino acid residues present in the molecule (i.e. D-phenylalanine, arginine). 
Between the two retrosynthetic strategies, plan B is more appealing than plan A, as both the amine and 
the carboxylic acid moieties in B are primary. For this reason, we planned the synthesis of 84 as shown 
in SCHEME 13. The same color code used in the previous schemes is maintained, thus acid-labile 
protecting groups are in green (PG1 = tBu, PG3 = Pbf, where Pbf = 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl), base-labile groups in cyan (PG4 = PG5 = PG6 = Fmoc), and 
hydrogenation-labile groups in orange (PG2 = Cbz). In the latter case, we preferred to use the 
 
 
 
FIGURE 32. Retrosynthesis of cyclic peptide 84. 
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SCHEME 13. Synthesis of cyclic peptide 84. Reagents and conditions: a) Fmoc-Asp(OH)-OtBu, HATU, HOAt, iPr2NEt, 
DMF, M.W., 90%; b) 1. 25% piperidine in DMF; 2. Fmoc-AA-OH, HATU, HOAt, iPr2NEt, DMF, M.W.; c) 1. 25% 
piperidine in DMF; 2. Cbz-Gly-OH, HATU, HOAt, iPr2NEt, DMF, M.W.; d) 1% TFA in CH2Cl2, r.t., 3 min × 24 times, 
73%; e) H2, 10% Pd/C, THF/H2O 2:1, overnight, r.t., quant.; f) HATU, HOAt, iPr2NEt, DMF/CH2Cl2 1:1 (1.4 mM), 
overnight, r.t., 39%; g) TFA/thioanisole/EDT/anisole 90:5:3:2, 2 h, r.t., 49%. 
carboxybenzyl- instead of the Fmoc-carbamate because of the traceless byproducts deriving from the 
Cbz-deprotection reaction. Moreover, the presence of a protecting group at the N-terminus of the peptide 
allowed the purification of the linear carboxylic acid after the cleavage from the resin by FC on silica 
gel. On the other hand, a zwitterion peptide, bearing protected side chains, would have been very 
difficult to purify using either direct or reverse phase chromatography. The synthesis of 84 started with 
the coupling reaction between Fmoc-Asp(OH)-OtBu and SASRIN resin (step a): the reaction proceeded 
without problems, especially thanks to the low steric hindrance around the β-carboxylic group involved. 
In any case, the reaction was performed two times to minimize the number of unreacted supported –OH 
groups. At the end of the second coupling, a few beads were subjected to Kaiser test: the test result was 
negative, thus the esterification of the resin was effective. We calculated the yield of the first step with 
the formula 
𝑦% =  
(𝑚𝑇𝑂𝑇 − 𝑚𝑅𝐸𝑆𝐼𝑁)
(𝑀.𝑊.𝐴𝐴 − 𝑀.𝑊.𝑊𝐴𝑇𝐸𝑅) 𝑛𝑅𝐸𝑆𝐼𝑁
% , 
where: 
 y% is the yield of the coupling reaction, expressed as percentage; 
 mTOT is the mass of the resin after the coupling reaction, expressed in mg; 
 mRESIN is the mass of the resin before the coupling reaction, expressed in mg; 
 M.W.AA is the molecular weight of the amino acid just attached to the resin; 
 
SCHEME 12. Retrosynthesis of cyclic peptide 84. 
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 M.W.WATER is the molecular weight of water, since, during the coupling reaction between the 
carboxylic acid and the SASRIN resin, extrusion of H2O takes place (●–OH + HOOC-R → 
●–OOC-R + H2O); 
 nRESIN is the amount of resin used, expressed in mmol. 
In this case, the y% of step a was 90%: the amounts of reagents for the next steps were calculated 
consequently. The double coupling procedure was applied in order to limit the formation of truncated 
byproducts during the SPPS: in particular, it is better to carry out the coupling reaction steps involving 
amino acids with a bulky side chain (in this case D-phenylalanine) two times. At this stage, we continued 
the solid-phase peptide synthesis (step b): alternating Fmoc deprotection (step b1) and coupling reaction 
with the next building block (step b2), the tetrapeptide was built on the solid support. The last treatment 
with 25% piperidine in DMF (step c1) afforded the amine that attacked Cbz-protected glycine, 
previously activated in the presence of HATU, HOAt and iPr2NEt (step c2). A 1% TFA solution in 
dichloromethane resulted effective in removing the peptide from the beads (step d), without touching 
the acid-labile groups (tBu ester and Pbf sulfonamide), that anyhow require harsher cleavage conditions. 
Step d was carried out until no peptide was spotted by eluting on TLC the liquid fractions from rinsing 
the resin: the crude compound 85 was obtained removing the solvent and purified by flash 
chromatography on silica gel. The linear amino acid 86 was obtained quantitatively by catalytic 
hydrogenation of Cbz-carbamate 85, using 10% Pd/C as catalyst, under hydrogen atmosphere in 2:1 
THF/H2O (step e). Compound 86 was subjected to macrocyclization under high dilution conditions in 
1:1 DMF/CH2Cl2 (step f): the reaction was stirred overnight at room temperature, then the mixture was 
concentrated and the crude compound 87 was purified by flash chromatography on silica gel. 
Deprotection in TFA with thioanisole, EDT and anisole scavengers gave the final compound 84 as 
trifluoroacetate salt, after reverse phase HPLC and freeze-drying from water (step g). 
2.3.2 CONFORMATIONAL AND BIOLOGICAL INVESTIGATIONS ON CYCLO[GISODGRF] 84 
The cyclic pentapeptide 84 was studied in terms of conformation and biological activity by the research 
group of Dr. Giovanna Musco, where Cristina was carrying out her PhD. For this reason, these studies 
are not reported in this Thesis. By the way, NMR and in vitro investigations pointed out substantial 
differences between the predicted properties of the synthesized peptide and the experimental results 
actually shown by 84. These findings allowed the optimization of the in silico model, leading to a 
reassessment of the variables involved in the force field calculations. 
2.4 CYCLO[DKP-RAD] PEPTIDOMIMETICS 
2.4.1 SYNTHESIS OF CYCLO[DKP-RAD] 88 AND CYCLO[DKP-RAD] 88-EPI 
The preparation of cyclic RAD-peptidomimetics bearing a DKP scaffold was achieved by following the 
procedure used in the synthesis of cyclo[DKP-RGD] compounds,27 introducing an alanine residue 
instead of glycine. We decided to synthesize cyclo[DKP3-RAD] and cyclo[DKP3-RaD] 
peptidomimetics (88 and 88-epi, respectively, FIGURE 33), since the related cyclo[DKP3-RGD] 17 has 
been investigated extensively as integrin ligand and inhibitor (see PARAGRAPH I – 2.1.2). Since 
diastereoisomers 88 and 88-epi may show different biological activities, we planned to test both isomers 
in in vitro binding assays. 
We chose to synthesize first 88, the isomer containing the alanine residue in the natural configuration. 
The synthesis of 88 is shown in SCHEME 14: compound 88-epi can be obtained following a similar 
strategy, but using D-alanine instead. The coupling reaction between protected arginine 89 and alanine 
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benzyl ester (90, step a) and Boc-
deprotection of the resulting dipeptide 91 in 
TFA/dichloromethane (step b) afforded 
amine 92. Carboxylic acid 94 was prepared 
according to reported procedures starting 
from the known azide scaffold 44, common 
intermediate in the preparation of both RGD 
and isoDGR ligands.27 In situ reduction and 
protection (step c) on 44 gave allyl ester 93 
that was cleaved in the presence of 
pyrrolidine, PPh3 and [Pd(PPh3)4] as catalyst 
(step d). 92 and 94 reacted forming 95 in 
good yields (step e). Treating Boc-carbamate 
95 with TFA in CH2Cl2 resulted in full 
conversion into the corresponding amine 96 (step f) that was directly coupled with Cbz-Asp(OtBu)-OH, 
using HATU and HOAt as condensing agents (step g). The linear protected compound 97 was submitted 
to catalytic hydrogenation with 10% Pd/C as catalyst to cleave both benzyl ester on alanine and 
carboxybenzyl carbamate on aspartic residues (step h): the linear deprotected amino acid 98 was isolated 
in quantitative yields. The macrocyclization on 98 (step i) turned out to be a crucial step of the synthesis. 
We performed the reaction under the well-established reaction conditions: the carboxylic acid (1.0 eq) 
was activated at 0 °C with HATU (4.0 eq), HOAt (4.0 eq) and iPr2NEt (6.0 eq) in high dilution (1.4 mM 
in DMF/CH2Cl2 1:1), then the reaction mixture was stirred overnight at room temperature. After solvent 
removal, the crude compound was purified by flash chromatography on silica gel and the expected 
desired compound was isolated as mixture of two inseparable isomers 99A and 99B. We suppose that 
 
 
FIGURE 33. Structures of peptidomimetics cyclo[DKP3-RAD] 88 
and cyclo[DKP3-RaD] 88-epi. 
 
SCHEME 14. Synthesis of peptidomimetic 88. Reagents and conditions. a) HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., 
overnight, 84%; b) TFA, CH2Cl2, r.t., 2 h; c) PMe3 in toluene, Boc-ON, THF, -20 °C to r.t., 5 h, 78%; d) [Pd(PPh3)4], 
pyrrolidine, PPh3, CH2Cl2, 0 °C, 1 h, quant.; e) 94, HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 65%; f) TFA, 
CH2Cl2, r.t., 2 h; g) Cbz-Asp(OtBu)-OH, HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 83%; h) H2, 10% Pd/C, 
THF/H2O 1:1, overnight, r.t., quant.; i) HATU, HOAt, iPr2NEt, DMF/CH2Cl2 1:1 (1.4 mM), 0 °C to r.t., overnight, 82%; 
j) TFA/thioanisole/EDT/anisole 90:5:3:2, 2 h, r.t., 30%. The synthesis was performed according to ref. 27. 
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racemization at the alanine stereocenter occurred during the amide bond formation, following a reported 
mechanism (FIGURE 34). After activation of the carboxylic acid A by condensing agents, the 
intramolecular attack by the adjacent residue on the activated ester moiety in B leads to the formation 
of oxazolone derivative C. At this stage, the nucleophilic attack (in red, FIGURE 34) and the 
deprotonation at 4 position in C (in blue, FIGURE 34) are competitive, depending on the reaction 
conditions: the former pathway opens up the oxazolone ring and furnish peptide F (desired product, 
obtained via undesired mechanism); the latter forms oxazololate D that can undergo reprotonation on 
both the faces of the heterocycle, thus evolving into oxazolone E or coming back to C. If the nucleophile 
attacks E, peptide G is produced: this mechanism could explain why a mixture of (diastereo)isomers 
was obtained in step i. 
 
FIGURE 34. Racemization mechanism possibly active during amino acid coupling reaction.  
The final deprotection on 99A + 99B (step j) afforded the crude compound, whose purification by 
reverse-phase HPLC allowed the separation of the two isomers, namely 88A and 88B, obtained in ca. 
1:1 ratio after freeze-drying from water (FIGURE 34). 
At the moment, we can adfirm that 88A and 88B are two isomers on the basis of MS analysis: further 
investigations are planned to elucidate the structure of each compound. In any case, if the hypothesis of 
alanine racemization will be confirmed, the synthetic strategy shown in SCHEME 14 will be useful to 
synthesize both cyclo[DKP3-RAD] 88 and cyclo[DKP3-RaD] 88-epi starting from L-alanine. 
 
FIGURE 34. HPLC purification and separation of isomers 88A and 88B. 
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2.4.2 BIOLOGICAL EVALUATION OF CYCLO[DKP-RAD] PEPTIDOMIMETICS 88A AND 88B 
2.4.2.1 BINDING ASSAYS ON ISOLATED RECEPTOR 
88A and 88B were tested in in vitro binding assays on isolated αVβ3 receptor to assess their activity as 
integrin ligands (TABLE 8). Cilengitide (4) and cyclo[DKP3-RGD] (17) are reported as reference 
compounds. The experimental IC50 values shown by 88A and 88B (entries 3 and 4) demonstrate that the 
substitution of glycine with alanine affects the ability of the peptidomimetic to bind αVβ3 integrin: in 
particular, compound 88B was found to be a very weak binder for the target integrin receptor, showing 
a 300-fold loss of potency when compared with the corresponding RGD ligand 17. These results are 
promising and disclose the possibility to synthesize RAD-based fragments bearing a handle for 
conjugation to payloads, aiming at preparing RAD-drug conjugates as negative control in anti-
proliferative assays. The low activity showed by peptidomimetics 88A and 88B is probably ascribable 
to the methyl group in alanine side chain, which may be responsible for critic steric clashes when the 
interaction with the integrin binding site takes place. 
TABLE 9. Evaluation of the binding affinity of compounds 88A and 88B on isolated αvβ3 receptor. 
Entry Compound Structure 
IC50 (nM)[a] 
αVβ3 αVβ5 
1 4 Cilengitide 0.6 ± 0.1[b] 11.7 ± 1.5[b] 
2 17 cyclo[DKP3-RGD] 4.5 ± 1.1 149 ± 25 
3 88A cyclo[DKP3-RAD] (r.t. 9.2 min) 360 ± 40 n.d. 
4 88B cyclo[DKP3-RAD] (r.t. 11.0 min) 1500 ± 500 n.d. 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of biotinylated 
vitronectin binding. Screening assays were performed by incubating the immobilized integrins αVβ3 and αVβ5 with 
increasing concentrations (10-12 – 10-5 M) of the RGD or RAD ligands in the presence of biotinylated vitronectin (1 
mg/mL), and measuring the concentration of bound vitronectin in the presence of the competitive ligands. [b] 
Calculated as the concentration of compound required for 50% inhibition of biotinylated vitronectin binding, see 
ref. 20. 
Moreover, the remarkable difference between RAD compounds may be addressed to different 
conformational preferences adopted by the tripeptide motif, as consequence of an inverted 
stereochemistry at the alanine α-carbon: as matter of fact, the 1H-NMR spectra of 88A and 88B differ 
in both chemical shifts and multiplet systems, suggesting the presence of two different conformations 
(FIGURE 36 and FIGURE 37). 
 PART I – 2 SYNTHESIS OF INTEGRIN LIGANDS 37 
 
 
FIGURE 36. 1H-NMR (400 MHz, D2O) spectrum of compound 88A. 
 
FIGURE 37. 1H-NMR (400 MHz, D2O) spectrum of compound 88B. 
3 CONCLUSIONS 
n the first part of this Thesis, I described the synthesis of different classes of peptidomimetics 
targeting integrin receptors. Both simple ligands and drug conjugates were synthesized and tested 
to assess their biological activity. 
First, I focused my attention on the synthesis of cyclo[DKP-isoDGR] ligands, expanding the library of 
peptidomimetics synthesized in our group with compounds cyclo[DKP5-isoDGR] (39) and 
cyclo[DKP7-isoDGR] (40). Ligands 39 and 40 showed only poor affinity for the isolated integrin 
receptors αVβ3 and αVβ5 in vitro: these observations suggested a major role of the DKP scaffold in the 
spatial arrangement of the isoDGR sequence, even more evident than the one observed in the 
correspoding cyclo[DKP-RGD] peptidomimetics. The previously reported cyclo[DKP3-isoDGR] (26) 
was confirmed as the best binder for integrin αVβ3 among the isoDGR ligands reported so far in the 
literature. For this reason, cyclo[DKP3-RGD] (17) and cyclo[DKP3-isoDGR] (26) were selected for 
further biological investigations in order to establish a comparison between the two different peptide 
sequences: both 17 and 26 exhibited a potent inhibitor effect on the phosphorylation of FAK and Akt, 
two proteins involved in integrin-mediated cellular processes. These experimental evidences qualified 
cyclo[DKP3-RGD] and cyclo[DKP3-isoDGR] as integrin antagonists: additional biological studies will 
be carried out to gather more information about the activity of these compounds in order to expand the 
RGD-isoDGR comparison. 
Next, we developed a new synthetic strategy to prepare cyclo[DKP3-isoDGR]-CH2NH2 56, a derivative 
of cyclo[DKP3-isoDGR] (26) bearing a benzylic amine moiety as suitable handle for further conjugation 
to different payloads, such as cytotoxic and imaging agents. The synthesis of 56 and its linkage to 
paclitaxel via a cleavable linker were carried out entirely in solution-phase. The resulting cyclo[DKP3-
isoDGR]-Val-Ala-PTX (55) showed a low nanomolar affinity towards purified αVβ3 integrin in vitro. 
Preliminary anti-proliferative assays assessed a remarkable targeting ability of 55 against cancer cells 
over-expressing integrin αVβ3. Lysosome extract digestion and stability tests on cyclo[DKP3-isoDGR]-
Val-Ala-PTX are ongoing in order to evaluate the ability of the conjugate to release the paclitaxel 
fragment within the tumor environment. These data will be compared with those already reported for 
the related prodrug cyclo[DKP3-RGD]-Val-Ala-PTX (31): in this way the targeting ability of the two 
RGD- and isoDGR-based conjugates will be assessed. Future developments of this project will include 
the conjugation of cyclo[DKP3-isoDGR]-CH2NH2 (56) to other payloads using both different peptide- 
and non-peptide linker systems. As a matter of fact, we already synthesized a small library of 
cyclo[DKP3-RGD]-drug conjugates, with cyclo[DKP3-RGD]-Val-Ala-PTX (31) as representative 
example. Among the peptide sequences suitable for the drug release, the well-known dipeptide valine-
citrulline (Val-Cit) is a specific substrate for cathepsin B,50 a lysosomal protease: the inclusion of this 
fragment into an SMDC will avoid the premature cleavage of the peptide linker in the extracellular 
environment. 
The design and synthesis of integrin ligands displaying the isoDGR motif was carried out also in 
collaboration with Cristina Paissoni, a PhD student working in the research group of Dr. Giovanna 
Musco (Ospedale San Raffaele, Milan). Based on computational studies carried out by Cristina, 
compound cyclo[GisodGRf] (84) was identified as promising cyclic peptide and synthesized using SPPS 
protocols. A panel of conformational and biological studies are ongoing on 84 to validate the developed 
I 
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in silico model: further optimization of the theoretical method will be required, since preliminary test 
results showed important inconsistencies between the predicted and the experimental properties of the 
cyclopeptide. 
At last, I focused my efforts on the synthesis of cyclo[DKP3-RAD] (88) and cyclo[DKP3-RaD] (88-epi) 
peptidomimetics: during the macrocyclization step in the synthesis of compound 88, epimerization at 
the α-carbon of alanine possibly occurred, leading to the formation of two diastereoisomers. Compounds 
88A and 88B were separated after the final deprotection reaction by reverse-phase HPLC and tested in 
vitro to measure their ability to bind integrin αVβ3. As expected, the replacement of Gly with Ala (RGD 
→ RAD) provoked a marked decrease in integrin affinity, with respect to the corresponding 
cyclo[DKP3-RGD] (17). The synthesis of RAD-containing peptidomimetics displaying a suitable 
functional group for the preparation of RAD-drug conjugates to be used as negative tools in anti-
proliferative assays is currently in progress. On the other hand, additional analysis on 88A and 88B will 
be devoted to elucidate their structural and conformational properties. 
 
PART II. TARGETING VEGFRS 
The second part of my Thesis deals with the vascular endothelial growth factor receptors and their 
ligands. 
A short presentation of this complex biological axis is given before showing some examples of 
molecules able to modulate VEGFRs activity by interacting either with the extracellular or with the 
intracellular domains of these proteins. 
Then, the role of integrin-VEGFR cross-talk will be presented, with some experimental evidences 
demonstrating how the disruption of this direct co-operation can inhibit angiogenesis. 
At last, I will describe the interaction of VEGF-C with its target receptors VEGFR-2 and VEGFR-3 and 
the reason why we considered this growth factor a privileged candidate for the preparation of a small 
library of VEGFR-selective peptides. 
Part of the work described in this Chapter was published in the following article: 
 Zanella, S.; Mingozzi, M.; Dal Corso, A.; Fanelli, R.; Arosio, D.; Cosentino, M.; Schembri, L.; 
Marino, F.; De Zotti, M.; Formaggio, F.; Pignataro, L.; Belvisi, L.; Piarulli, U.; Gennari, C. 
ChemistryOpen 2015, 4, 633; cited in “Spotlights on our sister journals”, Chem. Eur. J. 2015, 
21, 18510. 
 
1 VEGF RECEPTORS AND LIGANDS 
1.1 BIOLOGY OF THE VEGF-VEGFR SYSTEM 
ascular endothelial growth factors (VEGFs) play a key role in the regulation of vasculogenesis 
and angiogenesis. Mammals present five different VEGFs, together with the correspondent 
splice and processed isoforms. These proteins are able to bind a common pattern of three 
receptor tyrosine kinases (RTKs), namely VEGF receptor-1, -2, and -3 (VEGFR-1, VEGFR-2, and 
VEGFR-3). Moreover, VEGFs can interact with some co-receptors, i.e. heparan sulfate proteoglycans 
(HSPGs) and neuropilins, and induce their biological activity.51 The regulation mechanisms of these 
growth factors are very similar to those of well-known RTKs, e.g. the platelet-derived growth factor 
receptors (PDGFRs) and the epidermal growth-factor receptors (EGFRs). In general, VEGF ligands 
exert their biological activity by inducing receptor dimerization and activating the tyrosine kinase 
domain that transmit different signaling pathways related to cell migration, survival and proliferation. 
On the other hand, VEGFR activity is unique in transducing such signals responsible for the formation 
of vascular tube network and for the regulation of vascular permeability. In particular, VEGFR-1 is able 
to affect both the migration of monocytes and macrophages, and the signaling efficacy of VEGFR-2. A 
soluble isoform of VEGFR-1 participates in the downregulation of VEGFR-2 activity by preventing its 
interaction with endogenous ligands. Most of the physiological and pathological events in vascular 
endothelial cells are regulated by VEGFR-2 activity, whereas VEGFR-3 fulfills an essential role in the 
growth and function of lymphatic endothelial cell. Due to their fundamental tasks, cancer therapy started 
targeting VEGF receptors using anti-VEGF antibodies and small molecules, aiming at neutralizing the 
growth factors or inhibiting the tyrosine-kinase activity, respectively (see PARAGRAPH II – 1.2 for further 
discussion). In mammals, the VEGF family consists of five dimeric glycoproteins, such as VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placenta growth factor (PLGF). Different growth factors 
exhibit selectivity for different VEGFRs: these proteins can acquire specificity toward a new target 
receptor upon proteolytic 
processing of the native 
VEGF (FIGURE 38).51,52 
From the structural point 
of view, VEGFs present 
intra- and inter-chain 
disulfide bonds involving 
eight, well-conserved 
cysteine amino acids. In 
particular, the crystallized 
VEGF-A revealed that the 
protein is composed by 
two monomers having an 
anti-parallel orientation 
giving rise to a dimer 
presenting the receptor 
binding site at each pole 
V 
 
FIGURE 38. Selectivity of mammalian VEGFs towards homo- and heterodimeric 
VEGFRs. Adapted from ref. 51. 
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of the whole dimer (FIGURE 39).53 Although homodimers are formed preferentially, also some 
heterodimeric complexes have been observed. 
  
FIGURE 39. Receptor-binding domain of VEGF-A represented as monomer and homodimer (on the left) and VEGF-A 
interacting with VEGFR-1 as homodimer (on the right). Adapted from ref. 53a. 
VEGFs can be present in different isoforms originated by alternative splicing of the native proteins: this 
differentiation mechanism, together with a parallel proteolytic processing, affects the interaction of the 
isoform with the target receptors, stimulating the wide pattern of biological functions exerted by the 
VEGF-VEGFR system. For example, upon the proteolysis of specific chains in the early proteins, 
VEGF-C and VEGF-D are allowed to bind both VEGFR-2 and VEGFR-3. 
The VEGFRs belong to the receptor tyrosine kinases superfamily and share the subclass with PDGFRs 
and fibroblast growth factor receptors (FGFRs). Around 750 residues arranged into seven 
immunoglobulin-like folds compose the extracellular domain (ECD). In particular, the Ig domain-2 is 
responsible for ligand binding in VEGFR-1,54 whereas the Ig domain-3 of VEGFR-2 determines the 
ligand specificity.55 As well as VEGFs, VEGFRs can undergo splicing and/or proteolysis: for example, 
these transformations secrete processed VEGFR-1 and VEGFR-2, and a truncated variant of VEGFR-
3.56 
Neuropilins NRP-1 and NRP-2 were found to participate in VEGFR signaling: in particular, these co-
receptors are able to bind only specific VEGF isoforms and then to present them to VEGF receptors in 
a certain way that increase the efficacy of VEGF signal transduction. Neuropilins are type I 
transmembrane proteins that lack kinase activity, but strengthen the signaling of VEGFRs and act as 
reserve of VEGF. 
1.2 INTERFERING WITH THE VEGF-VEGFR SYSTEM IN ANTI-ANGIOGENIC 
THERAPY 
Similarly to integrins, VEGFRs are over-expressed by hypoxic tumor cells: this peculiarity has been 
exploited in cancer treatment with the aim of impairing the VEGF-VEGFR interaction. Apart from 
bevacizumab, mentioned in PARAGRAPH I.2, other molecules able to interfere and disrupt this signaling 
system have been developed: as instance, clinical trials on a VEGFR-1/VEGFR-2 fusion protein, called 
VEGF-Trap, and on antibodies targeting VEGFs and VEGFRs are ongoing.57 
Many efforts have been devoted to develop small molecules able to interfere with the activity of VEGF 
by targeting the intracellular tyrosine-kinase domain of VEGFRs:58 sunitinib and sorafenib are two well-
known examples. Sunitinib (Sutent™, 100, FIGURE 40) was developed as broad RTK inhibitor59 and 
approved by the FDA in 2006 for the treatment of renal cell carcinoma (RCC) and gastrointestinal 
stromal tumor (GIST).60 Sorafenib (Nexavar™, 101, FIGURE 40) was demonstrated to inhibit the activity 
of VEGFR-2, VEGFR-3 and PDGFRβ. First approved by US FDA in 2005 for the RCC-related therapy, 
in 2007 the use of sorafenib was extended to the treatment of hepatocellular carcinoma (HCC).61 
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FIGURE 40. Structures of sunitinib (100) and sorafenib (101). 
In addition, peptides and related derivatives have been proven efficient VEGF inhibitors: such 
compounds exert their biologically activity upon interaction with the extracellular portion of VEGFRs. 
Some examples of this class of molecules are shown in FIGURE 41, and they include peptoids (102-
103)62; helical peptides (104-105)63, designed starting from the Vammin hotspot; cyclopeptides (106)64; 
and foldamers (107)65. 
 
FIGURE 41. Peptides and related derivatives 102-107. 
In 2011, the research group of D’Andrea developed peptide 108 (FIGURE 42), which is characterized by 
a stable α-helical conformation in aqueous solution, a high affinity for VEGFRs and the ability to prevent 
the biological activity of VEGF on HUVECs.66 Furthermore, in vivo studies on 108 showed its potent 
inhibition of capillary formation mediated by VEGF, thus restraining tumor growth. This angiogenesis 
inhibitor was designed starting from the pro-angiogenic agent 109 (FIGURE 42) that was developed by 
the same group in 2005 reproducing the helix region 17-25 involved in VEGF binding.67 In this protein 
fragment, the authors decided to retain the three-dimensional disposition of amino acids interacting with 
the receptor and stabilized the helical folding by introducing capping sequences at both the peptide 
termini. Impressively, the modification of only two residues in 109 (Asn5→Met5 and Lys11→Ala11) 
completely modified the biological activity of the peptide compound: as a matter of fact, 109 is a potent 
angiogenesis agonist, whereas 108 was proved to inhibit morphogenesis efficiently. 
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FIGURE 42. The helical peptides 108 and 109 developed by D’Andrea and co-workers. 
In comparison with other examples shown above, 108 is a simple compound: indeed, this linear 
decapentapeptide can be easily synthesized by solid-phase peptide synthesis (SPPS). For this reason, we 
selected compound 108 as VEGFR-1 ligand and synthesized a dual action compound with the aim of 
targeting both integrin and VEGF receptors (see PARAGRAPH II – 1.2.1, 111, FIGURE 46). 
1.2.1 INTEGRIN-VEGFR CROSS-TALK 
As a matter of fact, cooperation between integrins and VEGFRs was found to be crucial in pathological 
processes, such as tumor growth and development (FIGURE 43), as these receptors participate in the 
regulation of tumor angiogenesis by cross-talk mechanisms involving association and cluster formation, 
and affecting the activity of single receptor proteins.68 
In 2000, Ruoslahti and colleagues reported a pioneer study in which the integrin αVβ3 portions 
interacting with VEGFR-2 and PDGFRβ were identified.69 In particular, the ECD of the integrin β3 
subunit demonstrated to associate with both growth factor receptors, even without ligand-mediated 
phosphorylation and activation. These findings suggested the possibility of a direct, physical 
cooperation involving integrins and RTKs. In this field, Byzova and co-workers have extensively 
studied the cross-talk existing between integrin and VEGF receptors: since 2003, the authors collected 
a number of experimental evidences, encompassing receptor cluster formation and co-localization.70 For 
instance, they demonstrated that VEGF stimulation was able to trigger the conformational change of 
integrin αVβ3 into the high affinity state and its subsequent co-localization with VEGFR-2 (FIGURE 
44).70b Therefore, the population of activated integrin αVβ3 was found increased in highly-vascularized 
tumor masses, where hypoxic conditions lead to the up-regulation of growth factors and related 
receptors. 
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FIGURE 43. Integrin-VEGFR cooperation and signaling. Adapted from ref. 68. 
 
 
FIGURE 44. Co-localization of integrin αVβ3 and VEGFR-2 receptors. Adapted from ref. 70b. 
In view of these experimental observations, the research group of Cochran designed and synthesized a 
dual action fusion protein, namely scVEGF (FIGURE 45, on the left), by equipping the natural VEGF 
(scVEGFwt) with an additional RGD recognition motif, maintaining the original biological activity of 
the growth factor.71 
The benefit of displaying at the same time both the VEGFR and the integrin (RGD) binding motifs was 
demonstrated by inhibitory studies in which the interaction with these two receptors allowed to block 
the VEGFR-mediated cell proliferation. Moreover, in vitro test on HUVE cells qualified the dual 
specific variant scVEGF 7I as the most potent anti-angiogenic fusion protein among the three prepared 
(FIGURE 45, on the right). Indeed, scVEGF mut and scVEGF m27I, possessing only one binding epitope, 
showed incomplete inhibition of blood vessel formation. This strong inhibitory effect obtained when 
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VEGFR-2 and integrin αVβ3 are simultaneously targeted is due to the disruption of the cross-talk 
interaction existing between these two receptor families. Intrigued by these results, in 2015 our research 
group reported the mixed solid-phase/solution-phase synthesis of a small dual action molecule targeting 
both integrin αVβ3 and VEGFR (111, FIGURE 46).72 Our RGD-containing peptidomimetic 30 (see 
PARAGRAPH I – 1.5) and the peptide 110, a derivative of 108 described by D’Andrea and colleagues, 
were chosen as integrin and VEGFR ligands, respectively, and linked covalently using an appropriate 
polyethylene glycol (PEG) spacer. We decided to protect the side chain of Lys13 in compound 110 since 
a free amino moiety could have interfered with the electrostatic interaction established by the RGD 
binding to integrin receptor.73 On the other hand, the ε-NH2 group of the N-terminal Lys1 was exploited 
to link the helical peptide and the peptidomimetic 30 by click chemistry. 
 
FIGURE 46. The helical peptide 108, its derivative 110 and the dual action conjugate 111 developed in our group. 
  
FIGURE 45. The engineered fusion protein scVEGF (on the left) and angiogenesis assay on the synthesized 
compounds. Adapted from ref. 71. 
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Circular dichroism (CD) studies on the final conjugate 111 showed 
that the VEGFR ligand almost retained its active conformation, 
considering that even minor structure modifications could affect 
the biological activity in a certain extent. The CD spectrum of 111 
(FIGURE 47) demonstrated that, depending on the solvent, the 
VEGFR ligand presents a certain conformational flexibility: 
passing from water, to trifluoroethanol, to methanol, the secondary 
structure of the peptide adopted a more pronounced helical folding. 
Indeed, both the alcoholic solvents are known to induce 
specifically helicoidal conformation in peptides. Nevertheless, in 
aqueous medium, which is the most relevant considered that it 
resembles the natural cellular environment, the portion of 110 
included in the conjugate still retains the native α-helix 
arrangement in a certain extent, thus its ability to interact with the 
target VEGF receptor. Compound 111 proved to interact in vitro 
with the isolated integrin αVβ3 and VEGFR-1 receptors and showed 
a potent inhibitory effect against VEGF-mediated angiogenesis on HUVE cells (FIGURE 48B). Control 
experiments were carried out in the presence of VEGF alone (FIGURE 48A) and of VEGF + 112 (Ac-
Lys-Gln-Met-Tyr-Leu-Glu-Leu-Gly-Tyr-Ala-Thr-Ile-Lys-Trp-Leu-amide, FIGURE 48C), a negative 
control presenting the amino acid residues of peptide 108 in a scrambled order. 
 
FIGURE 48. Phase contrast photomicrographs of HUVE cells on Matrigel plates, treated with: A) VEGF165 
(10 ng/mL); B) VEGF165 (10 ng/mL) + 111 (1 µM); C) VEGF165 (10 ng/mL) + 112 (1 µM). Images were 
elaborated by phase-contrast microscopy using a fluorescence microscope. Adapted from ref. 72. 
1.2.2 VEGF-C DERIVED LIGANDS FOR VEGFR-2 AND VEGFR-3 
Encouraged by the promising activity of the dual action conjugate 111, we decided to further investigate 
the field of VEGFR ligands and, in particular, those able to selectively target VEGFR-2 and VEGFR-3 
in order to prepare more potent and selective anti-angiogenic agents. With this aim, we focused our 
attention on VEGF-C, which demonstrated to be a multifaceted effector involved in progression of 
different cancer types by regulating tumor angiogenesis, upon interaction with both VEGFR-2 and 
VEGFR-3. In 2012, the binding affinity of vascular endothelial growth factor C towards the extracellular 
domain of VEGFR-2 was measured by calorimetry titration experiments and the experimental 
dissociation constant was Kd = 1210 nM.74 Later, using a similar strategy, the Kd for the interaction 
VEGF-C -VEGFR-3 was determined (Kd = 5.6 nM).75 The analysis on the crystal structure of VEGF-C 
bound to the high-affinity binding site of VEGFR-2 showed that the N-terminal α-helix (Ile122-Gln130 
portion, in FIGURE 49) in the growth factor is responsible for the selectivity towards VEGFR-2 (FIGURE 
50 on the left). In this nonapeptide sequence, one hydrophobic interaction (Ile122-Trp126) and two 
bridge salts (Asp123-Arg127 and Glu125-Lys128) stabilize the helical secondary structure of the 
backbone (FIGURE 50 on the right).76  
 
Figure 47. CD spectrum of dual action 
compound 111 in different solvents. 
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FIGURE 49. The α-helix Ile122-Gln130 deriving from the N-terminal natural 
sequence of VEGF-C (the numbers are referred to the natural amino acid chain). 
This helical fragment represents an attractive candidate for further structure optimization in order to 
obtain more potent and selective VEGFR-2 ligands to exploit in VEGFR-targeted anti-angiogenesis 
therapy. For this reason, in collaboration with Professor Lorenzo Stella (Università di Roma Tor 
Vergata, Rome), we designed and synthesized a small library of VEGF-C derived peptides starting from 
the natural portion Ile122-Gln130 (see PARAGRAPH II – 2.1 and II – 2.2). 
  
FIGURE 50. Fragment Ile122-Gln130 interacting with the high-affinity binding site of VEGFR-2 (on the left) and the three 
stabilizing interactions present along the peptide chain, Ile122-Trp126, Asp123-Arg127 and Glu125-Lys128 (on the right). 
2 SYNTHESIS OF VEGFR LIGANDS 
2.1 STRATEGY 
he portion Ile122-Gln130 is located at the N-terminal helix of VEGF-C: this fragment is not 
only responsible for the protein-protein interaction with the target receptors, but also for the 
intrinsic selectivity of the growth factor C towards VEGFR-2 and VEGFR-3, with respect to 
VEGFR-1. The biological activity of this small sequence, composed by nine amino acids, relies on the 
native helical folding, which displays relevant residue side chains in a proper orientation to engage the 
receptor hotspots during the interaction. The stability of this structural conformation arises from three 
fundamental intra-chain interactions: Ile122-Trp126, Asp123-Arg127 and Glu125-Lys128. 
In collaboration with Professor Lorenzo Stella (Università di Roma Tor Vergata, Rome), we designed 
and synthesized VEGFR ligands deriving from the VEGF-C Ile122-Gln130 portion. We started 
preparing the nonapeptide 113, a congener of the natural fragment in which both the N- and the C-
terminal residues were capped (FIGURE 50). Since such short peptides seldom retain their biologically 
active secondary structure, we modified the native sequence by introducing both natural and non-natural 
amino acids. In a first approach, we synthesized peptide 114 (FIGURE 51) by replacing Ile122 and 
Gln130 with tryptophan residues, whose aromatic indole ring would have strengthened the pre-existing 
hydrophobic interactions with Trp126 and, at the same time, embedding an amine functionality able to 
participate in hydrogen bonds. Moreover, both Ile122 and Gln130 are involved in the interaction with 
hydrophobic regions of the receptor: for this reason, the substitution with two Trp residues would also 
improve the ligand-receptor binding. 
 
FIGURE 51 Overview of the natural portion 113 and the derived peptides 114-118. The modifications are underlined. 
On the other hand, we introduced non-natural residues bearing a quaternary stereocenter at the Cα, since 
α,α-disubstituted amino acids are known to induce helical folding. 2-Aminoisobutyric acid (Aib), α-
methylaspartic acid [(α-Me)Asp] and 4-aminopiperidine-4-carboxylic acid (Api) were selected as 
achiral (Aib, Api) and chiral [(α-Me)Asp] amino acids to be introduced along 113 and 114 peptide 
sequences. We thus prepared compounds 115-118, where the residues not involved in the interaction 
with the receptor were replaced or the (α-Me)Asp residue was employed to replace the cardinal residue 
Glu125 without impairing the ligand binding. Indeed, while the introduction of Aib residues allowed to 
T 
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increase the backbone rigidity enhancing the helical folding, the quaternary residues (α-Me)Asp and Api 
had the additional advantage of displaying a carboxylate and an amine portions in the side chains, 
respectively. The α-NH2 group of the N-terminal residue could be exploited as handle to conjugate these 
congeners to other molecular entities. Such direct manipulation of the backbone could affect the 
conformational structure of the peptide: for this reason, an Api residue was placed at position 1 in 
compound 118, giving the possibility to exploit the secondary amine moiety in the side chain for further 
functionalization. 
2.2 SYNTHESIS OF PEPTIDES 113-118 
A semi-automatic synthesizer was used to prepare sequences 113-118 via SPPS on Rink Amide MHBA 
resin with the Fmoc/tBu strategy and assisting each coupling reaction with microwaves. A schematic 
representation of the SPPS is shown in SCHEME 15. First, the resin was swallen in DMF and treated with 
a 25% solution of piperidine in DMF to remove the Fmoc-protecting group, releasing the reactive amino 
moiety on the beads (step a). The Fmoc-amino acid to be attached to the solid support was activated 
with DIC and HOAt condensing agents in the presence of iPr2NEt in DMF: after stirring for 25 min at 
0 °C, the mixture was added to the resin and a cycle of coupling, capping and deprotection was 
performed by the semi-synthesizer (step b). This procedure was repeated until the sequence was 
completed, then the N-terminal residue was acetylated and the beads were treated with TFA, using 
thioanisole, EDT and anisole as scavengers. Subsequent purification of the crude peptide with RP-HPLC 
and freeze-drying from glacial acetic acid gave the pure compound as a fluffy foam. 
amideAcHN
Fmoc-HN H2N
H2N
 
SCHEME 15. Synthesis of sequences 113-118. Reagents and conditions: a) 25% piperidine in DMF; b) SPPS (repeat): 
1. Fmoc-AA-OH (4.0 eq), DIC, HOAt, iPr2NEt, DMF, microwaves; 2. 25% Ac2O in DMF; 3. 25% piperidine in DMF; 
c) Capping and peptide cleavage: 1. 25% Ac2O in DMF; 2. TFA/thioanisole/EDT/anisole 90:5:3:2 v/v/v/v, r.t., 3 h, 7-30%. 
α,α-Disubstituted residues are poorly reactive, even upon activation, because of the high steric 
congestion around the reactive ester moiety. For this reason, double coupling reactions were performed 
when a quaternary amino acid had to be attached to the resin: using this procedure, after the first coupling 
step, a second aliquot of the activated amino acid was added to the resin to perform another condensation 
reaction and to saturate free –NH2 that did not react during the first coupling step. 
2.3 STRUCTURAL INVESTIGATIONS ON PEPTIDES 113-118 
2.3.1 CIRCULAR DICHROISM (CD) EXPERIMENTS 
In collaboration with Professor Fernando Formaggio and Dr. Marta De Zotti (Università degli Studi di 
Padova, Padua), VEGF-C derived peptides 113-118 were studied with NMR and CD spectroscopy to 
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evaluate their secondary structure. The CD spectrum arises from the sum of the contributes of each 
amide moiety present in the peptide. When a peptide folds into a helical conformation, the spatial 
distribution and orientation of its chromophores generate a CD spectrum, which usually consists of two 
major bands, corresponding to the π→π* and n→π* electronic transitions, located at about 208 and 220 
nm (the wavelength values can be different due to the helix type, α-helix or 310-helix). Usually, in a CD 
spectrum the wavelength values are reported on the x-axis, while the molar ellipticity [θ] is on the y-
axis. [θ] can be either positive or negative, depending on the rotatory direction of the helix: in the 
presence of a right-handed helical structure the ellipticity assumes negative values; instead, left-handed 
helices are characterized by positive [θ] values. 
Compounds 113 and 114 exhibited a pronounced helical folding, mainly corresponding to a 310-helix, 
based on the corresponding CD spectra in FIGURE 52. This folding type is characterized by i-i+4 
interactions along the peptide chain, and it is similar to the more compact α-helix that presents a i-i+5 
hydrogen bonding pattern. In the CD spectra of 115 and 116 (FIGURE 52), the negative peaks at ≈200 
nm were characterized by a lower intensity band with respect to the corresponding sequences 113 and 
114, in which the Aib residue was not present. On the other hand, the intensity of the transitions at ≈218 
nm were not affected by the presence of aminoisobutyric acid. Moreover, the CD curve of 116 exhibited 
an additional negative peak at ≈238 nm that was not observed in the spectrum of the parental peptide 
114. Three tryptophan residues were included in the backbone of peptide 116 and their aromatic 
chromophores contributed to the absorbance in the near-UV region. In particular, this effect was 
enhanced by the higher structural rigidity resulting from quaternary Aib residues. This hypothesis was 
validated recording the near-UV CD spectra of 115 and 116 (FIGURE 53), which showed a positive 
transition at ≈270 nm that is absent in the near-UV spectrum of 113 and irrelevant in the spectrum of 
114 (FIGURE 54). In the CD spectrum of peptide 116, a further minimum was identified at ≈238 nm: this 
band could be due to stacking interactions between the indole portions of Trp side chains (Ac-U-W-D-
N-U-W-R-K-U-W-amide, with U = Aib = 2-aminoisobutyric acid), or other effects provoked by peptide 
aggregation in the aqueous medium. In conclusion, the remarkable contribution of tryptophan amino 
acids in the CD spectra of 115 and 116 is strictly related to the higher backbone rigidity due to the 
presence of the Aib residues. 
Sequences 117 and 118 exhibited a α-helical folding (FIGURE 52): these compounds showed a different 
conformational behavior with respect to that of 115 and 116, probably due to the replacement of Aib 
with (α-Me)Asp and Api fragments, which imparted a lower, but still essential, rigidity to the backbone. 
As a matter of fact, the helical structure of 117 and 118 was slightly more flexible with respect to those 
of compounds 115 and 116. 
   
FIGURE 52. CD spectra of compounds 113-118 (ca. 10-4 M in H2O). 
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FIGURE 53. Near-UV CD spectra of compounds 115 and 116 (ca. 10-4 M in H2O, pathlenght 1 cm). 
  
FIGURE 54. Near-UV CD spectra of compounds 113 and 114 (ca. 10-4 M in H2O, pathlenght 1 cm). 
2.3.2 BIDIMENSIONAL NMR EXPERIMENTS 
Compound 115 was selected as example peptide and further investigated with 2D-NMR experiments. 
The ROESY (Rotating-frame nuclear Overhauser Effect Spectroscopy) spectrum of compound 115 is 
shown in FIGURE 55. The presence of the NHi → NHi+1 cross-peaks confirmed that 115 adopts a helical 
conformation in solution. Moreover, the fingerprint region of the spectrum provided an additional 
evidence of the helical secondary structure of 115: as a matter of fact, the presence of αHi → NHi+n 
cross-peaks allowed the identification of the helical structure type (FIGURE 56). 
Indeed, αHi → NHi+3 cross-peaks are common features of both α-helices and 310-helices, but αHi → 
NHi+2 cross-peaks are typical of 310-helices, while αHi → NHi+4 cross-peaks are present only in α-helical 
structures. In the first part of the peptide chain, the interaction αH3 → NH5 denoted that the N-terminal 
fragment adopts a 310-helical conformation, while the αH6 → NH9 cross-peak demonstrated only that 
the C-terminal part of the peptide is characterized by a helical folding, although neither the 310-helix 
typical cross-peaks nor those of the α-helix were observed. In conclusion, ROESY experiments on 115 
confirmed the helical secondary structure adopted by the peptide. The helix type was prevalently a 310-
helical structure for the N-terminal region. The C-terminal region presented a similar folding, but a 
certain conformational flexibility was observed and it was not possible to assign a defined helical 
subtype to this peptide portion. 
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FIGURE 55. Portion of the ROESY spectrum of 115 [298 K, 600 MHz] in H2O/D2O 9:1 (pH ≈4). 
 
FIGURE 56. Fingerprint region of the ROESY spectrum of 115 [298 K, 600 MHz] in H2O/D2O 9:1 (pH ≈4). 
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2.4 BIOLOGICAL INVESTIGATIONS ON PEPTIDES 114-118 
2.4.1 BINDING ASSAYS ON ISOLATED VEGFR-1 
In collaboration with Dr. Daniela Arosio (CNR-ISTM, Milan), the VEGF-C derived peptides 114-118 
were investigated with in vitro binding assays to evaluate the affinity of the synthesized peptides towards 
the isolated VEGFR-1 receptor (TABLE 10). 
TABLE 10. Inhibition of biotinylated VEGF165 binding to isolated VEGFR-1. 
Compound Sequence % Inhibition[a] IC50 (μM)[b] 
114 Ac-Trp-Asp-Asn-Glu-Trp-Arg-Lys-Thr-Trp-amide 29.2  6.9 n.d. 
115 Ac-Aib-Ile-Asp-Asn-Aib-Trp-Arg-Lys-Aib-Gln-amide 86.3  1.2 125 
116 Ac-Aib-Trp-Asp-Asn-Aib-Trp-Arg-Lys-Aib-Trp-amide 35.1  12.7 n.d. 
117 Ac-Trp-(α-Me)Asp-Asn-(α-Me)Asp-Trp-Arg-Api-Thr-Trp-amide 81.8  0.7 52 
118 Ac-Api-Trp-Asp-Asn-(α-Me)Asp-Trp-Arg-Api-Thr-Trp-amide 82.6  2.5 69 
[a] % of inhibition of biotinylated VEGF165 binding to VEGFR-1 at 500 μM. [b] IC50 values were extrapolated by GraphPad Prism. 
Peptides 115, 117 and 118 showed a remarkable inhibition of biotinylated VEGF165 binding to isolated 
VEGFR-1 and the corresponding IC50 values were calculated by extrapolation. For this reason, these 
data have to be considered as range of concentrations, but in any case they are still indicative of the in 
vitro biological activity of the tested compounds. The introduction of quaternary amino acids resulted 
in a beneficial effect in terms of affinity towards VEGFR-1 receptor, except for peptide 116, which 
derives from 115 by replacement of Ile2 and Gln10 with Trp. This modification enhanced both the 
helical content of the peptide backbone (as demonstrated by the CD analysis) and the hydrophobicity of 
the compound with a possible negative effect on its solubility. As mentioned above, the CD spectrum 
in the near-UV of peptide 116 exhibited an additional minimum at 238 nm that possibly arose from 
aggregation phenomena (FIGURE 52 and FIGURE 53). This fact could also have affected the affinity of 
peptide 116. On the contrary, compounds 117 and 118 represented a good compromise between the 
conformational rigidity of the backbone and the biological activity of the peptide. The introduction of 
α,α-disubstituted amino acids like (α-Me)Asp and Api had two main advantages: decreasing the 
conformational flexibility and retaining the important functional groups (such as a carboxylate and a 
secondary amine functionalities) in the side chains. Indeed, with respect to Aib residues, the FGs in α-
methylaspartate and 4-aminopiperidine-4-carboxylate could play a fundamental role both in the 
interaction with the receptor and in the peptide solvation, thus explaining the promising results obtained 
with in vitro affinity assays on VEGFR-1. 
The next step will be the evaluation of the affinity of all the synthesized peptides towards isolated 
VEGFR-2: indeed, since these sequences derive from the VEGF-C N-terminal helix, they should bind 
preferentially VEGFR-2 and VEGFR-3 with respect to VEGFR-1. We decided to perform in any case 
in vitro assays on isolated VEGFR-1 since the experimental protocol was already assessed and exploited 
to evaluate the affinity of the dual action compound 111 (FIGURE 46): the results obtained on VEGFR-
1 (TABLE 10), can be used to set a preliminary comparison among the tested peptides. For this reason, 
the two promising sequences 117 and 118 were subjected to additional biological investigations. 
2.4.2 MORPHOGENESIS ASSAYS 
In collaboration with Dr. Marino (Università degli Studi dell’Insubria, Varese), peptides 117 and 118 
were further studied in vitro on HUVE cells. FIGURE 57 shows the macroscopic effects resulting from 
the administration of either 117 or 118 to HUVECs, in the presence of VEGF165 as angiogenesis agonist: 
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in comparison with the control experiment (FIGURE 57A), 117 and 118 (FIGURE 57B and FIGURE 57C, 
respectively) prevented the formation of capillary network efficiently. Interestingly, peptides 117 and 
118 exhibited a remarkable anti-angiogenic activity in the concentration range 10-9 – 10-6 M (FIGURE 58): 
in particular, compound 117 was found more effective than 118 in reducing both loops and branches 
formation. This pronounced biological activity against VEGF-mediated morphogenesis could be 
ascribed to the interference of the tested compounds with the VEGF-VEGFR axis. The in vitro binding 
studies presented in PARAGRAPH II – 2.4.1 demonstrated the ability of these compounds to interact with 
VEGFR-1. The biological activity of such compounds could be the result of a complex mechanism of 
signalling involving different effectors and related receptors. In this case, VEGF165 was used as only 
stimulator of angiogensis, thus the inhibition of morphogenesis suggests that compounds 117 and 118 
can interfere with the interaction of VEGF165 with its biological targets (i.e. VEGFR-1 and VEGFR-2). 
Based on these experimental results, the evaluation of the affinity towards VEGFR-2 receptor becomes 
more and more important: screening all the synthesized peptides will allow to identify the most 
promising ones, which will be further optimized by computational studies. 
  
   
FIGURE 57. Representative phase contrast photomicrographs of HUVE cells plated on Matrigel in the presence of: A) 
VEGF165 (10 ng/mL); B) VEGF165 (10 ng/mL) + 117 (1 μM); C) VEGF165 (10 ng/mL) + 118 (1 μM). 
  
FIGURE 58. Inhibition of VEGF-mediated angiogenesis on HUVE cells upon treatment with compound 117 or 118. 
A) B) C) 
3 CONCLUSIONS 
ith the aim of synthesizing potent VEGFR ligands, we selected the N-terminal helix of 
VEGF-C, the natural ligand of VEGFR-2 and VEGFR-3, and designed a small library of 
peptides (113-118) by introducing systematic modifications along the native sequence. In 
particular, both natural and non-natural amino acids were included in the new peptides, in order to 
stabilize the helical folding that is essential for the biological activity of such compounds. For this 
reason, tryptophan residues, as well as 2-aminoisobutyrric acid (Aib), α-methylaspartic acid [(α-
Me)Asp] and 4-aminopiperidine-4-carboxylic acid (Api) were placed at specific backbone positions. 
The synthesis of sequences 113-118 was carried out with a semi-automatic synthesizer using SPPS 
protocols: the procedure was straightforward and the cleavage from the resin afforded the desired 
peptides upon HPLC purification and freeze-drying. 
Structural investigation on the synthesized compounds were conducted by NMR and CD spectroscopy. 
The CD spectra of 113-118 presented the typical features of a helical folding, with certain variations in 
the position and intensity of UV transitions due to the presence of specific amino acids along the chain. 
Moreover, compound 115 was selected as example and it was studied using bidimensional NMR 
experiments (ROESY): the fingerprint region presented the diagnostic cross-peaks of a 310-helical 
conformation. 
Peptides 114-118 were tested in vitro to determine their ability to bind isolated VEGFR-1 receptor: 
compounds 117-118 turned out to be the most promising ones, with IC50 values in the range of 50-70 
μM. Further investigations on compounds 117-118 demonstrated their potent biological activity as 
inhibitors of VEGF165-mediated angiogenesis in HUVE cells: in particular, both the tested compounds 
were active in the 10-9 – 10-6 M range. 
The affinity of compounds 114-118 towards VEGFR-2 is currently ongoing and, together with the 
biological data already in our hands, will allow the identification of the best peptide sequences that will 
be optimized by computational studies, aimed at designing a non-peptide VEGFR-2 binder. The latter 
compound will be also exploited in the preparation of dual-action ligands able to interact with both 
integrin and VEGF receptors and thus impair the tumor angiogenesis.  
W 
   
EXPERIMENTAL PART 
GENERAL REMARKS AND PROCEDURES 
MATERIALS AND METHODS 
All manipulations requiring anhydrous conditions were carried out in flame-dried glassware, with 
magnetic stirring and under a nitrogen atmosphere. All commercially available reagents were used as 
received. Anhydrous solvents were purchased from commercial sources and withdrawn from the 
container by syringe, under a slight positive pressure of nitrogen. The reactions were monitored by 
analytical TLC using silica gel 60 F254 pre-coated glass plates (0.25 mm thickness). Visualization was 
accomplished by irradiation with a UV lamp and/or staining with a potassium permanganate alkaline 
solution, ninhydrin or ceric ammonium molibdate solution. Flash column chromatography was 
performed according to the method of Still and co-workers77 using Chromagel 60 ACC (40-63 μm) silica 
gel. Proton NMR spectra were recorded on a spectrometer operating at 400.16 MHz. Proton chemical 
shifts are reported in ppm (δ) with the solvent reference relative to TMS employed as the internal 
standard. The following abbreviations are used to describe spin multiplicity s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, bs = broad signal, dd = doublet of doublet, ddd = doublet of doublet 
of doublet, ddt = doublet of doublet of triplet. Carbon NMR spectra were recorded on a spectrometer 
operating at 100.63 MHz, with complete proton decoupling. Carbon chemical shifts are reported in ppm 
(δ) relative to TMS with the respective solvent resonance as the internal standard. In the case of 2D-
NMR experiments for conformational studies, all NMR spectra were acquired on a Bruker Avance 
DMX-600 instrument, using the TOPSPIN 1.3 software package. A CLEAN-TOCSY spectrum (spin-
lock pulse, 70 ms)78 was acquired by collecting 200 recordings of 40 scans each, whilst, for the NOESY 
spectrum, 400 recordings, each one consisting of 64 scans, were acquired. The NOESY experiment 
(mixing time, 150 ms) was exploited for the sequential assignment. ESI-MS spectra were recorded on 
the ion trap mass spectrometer Finnigan LCQ Advantage. The MALDI-TOF-MS spectra were recorded 
on the instrument Bruker Microflex™ LT, supporting the sample on the 2,5-dihydroxybenzoic acid 
(DHB), α-cyano-4-hydroxycinnamic acid (HCCA) and sinapinic acid (SIN) matrices. The peptide 
calibration standard (300-3000 Da range), which consisted of Angiotensin II, Angiotensin I, Substance 
P, Bombesin; ACTH clip 1-17, ACTH clip 18-39, Somatostatin 28, was purchased from Bruker 
Daltonics® and used to calibrate the MALDI-TOF-MS instrument. The sample was mixed in equal 
volumes with the matrix solution: a small amount (1 μL) of this mixture was spotted on the target 
surface. The target matrix was dried at room temperature and then analyzed. 
EP.1 RP-HPLC PURIFICATION 
The HPLC purifications were performed using a Dionex Ultimate 3000 instrument equipped with a 
Dionex RS Variable Wavelength Detector (column: Atlantis® Prep T3 OBDTM 5 μm 19 × 100 mm). 
The crude reaction mixture was dissolved in H2O or, if the compound was insoluble in water, adding 
first DMF, then diluting slowly with H2O until reaching a 1:1 mixture DMF/H2O (ultrasonic sonicator 
was used to assist the dissolution). The solution so obtained was filtered (polypropylene, 0.45 µm, 13 
mm ø, PK/100) and injected in the HPLC, affording purified products. 
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EP.2 RP-HPLC ANALYSIS 
Purity analyses were carried on a Dionex Ultimate 3000 instrument equipped with a Dionex RS Variable 
Wavelenght detector (column: Atlantis® Prep T3 OBDTM 5 μm 19 x 100 mm). 1 mg of analyte was 
dissolved in 1 mL of H2O and was injected using the same gradient used in the purification step. The 
analysis of the integrals and the relative percentage of purity was performed with the software 
Cromeleon 6.80 SR11 Build 3161. 
EP.3 FREEZE-DRYING 
The product was dissolved in water or glacial acetic acid and frozen with dry ice: the freeze-drying was 
carried out at least for 48 h at -50 °C using the instrument 5Pascal Lio5P DGT. 
EP.4 CIRCULAR DICHROISM SPECTROSCOPY 
The circular dichroism measures were registered on the CD instrument Jasco J-715 with Hellma 0.1 cm 
quartz cell in milliQ H2O as solvent. The spectra were elaborated with Origin and the Jasco instrument 
associated software. The values are reported as total molar ellipticity [θ]T (deg × cm2 × dmol-1). 
EP.5 SOLID PHASE RECEPTOR BINDING ASSAYS 
INTEGRIN RECEPTOR 
Purified αvβ3 receptor (Chemicon International, Inc., Temecula, CA) were diluted to 0.5 μg/mL in 
coating buffer containing 20 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L MnCl2, 2 mmol/L 
CaCl2 and 1 mmol/L MgCl2. An aliquot of diluted receptors (100 μL/well) was added to 96-well 
microtiter plates (NUNC MW 96F MEDISORP STRAIGHT) and incubated overnight at 4 °C. The 
plates were then incubated with blocking solution (coating buffer plus 1% bovine serum albumin) for 
additional 2 hours at room temperature to block nonspecific binding followed by 3-hour incubation at 
room temperature with various concentrations (10-12 – 10-5 M) of test compounds in the presence of 1 
μg/mL vitronectin biotinylated using EZ-Link Sulfo-NHS-Biotynilation kit (Pierce, Rockford, IL). After 
washing, the plates were incubated for 1 hour at room temperature with streptavidin-biotinylated 
peroxidase complex (Amersham Biosciences, Uppsala, Sweden) followed by 30 minutes incubation 
with 100 μL Substrate Reagent Solution (R&D Systems, Minneapolis, MN) before stopping the reaction 
by addition of 50 μL of 1 N H2SO4. Absorbance at 415 nm was read in a Synergy™ HT Multi-Detection 
Microplate Reader (BioTek Instruments, Inc.). Each data point is the result of the average of duplicate 
wells and was analysed by nonlinear regression analysis with Prism GraphPad program. 
VEGF RECEPTOR 
The surface of white high-binding 96-well microplates (Corning Life Sciences, Netherlands) was coated 
with 100 μL of phosphate-buffered saline solution (PBS, pH 7.4) containing 200 ng/mL of VEGFR-1 
ECD/Fc chimera (R& D Systems, Minneapolis, MN, USA) and incubated overnight at 4 °C. After three 
washes with 150 μL of PBS 0.1%, (v/v) Tween 20 (buffer A), the plate was blocked by 160 μL of PBS 
with 3% (w/v) of BSA and incubated at r.t. for 2 h. The plate was washed three times with buffer A. 
Then, 100 μL of a solution of btVEGF165 at 131 pM (5 ng/mL) and the tested compounds at various 
concentrations diluted in PBS containing 5% DMSO were added to each well. After 3 h at 37 °C, the 
plate was washed three times with buffer A and 100 μL of streptavidin–horseradish peroxidase diluted 
at 1:1000 in PBS containing 0.1% (v/v) Tween 20 and 0.3% (w/v) BSA were added per well. After 1 h 
of incubation at r.t., the plate was washed five times with 150 μL of buffer A and 100 μL of SuperSignal 
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA) were added. The remaining bt-
VEGF165 was detected by chemiluminescence, which was quantified with a Synergy™ HT Multi-
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Detection Microplate Reader (BioTek Instruments, Inc.). The percentages of btVEGF165 displacement 
were calculated by the following formula: percentage of displacement = 100×[1−(S−NS) / (MS−NS)], 
where S is the signal measured, NS is the nonspecific binding signal and MS is the maximum binding 
signal observed with btVEGF165 without tested compounds. 
EP.6 EVALUATION OF INTEGRIN EXPRESSION BY FLOW CYTOMETRY 
Cells were collected, washed with PBS and counted. For each sample, 5×105 cells were resuspended in 
100 μL of 1% BSA-PBS containing (or not in the case of the negative control) the anti-αVβ3 antibody 
(clone LM609-Millipore MAB 1976) at 1:50 dilution. After incubation for 30 min at 4 °C, samples were 
washed with PBS and incubated with the secondary antibody (CF488A-goat anti-mouse IgG, Biotium 
20011) diluted 1:300 for 30 min at 4 °C. After washing, samples were acquired by a Facscalibur (Becton 
Dickinson) cytometer and analyzed by CellQuest software. 
EP.7 CELL PROLIFERATION ASSAY 
Cells were seeded in 96-well plates with the appropriate complete medium (RPMI 1640 medium with 2 
mM L-glutamine, 10% fetal calf serum, 10 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid, 
and 1 mM sodium pyruvate). 48 h after seeding, the medium was replaced with medium containing serial 
dilutions of the test compounds. The cells were incubated for 144 h at 37 °C. Cell viability was assessed 
with the CellTiter-Glo luciferase-based ATP detection assay (Promega) by following manufacturer’s 
instructions. Growth inhibitory activity was evaluated at the end of incubation by using GraphPad Prism 
software. Experimental data were normalized versus untreated control samples and interpolated by 
nonlinear regression analysis with GraphPad Prism software to generate dose-response curves. IC50 
values were calculated by using sigmoidal interpolation curve fitting. 
EP.8 CELL CULTURES 
HUVE cells were cultured in a medium supplemented with FBS (2%), L-glutamine (10 mM), heparin 
sulfate (0.75 U/mL), VEGF (15 ng/mL), EGF (5 ng/mL), FGF2 (5 ng/mL), IGF-I (15 ng/mL) and 
ascorbic acid (50 µg/mL) at 37 °C, in a moist atmosphere of 5% CO2. HUVECs were used for the 
experiment between passage 2 to 10. 
EP.9 IN VITRO MORPHOGENESIS ASSAYS ON HUVEC 
To assess anti-angiogenic activity, HUVECs (2.5×104 cells) were seeded in a 24-well plate coated with 
100 μL/well of Matrigel previously polymerized for 1 h at 37 °C. Cells were then incubated for 5 h at 
37 °C in a moist atmosphere of 5% CO2 without or with tested compounds under either resting (cell 
cultured in EndoGRO medium alone, without FBS and all the growth factors) or stimulated conditions 
(addition of VEGF, 10 ng/mL). Network formation was evaluated by phase-contrast microscopy using 
a fluorescence microscope (Axiovert 40CFL, Carl Zeiss S.p.A. Milan, Italy). Network formation was 
finally quantified in terms of total length of the branches. For the purpose of the analysis, open 
ramifications were considered as branches. The total branch length (pixels) was quantified using the 
ImageJ image analysis software (http://rsbweb.nih.gov/ij/). 
EP.10 STATISTICAL ANALYSIS 
Data are shown as means ± standard deviation (SD) unless otherwise indicated. Statistical significance 
of the differences was assessed by two-tailed Student’s t test for paired data. Calculations were 
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performed using a commercial software (GraphPad Prism version 5.00 for Windows, GrapPad Software, 
San Diego California USA, www.graphpad.com). 
EP.11 GENERAL PROCEDURES FOR SOLID-PHASE SYNTHESIS 
GP1. GENERAL PROCEDURE 1 FOR KAISER TEST 
A few drops of solution A (80% phenol solution in ethanol), solution B (6% ninhydrin solution in 
ethanol) and solution C (98:2 pyridine/KCN aq. 0.1 mM) were added to a small sample of the resin and 
then shaken at 100 °C for 1 min. If the solution maintained its yellow color, quantitative coupling was 
achieved. On the contrary, in case of a slight blue color, the coupling step was not fully completed and 
it was then repeated. 
GP2. GENERAL PROCEDURE 2 FOR SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) 
The SPPS was accomplished using the semi-automatic synthesizer Biotage® InitiatorTM assisted by 
microwaves. Fmoc/tBu strategy and Rink Amide MHBA Resin (100-200 mesh; loading: 0.5 mmol/g) 
were used for the synthesis of compounds 113-118. Fmoc/tBu strategy and SASRINTM Resin (200-400 
mesh, loading: 1.02 mmol/g) were used for the synthesis of compounds 39, 40 and 84. 
Each coupling step consisted in: 
1) activation of the Fmoc-protected amino acid; 
2) addition of the activated amino acid to the resin at the synthesizer to start the coupling; 
3) steps of capping, deprotection and washing. 
SOLUTIONS AND SOLVENTS 
To perform the automated SPPS, two solutions and two solvents were prepared: 25% Ac2O in DMF 
(v/v), 25% piperidine in DMF (v/v), methanol and DMF. While MeOH was used only as washing 
solvent, DMF was necessary either for washings and as solvent for the reactions of coupling, capping 
and deprotection. 
RESIN PREPARATION 
The resin was weighted in a 10 mL Teflon vial (Biotage®) and processed with the swelling task and the 
swelling-Fmoc deprotection task, required when using Rink Amide MHBA Resin. At the end of these 
operations the resin was ready for the SPPS. 
ACTIVATION OF FMOC-AA-OH AMINO ACIDS 
Procedure A: To a solution of the desired Fmoc-AA-OH (4.0 eq with respect to the resin) in DMF (3.5 
mL, dry solvent) DIC (4.0 eq), HOAt (4.0 eq) and iPr2NEt (8.0 eq) were added at 0 °C, under stirring 
and inert atmosphere. After 25 min, the reaction mixture was added to the resin in the reaction vessel of 
the synthesizer. 
Procedure B: To a solution of the desired Fmoc-AA-OH (3.0 eq with respect to the resin) in DMF (3.5 
mL, dry solvent) HATU (3.0 eq), HOAt (3.0 eq) and iPr2NEt (6.0 eq) were added at 0 °C, under stirring 
and inert atmosphere. After 25 min, the reaction mixture was added to the resin in the reaction vessel of 
the synthesizer. 
RESIN STORAGE 
SASRIN™ Resin: The resin was washed several times with dichloromethane and dried under high 
vacuum. The dry beads were stored at -20 °C. The next SPPS cycle restarted with a swelling-
deprotection step, before continuing the peptide synthesis. 
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Rink Amide MHBA Resin: The on-beads peptides were stored at -20 °C in a small volume of DMF (2-
3 mL), with the terminal amino group of the peptide left Fmoc-protected. The next SPPS cycle restarted 
with a swelling-deprotection step before continuing the peptide synthesis. 
BIOTAGE® INITIATOR PROGRAMS 
The programs “Tasks” used in the SPPS instrument are reported below. Each task can be modified in 
every parameter and it was performed under mechanical stirring at 1000 rpm. 
Swelling 
DMF (3.0 mL) was added to the resin: the swelling was accomplished at r.t. in 30 min. At the end of the 
swelling step, the liquid phase was drained. 
Swelling-Fmoc deprotection 
DMF (3.5 mL) was added to the resin and the swelling step was performed at r.t. for 15 min. Two 
deprotection steps were carried out adding 25% piperidine in DMF (3.0 mL for each step): the reaction 
was performed at r.t. under inert atmosphere for 5 min and 15 min for the first and the second 
deprotection step, respectively. The resin was washed eight times with DMF (3 mL × 30 s for every 
wash). At the end of each step, the liquid phase was drained. 
Coupling (Double coupling)-capping-Fmoc deprotection 
The activated Fmoc-AA-OH residue was added to the resin in the reaction vessel of the synthesizer and 
the coupling reaction assisted by microwaves was carried out at 70 °C under inert atmosphere for 12 
min. When a double coupling was required, another aliquot of the activated Fmoc-AA-OH residue was 
added to the resin and a second coupling reaction was performed. The beads were washed six times with 
DMF (2.5 mL × 20 s for every wash). The capping solution (3 mL) was added to the resin: the capping 
step was performed at r.t. under inert atmosphere for 15 min. The beads were washed six times with 
DMF (2.5 mL × 20 s for every wash). Two deprotection steps were carried out adding the deprotection 
solution (3.0 mL for each step) to the beads: the reaction was performed at r.t. under inert atmosphere 
for 5 min and 7 min for the first and the second deprotection step, respectively. The beads were washed 
twice with DMF, MeOH, DMF, MeOH and DMF (3.0 mL × 20 s for every wash; 3.0 mL × 20 s for the 
last washes in MeOH and DMF). At the end of each step, the liquid phase was drained. 
Coupling (Double coupling)-capping 
The activated Fmoc-AA-OH residue was added to the resin in the reaction vessel of the synthesizer, and 
the coupling reaction assisted by microwaves was carried out at 70 °C under inert atmosphere for 12 
min. When a double coupling was required, another aliquot of the activated Fmoc-AA-OH was added 
to the resin and a second coupling reaction was performed. The beads were washed six times with DMF 
(2.5 mL × 20 s for every wash). The capping solution (3 mL) was added to the resin: the capping step 
was performed at r.t. under inert atmosphere for 15 min. The beads were washed six times with DMF 
(2.5 mL × 20 s for every wash). The beads were washed twice with DMF, MeOH, DMF, MeOH (3.0 
mL × 20 s for every wash). Eventually, the beads were washed eight times with DMF (3.0 mL × 30 s). 
At the end of each step, the liquid phase was drained. 
Capping 
The solution 25% Ac2O in DMF (3 mL) was added to the resin: the capping step was performed at r.t. 
under inert atmosphere for 15 min. The beads were washed six times with DMF (2.5 mL × 20 s for every 
wash). The beads were washed twice with DMF, MeOH, DMF (3.0 mL × 20 s for every wash). 
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Eventually, the beads were washed twice with MeOH (3.0 mL × 30 s) and eight times with DMF (3.0 
mL × 30 s). At the end of each step, the liquid phase was drained. 
GP3. GENERAL PROCEDURE 3 FOR AZIDE REDUCTION ON RESIN 
Azidopeptidyl resin (1.0 eq) was suspended in a 4:1 mixture of dioxane/water. Trimethylphosphine (1 
M solution in toluene, 6.0 eq) was added and the reaction vessel was shaken for 40 min. The resin was 
then washed with dioxane (three times) and the conversion was checked by Kaiser test (GP3). 
GP4. GENERAL PROCEDURE 4 FOR PEPTIDE CLEAVAGE 
All the cleavage reactions from the resin were performed manually, under inert atmosphere and vortex 
mixing. 
Rink Amide MHBA Resin: The protected on-beads peptide was swollen first with DMF (3.5 mL), then 
with dichloromethane (3.5 mL). Under stirring and nitrogen atmosphere, the beads were treated three 
times with the cleavage cocktail (3.0 mL per 0.1 mmol of resin) 90:5:3:2 TFA / thioanisole / EDT / 
anisole (v/v/v/v). After 1 h, the liquid phase was filtered off under nitrogen flow and collected in a round 
bottom flask: the beads were washed with neat TFA (1.0 mL) that was collected. The combined filtered 
fractions were concentrated and poured in cold diethyl ether, provoking precipitation of the product. 
Diethyl ether was removed with a syringe, affording the crude product, which was purified with RP-
HPLC and freeze-dried. 
SASRIN™ Resin: The resin was thoroughly washed with dichloromethane (ten times) and then treated 
with 1% TFA in dichloromethane (2 mL) for 2-5 min. The mixture was filtered off with a N2 pressure 
into a vial containing 0.2 mL of 12% of pyridine in MeOH. The presence of the peptide was monitored 
by TLC (CH2Cl2/MeOH 9:1): after 5-8 cycles the peptide was completely cleaved from the resin. The 
fractions were collected and concentrated at reduced pressure. The mixture was then diluted with AcOEt 
and washed with 1 M KHSO4 (four times). The organic layer was dried over Na2SO4 and concentrated 
affording a white solid. The crude compounds were purified by flash chromatography on silica gel 
(gradient: CH2Cl2/MeOH 95:5 to 8:2) to give the desired products. 
EP.12 GENERAL PROCEDURES FOR SOLUTION-PHASE SYNTHESIS  
GP5. GENERAL PROCEDURE 5 FOR BOC DEPROTECTION REACTIONS 
To a solution of the N-Boc-protected amino acid or peptide in CH2Cl2 (0.13 M) was added half volume 
of TFA and the reaction was stirred at r.t. for 2 h. The solvent was evaporated, toluene (two times) was 
added followed by evaporation, and then ether was added and evaporated to afford the corresponding 
TFA salt. 
GP6. GENERAL PROCEDURE 6 FOR CBZ-CARBAMATE AND BENZYL ESTER HYDROGENOLYTIC CLEAVAGE 
Protected compound (1.0 eq) was dissolved in a mixture of THF/H2O (1:1) and Pd/C 10% (0.1 eq) was 
added. The reaction mixture was subjected to three vacuum/hydrogen cycles and then left stirring 
overnight at room temperature under 1 bar of hydrogen. The mixture was filtered through Celite, and 
the cake was washed thoroughly with THF/H2O (1:1) or MeOH. The filtrate was concentrated and dried. 
GP7. GENERAL PROCEDURE 7 FOR MACROLACTAMIZATION REACTIONS 
Procedure A: HATU (4.0 eq), HOAt (4.0 eq) and iPr2NEt (6.0 eq) were added successively to a solution 
of deprotected linear compound (1.0 eq) in DMF (1.4 mM), under a nitrogen atmosphere at 0°C. After 
stirring the reaction mixture at 0 °C for 1 h, it was allowed to reach room temperature and stirred 
overnight. DMF was then removed under reduced pressure. 
Procedure B: HATU (4.0 eq), HOAt (4.0 eq) and iPr2NEt (6.0 eq) were added successively to a solution 
of deprotected linear compound (1.0 eq) in DMF/CH2Cl2 1:1 (1.4 mM), under a nitrogen atmosphere at 
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0 °C. After stirring the reaction mixture at 0 °C for 1 h, it was allowed to reach room temperature and 
stirred overnight. DMF was then removed under reduced pressure. 
GP8. GENERAL PROCEDURE 8 FOR MTR AND OTBU ESTER REMOVAL 
Procedure A: Protected macrolactam was treated for 2 h with TFA (0.01 M), in the presence of ion 
scavengers: thioanisole (5%), ethanedithiol (3%), anisole (2%). After TFA removal under reduced 
pressure, the residue was dissolved in a 1:1 mixture of diisopropyl ether/water. Phases were separated 
and the aqueous layer was washed several times with diisopropyl ether. The aqueous phase was 
concentrated under reduced pressure to give the crude product, which was purified by HPLC. 
Procedure B: Protected macrolactam was treated for 2 h with TFA (0.01 M), in the presence of ion 
scavengers. For 10 mL of TFA, thioanisole (1.5 mL), ethanedithiol (0.75 mL) and phenol (150 mg) were 
required. The mixture was cooled to 0 °C and flushed with N2. Trimethylsilylbromide (2 mL) was then 
added, the flask was open and the mixture warmed up to room temperature and stirred for 2 h. After 
TFA removal under reduced pressure, the residue was dissolved in a 1:1 mixture of diisopropyl 
ether/water. Phases were separated and the aqueous layer was washed several times with diisopropyl 
ether. The aqueous phase was concentrated under reduced pressure to give the crude product, which was 
purified by HPLC. 
  
66 EXPERIMENTAL PART  
 
SYNTHESIS OF SCAFFOLDS N3-DKP5-COOH 41 AND N3-DKP5-COOH 42 
N3-DKP5-COOAllyl 53, N3-DKP7-COOAllyl 54, N3-DKP2-COOAllyl 43, N3-DKP3-COOAllyl 44, 
cyclo[DKP2-isoDGR] 25 and cyclo[DKP3-isoDGR] 26 were synthesized according to literature 
procedure and their analytical data were in agreement with those already published.27 
 
Reagents and conditions: a) KHMDS, BnBr, THF/DMF, -70 to -40 °C, 5 h, 66%; b) [Pd(PPh3)4], N-methylaniline, CH2Cl2, 0 
°C, 1 h, 70%. 
N3-DKP5-COOAll 53 and N3-DKP7-COOAll 54 
 
The reaction was performed in a flame-dried flask under nitrogen atmosphere. KHMDS (111 mg, 0.55 
mmol, 1.1 eq) was dissolved in dry toluene to give a 0.5 M solution. The solution was cooled to -70 °C 
and 43 or 44 (180 mg, 0.5 mmol, 1.0 eq), previously dissolved in dry THF (9.9 mL), was added dropwise. 
The mixture was stirred under these conditions for 30 minutes, then benzyl bromide (0.30 μL, 2.5 mmol, 
5.0 eq) and DMF (4.2 mL) were sequentially added under these conditions. The reaction was allowed 
to reach -40 °C and it was stirred under these conditions for 5 h. After this time, a saturated solution of 
NH4Cl was added and the mixture was extracted three times with AcOEt (3 × 40 mL). Organic layers 
were combined, washed with brine and dried over Na2SO4 anhydrous. Volatiles were removed under 
reduced pressure then the crude was purified by flash chromatography on silica gel eluting 
Hexane/AcOEt (from 7:3 to 6:4). The product was recovered as a transparent oil (134 mg, 66%). 
Rf = 0.4 (Hexane/AcOEt 6:4); 1H-NMR (400 MHz, CDCl3,) δ 7.40 – 7.23 (m, 10H, overlapped with 
solvent signal), 5.82 (ddt, J = 16.4, 10.8, 5.9 Hz, 1H), 5.36 (dd, J = 15.4, 6.3 Hz, 2H), 5.31 – 5.21 (m, 
2H), 4.50 (ddd, J = 45.8, 13.0, 5.9 Hz, 2H), 4.27 – 4.20 (m, 1H), 4.17 – 4.16 (m, 1H), 4.16 (d, J = 15.3 
Hz, 1H), 4.10 (d, J = 14.8 Hz, 2H), 3.74 (dd, J = 12.8, 3.1 Hz, 1H), 3.31 (dd, J = 17.6, 2.7 Hz, 1H), 2.93 
(dd, J = 17.6, 5.0 Hz, 1H). 13C-NMR (101 MHz, CDCl3) δ 169.5, 166.1, 164.9, 135.3, 131.8, 128.8, 
128.8, 128.6, 128.1, 128.0, 127.9, 127.8, 127.8, 127.3, 126.6, 118.4, 103.7, 65.6, 58.4, 55.0, 51.4, 47.1, 
47.0, 34.8. MS (ESI) m/z calcd. for [C24H24N5O4Na]+: 470.2; found: 470.4 [M+Na]+. 
N3-DKP5-COOH 41 and N3-DKP7-COOH 42 
 
N3-DKP5-COOAll (53) or N3-DKP7-COOAll (54) (120 mg, 0.27 mmol, 1.0 eq) was dissolved in 
CH2Cl2 (2.7 mL) under a nitrogen atmosphere, and the mixture was cooled to 0 °C. [Pd(PPh3)4] (94 mg, 
0.08 mmol, 0.3 eq) and freshly distilled N-methylaniline (35 μL, 0.32 mmol, 1.2 eq) were added 
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successively. The mixture was then allowed to reach room temperature. After 1 h of stirring, the mixture 
was diluted with AcOEt (40 mL) and extracted with aqueous NaHCO3 (4 × 20 mL). The combined 
aqueous phases were acidified to pH 2 by adding KHSO4 (1 M solution) and then extracted with CH2Cl2 
(4 × 20 mL). The resulting organic phase was dried over Na2SO4 and the solvent was evaporated to 
afford the desired product as a slightly yellow solid (77 mg, 70%) which was used without further 
purification. 
Rf = 0.20 (Hexane/AcOEt 1:1); 1H-NMR (400 MHz, CDCl3) δ 7.40 – 7.27 (m, 10H, overlapped with 
solvent signal), 5.46 (dd, J = 40.1, 15.4 Hz, 2H), 4.25 (s, 1H), 4.11 – 4.06 (m, 2H), 4.04 (s, 1H), 4.00 (s, 
1H), 3.76 (dd, J = 12.7, 2.9 Hz, 1H), 3.36 (dd, J = 17.7, 2.2 Hz, 1H), 2.96 (dd, J = 17.7, 5.0 Hz, 1H). 
13C-NMR (101 MHz, CDCl3) δ 173.8, 166.1, 165.3, 134.8, 134.4, 129.1, 129.0, 128.2, 128.1, 127.9, 
127.8, 58.2, 54.3, 51.4, 47.1, 46.9, 34.2. MS (ESI) m/z calcd. for [C21H20N5O4Na]+: 430.15; found: 
430.10 [M+Na]+. 
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SYNTHESIS OF CYCLO[DKP5-ISODGR] 39 AND CYCLO[DKP7-ISODGR] 40 
The synthesis of cyclo[DKP5-isoDGR] (39) and cyclo[DKP7-isoDGR] (40) was accomplished as 
described in EP.11 GENERAL PROCEDURES FOR SOLID-PHASE SYNTHESIS, using SASRINTM: the exact 
amounts of reagents used in the solid-phase peptide synthesis are reported in TABLE 11 for cyclo[DKP5-
isoDGR] (39) and in TABLE 12 for cyclo[DKP7-isoDGR] (40). 
 
Reagents and conditions: a) Fmoc-Gly-OH, DIC, DMAP (cat.), DMF; b) 2% piperidine and 2% DBU in DMF; c) Fmoc-
Asp(OH)-OtBu, DIC, HOAt, DMF; d) 2% piperidine and 2% DBU in DMF; e) 41-42, DIC, HOAt, DMF; f) PMe3, 
dioxane/water 4:1, 20 min × 3 times; g) Cbz-Arg(Mtr)-OH, DIC, HOAt, DMF; h) 1% TFA in CH2Cl2, r.t., 5 min × 10 times, 
71-81%; i) H2, 10% Pd/C, THF/H2O 1:1, 98%-quant.; j) HATU, HOAt, iPr2NEt, DMF (1.4 mM), 32%; k) 
TFA/thioanisole/EDT/anisole 90:5:3:2, 25-37%. 
TABLE 11. Amounts of reagents used in the SPPS of compound 39. 
REAGENTS eq or concentration mmol amounts 
SASRINTM Resin 1.0 eq 0.2 200 mg 
Fmoc-Gly-OH* 4.0 eq 0.8 238 mg 
DIC 4.0 eq 0.8 124 µL 
DMAP 0.1 eq 0.02 2.4 mg 
DMF 0.27 M / 3 mL 
Fmoc-L-Asp(OH)-OtBu* 3.0 eq 0.6 247 mg 
DIC 3.0 eq 0.6 93 µL 
HOAT 3.0 eq 0.6 82 mg 
DMF 0.20 M / 3 mL 
N3-DKP5-COOH 45 2.3 eq 0.46 185 mg 
DIC 2.3 eq 0.46 71 µL 
HOAT 2.3 eq 0.46 63 mg 
DMF 0.15 M / 3 mL 
Cbz-L-Arg(Mtr)-OH ∙ CHA* 2.5 eq 0.5 310 mg 
DIC 2.5 eq 0.5 77 µL 
HOAT 2.5 eq 0.5 68 mg 
DMF 0.17 M / 3 mL 
* a double coupling step was performed. 
 EXPERIMENTAL PART 69 
 
TABLE 12. Amounts of reagents used in the SPPS of compound 40. 
REAGENTS eq or concentration mmol amounts 
SASRINTM resin 1.0 eq 0.1 100 mg 
Fmoc-Gly-OH* 4.0 eq 0.4 119 mg 
DIC 4.0 eq 0.4 62 µL 
DMAP 0.1 eq 0.01 1.2 mg 
DMF 0.27 M / 1.5 mL 
Fmoc-L-Asp(OH)-OtBu* 3.0 eq 0.3 124 mg 
DIC 3.0 eq 0.3 47 µL 
HOAT 3.0 eq 0.3 41 mg 
DMF/DCM 0.20 M / 1.5 mL 
N3-(3S,6R)-DKP-COOH 9 2.3 eq 0.23 93 mg 
DIC 2.3 eq 0.23 36 µL 
HOAT 2.3 eq 0.23 32 mg 
DMF/DCM 0.15 M / 1.5 mL 
Cbz-L-Arg(Mtr)-OH ∙ CHA* 2.5 eq 0.25 155 mg 
DIC 2.5 eq 0.25 39 µL 
HOAT 2.5 eq 0.25 34 mg 
DMF 0.17 M / 1.5 mL 
* a double coupling step was performed. 
Cbz-Arg(Mtr)-DKP5-isoAsp(OtBu)-Gly-OH (45) 
Cbz-Arg(Mtr)-DKP7-isoAsp(OtBu)-Gly-OH (46) 
 
The linear carboxylic acids 41 and 42 were obtained by cleaving the corresponding supported 
compounds from the resin according to GP4. The desired products were obtained as white foams (45: 
157 mg, 71%; 46: 90 mg, 81%). 
Compound 45: 
Rf = 0.15 (CH2Cl2/MeOH 9:1); 1H-NMR (400 MHz, CD3OD) δ 7.43 – 7.20 (m, 15H), 6.63 (s, 1H), 5.39 
(d, J = 15.4 Hz, 1H), 5.14 – 4.99 (m, 3H), 4.57 (t, J = 6.2 Hz, 1H), 4.38 (s, 1H), 4.32 (dd, J =15.5, 6.9 
Hz, 2H), 4.09 (s, 1H), 4.03 (s, 1H), 3.80 (s, 5H), 3.74 (s, 2H), 3.19 – 3.04 (m, 3H), 2.90 (dd, J = 16.9, 
4.5 Hz, 1H), 2.72 – 2.64 (m, 5H), 2.59 (s, 3H), 2.10 (s, 3H), 1.68 (s, 1H), 1.58 – 1.38 (m, 12H). 13C-
NMR (101 MHz, CD3OD) δ 178.2, 175.4, 172.1, 171.5, 171.1, 168.7, 167.8, 159.9,158.4, 158.2, 139.5, 
138.1, 137.9, 137.1, 136.8, 134.8, 130.0, 130.0, 129.5, 129.4, 129.0, 128.9,125.7, 112.8, 83.2, 67.9, 59.8, 
56.8, 56.3, 56.0, 51.6, 44.5, 40.5, 38.6, 36.4, 30.1, 28.3, 24.4, 18.9, 12.1. MS (ESI) m/z calcd. for 
[C55H70N9O14S]+: 1112.5; found: 1112.5 [M+H]+. 
Compound 46: 
Rf = 0.15 (CH2Cl2/MeOH 9:1); 1H NMR (400 MHz, CD3OD) δ 7.43 – 7.20 (m, 15H), 6.63 (s, 1H), 5.39 
(d, J = 15.4 Hz, 1H), 5.14 – 4.98 (m, 3H), 4.57 (t, J = 6.2 Hz, 1H), 4.38 (bs, 1H), 4.32 (dd, J = 15.4, 6.9 
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Hz, 2H), 4.09 (bs, 1H), 4.03 (bs, 1H), 3.80 (bs, 5H), 3.74 (s, 2H), 3.21 – 3.08 (m, 3H), 2.90 (dd, J = 
16.9, 4.5 Hz, 1H), 2.72 – 2.64 (m, 5H), 2.59 (s, 3H), 2.10 (s, 3H), 1.75 – 1.63 (m, 1H), 1.63 – 1.39 (m, 
13H). 13C NMR (101 MHz, CD3OD) δ 172.3, 171.4, 171.0, 168.5, 167.8, 159.9, 159.4, 158.2, 139.5, 
137.9, 137.6, 136.7, 130.0, 129.9, 129.6, 129.2, 128.9, 125.7, 112.8, 83.2, 67.78, 59.7, 57.2, 56.0, 54.0, 
51.1, 50.5, 47.9, 42.5, 40.4, 38.4, 37.0, 30.5, 28.2, 24.3, 18.8. MS (ESI) m/z calcd. for [C55H70N9O14S]+: 
1156.4; found: 1156.6 [M+2Na-H]+. 
H-Arg(Mtr)-DKP5-isoAsp(OtBu)-Gly-OH (47) 
H-Arg(Mtr)-DKP7-isoAsp(OtBu)-Gly-OH (48) 
 
Compound 45 or 46 (45: 145 mg, 0.14 mmol, 1.0 eq; 46: 90 mg, 0.08 mmol, 1.0 eq) was treated with 
10% Pd/C (45: 14 mg, 0.014 mmol, 0.1 eq; 46: 8 mg, 0.008 mmol, 0.1 eq) under the conditions described 
in GP6. The desired products were obtained as white solids (47: 134 mg, 98%; 48: 80 mg, quantitative 
yield) and they were used without further purification. 
Compound 47: 
1H-NMR (400 MHz, CD3OD) δ 7.44 – 7.15 (m, 10H), 6.64 (s, 1H), 5.45 (d, J = 15.4 Hz, 1H), 4.58 (t, J 
= 4.9 Hz, 1H), 4.43 (d, J = 15.4 Hz, 1H), 4.34 (bs, 1H), 4.24 (d, J = 15.7 Hz, 1H), 4.11 (bs, 1H), 3.90 
(s, 3H), 3.79 (s, 3H), 3.71 (dd, J = 14.2, 5.9 Hz, 1H), 3.24 – 3.10 (m, 2H), 3.06 (d, J = 15.2 Hz, 1H), 
2.92 (dd, J = 16.8, 4.9 Hz, 1H), 2.72 (d, J = 6.0 Hz, 2H), 2.66 (s, 3H), 2.59 (s, 3H), 2.10 (s,3H), 1.88-
1.75 (m, J = 14.3, 7.1 Hz, 2H), 1.61-1.49 (m, 2H), 1.43 (s, 9H), 1.46 – 1.35 (m, 2H). 13C-NMR (101 
MHz, CD3OD) δ 172.4, 171.3, 171.0, 170.8, 168.7, 167.8, 163.0, 162.7, 159.9, 158.1, 139.4, 137.9, 
137.3, 136.6, 134.5, 129.9, 129.8, 129.4, 129.1, 128.8, 128.1, 126.1, 125.7, 112.8, 83.2, 59.2, 57.7, 56.9, 
56.0, 53.9, 51.3, 50.4, 49.8, 48.0, 41.9, 40.7, 38.3, 36.4, 35.8, 30.8, 30.7,30.5, 29.6, 28.2, 24.3, 18.8, 
12.1. MS (ESI) m/z calcd. for [C47H64N9O12S]+: 978.4; found: 978.7 [M+H]+. 
Compound 48: 
MS (ESI) m/z calcd. for [C47H63N9O12SNa]+: 1000.4; found: 1000.5 [M+Na]+. 
Cyclo[DKP5-isoAsp(OtBu)-Gly-Arg(Mtr)] (49) 
Cyclo[DKP7-isoAsp(OtBu)-Gly-Arg(Mtr)] (50) 
 
Compound 47 (127 mg, 0.13 mmol, 1.0 eq) was cyclized in the presence of HATU (198 g, 0.52mmol, 
4.0 eq), HOAt (71 mg, 0.52 mmol, 4.0 eq) and iPr2NEt (136 μL, 0.78 mmol, 6.0 eq) under the conditions 
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described in GP7 (Procedure A). The crude product was purified by RP-HPLC (gradient: 90% H2O + 
0.1% TFA / 10% CH3CN + 0.1% TFA to 100% CH3CN + 0.1% TFA in 10 min; tR (product) = 4.6 min) 
to afford the desired product 49 as a white foam (39 mg, 32%). 
Compound 49: 
1H-NMR (400 MHz, CD3OD) δ 7.44 – 7.15 (m, 10H), 6.68 (s, 1H), 5.37 (d, J = 15.1 Hz, 1H), 5.26 (d, 
J = 16.0 Hz, 1H), 5.15 (d, J = 8.0 Hz, 1H), 4.73-4.62 (m, J = 5.4 Hz, 1H), 4.40 (d, J = 16.1 Hz,1H), 4.29 
– 4.07 (m, 4H), 3.99 (s, 1H), 3.83 (s, 3H), 3.68 (d, J = 16.5 Hz, 1H), 3.47 (d, J = 13.5 Hz,1H), 3.37 (s, 
1H), 3.28 – 3.15 (m, 2H), 2.86 (dd, J = 14.6, 3.3 Hz, 1H), 2.77 (d, J = 6.6 Hz, 2H), 2.70 (s, 3H), 2.64 
(s, 3H), 2.34 – 2.23 (m, 1H), 2.15 (s, 3H), 1.80 – 1.55 (m, J = 18.4, 14.0, 5.9 Hz, 3H), 1.49 (s, 9H). 13C-
NMR (101 MHz, CD3OD) δ 175.4, 172.2, 171.7, 171.2, 171.1, 167.8, 167.1, 160.0, 157.9, 139.5, 138.8, 
136.8, 130.1, 129.8, 129.5, 129.2, 128.9, 128.4, 128.1 , 125.8, 112.9, 83.4, 60.0, 59.4, 56.0, 55.0, 51.8, 
51.3, 49.9, 47.7, 42.8, 40.5, 38.8, 29.0, 28.2, 24.3, 18.8, 12.1. MS(ESI) m/z calcd. for [C47H62N9O11S]+: 
960.4 [M+H]+; found: 960.6. 
Compound 48 (40 mg, 0.04 mmol, 1.0 eq) was cyclized in the presence of HATU (60 mg, 0.16 mmol, 
4.0 eq), HOAt (22 mg, 0.16 mmol, 4.0 eq) and iPr2NEt (62 μL, 0.24 mmol, 6.0 eq) under the conditions 
described in GP7 (Procedure A). The residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH 97:3 to 9:1, solid load) affording the crude product 50 as a pale yellow foam. 
Compound 50: 
Rf = 0.16 (CH2Cl2/MeOH 9:1). MS (ESI) m/z calcd. for [C47H62N9O11S]+: 960.4; found: 960.6 [M+H]+. 
Cyclo[DKP5-isoDGR] (39) 
Cyclo[DKP7-isoDGR] (40) 
 
Compound 49 (39 mg, 0.04 mmol, 1.0 eq) or 50 (15 mg, 0.015 mmol, 1.0 eq) was deprotected under the 
conditions described in GP8 (Procedure A). The crude product was purified by RP-HPLC (compound 
39 = gradient: 90% H2O + 0.1% TFA / 10% CH3CN + 0.1% TFA to 100% CH3CN + 0.1% TFA in 10 
min; flow: 15 mL/min, tR (product) = 5.7 min; compound 40 = gradient: 100% H2O + 0.1% TFA to 50% 
H2O + 0.1% TFA / 50% CH3CN + 0.1% TFA in 11 min; tR (product) = 9.6 min). The pure fractions 
were concentrated and freeze-dried from water, affording 39 or 40 as a white solid (39: 12.5 mg, 37%; 
40: 3.0 mg, 25%). 
Compound 39: 
1H-NMR (400 MHz, D2O) δ 7.54 – 7.31 (m, 10H), 5.26 (d, J = 15.3 Hz, 1H), 5.09 – 5.00 (m, 2H), 
4.79(d , 1H), 4.67 (d, J = 16.4 Hz, 1H), 4.33 – 4.30 (m, 1H), 4.29 – 4.17 (m, 3H), 4.11 (dd, J = 14.7, 
3.6Hz, 1H), 3.91 (d, J = 16.8 Hz, 1H), 3.68 (dd, J = 14.6, 1.6 Hz, 1H), 3.25 (t, J = 6.8 Hz, 2H), 3.02 (dd, 
J = 14.8, 3.9 Hz, 1H), 2.90 (d, J = 5.9 Hz, 2H), 2.45 (dd, J = 14.8, 11.2 Hz, 1H), 1.88 – 1.55 (m, 4H).13C-
NMR (101 MHz, D2O) δ 175.3, 174.2, 172.1, 171.5, 170.5, 156.8, 135.8, 135.1, 129.2,128.9, 128.3 
128.1, 127.7, 126.8, 66.6, 59.1, 57.7, 54.2, 50.1, 49.7, 47.2, 41.6, 40.7, 40.4, 39.8, 37.3, 27.5, 24.4. 
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Compound 40: 
1H-NMR (400 MHz, CD3OD) δ 7.48 – 7.15 (m, 10H), 5.20 (d, J = 15.4 Hz, 1H), 4.68 – 4.56 (m, 2H), 
4.50 (dd, J = 9.4, 2.4 Hz, 1H), 4.43 – 4.37 (m, 1H), 4.27 (d, J = 5.4 Hz, 1H), 4.19 (d, J = 15.4 Hz,1H), 
4.07 (d, J = 8.8 Hz, 1H), 4.03 (d, J = 5.4 Hz, 1H), 3.75 – 3.65 (m, 2H), 3.13 (dd, J = 11.7, 6.5Hz, 2H), 
2.96 (dd, J = 15.3, 8.6 Hz, 1H), 2.83 (dd, J = 14.5, 2.4 Hz, 1H), 2.67 (dd, J = 15.3, 3.8 Hz,1H), 2.55 (dd, 
J = 14.5, 9.5 Hz, 1H), 1.94-1.83 (m, 1H), 1.62-1.48 (m, 3H), 1.32-1.20 (m, 2H); 13C-NMR (101 MHz, 
CD3OD, HSQC projection) δ 135.2, 129.2, 129.0, 128.3, 127.7, 126.7, 59.7, 56.3, 53.2, 52.2, 47.8, 40.5, 
39.4, 36.5, 26.9, 24.4.  
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SYNTHESIS OF CYCLO[DKP3-ISODGR]-CH2NH2 PEPTIDOMIMETIC 56 
N3-DKP3(CH2NHMtr)-COOAllyl 57 was synthesized according to literature procedure and its 
analytical data were in agreement with those already published.40 
 
Reagents and conditions: a) TFA, CH2Cl2, r.t., 2 h; b) Cbz-Arg(Mtr)-OH, HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 
94% over 2 steps; c) HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 86%; d) piperidine, DMF, 2 h, r.t., 67%; 
e) [Pd(PPh3)4], N-Methylaniline, CH2Cl2, 0 °C, 1 h, 88%; f) 62, HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 95%; 
g) H2, 10% Pd/C, THF/H2O 1:1, overnight, r.t., 95%; h) HATU, HOAt, iPr2NEt, DMF/CH2Cl2 1:1 (1.4 mM), 0 °C to r.t., 
overnight, 79%; i) TFA/TMSBr/thioanisole/EDT/phenol 70:14:10:5:1, 2 h, r.t., 47%. 
FmocHN-isoAsp(OtBu)-Gly-OBn (61) 
 
To a solution of Fmoc-L-Asp(OH)-OtBu (1.15 g, 2.80 mmol, 1.2 eq) in DMF (28 mL), at 0 °C and under 
nitrogen atmosphere, HATU (1.06 g, 2.80 mmol, 1.2 eq), HOAt (380 mg, 2.80 mmol, 1.2 eq) and 
iPr2NEt (810 µL, 4.66 mmol, 2.0 eq) were added: the reaction mixture was stirred at 0 °C for 30 min. A 
solution of H2N-Gly-OBn∙TFA (650 mg, 2.3 mmol, 1.0 eq) in DMF (30 mL) and iPr2NEt (1.22 mL, 
2.33 mmol, 3.0 eq) was added dropwise to the previous solution: the reaction mixture was stirred at 0 
°C for 1 h and at room temperature overnight. The mixture was diluted with AcOEt (500 mL) and 
washed with KHSO4 1 M (3 × 100 mL), saturated aqueous NaHCO3 (3 × 100 mL) and brine (1 × 100 
mL). The organic phase was dried over Na2SO4 and volatiles were removed under reduced pressure. 
The residue was purified by flash chromatography on silica gel (CH2Cl2 100% to CH2Cl2/MeOH 9:1, 
solid load) affording the desired product 61 as a white foam (1.3 g, quantitative). 
Rf = 0.8 (CH2Cl2/MeOH 9:1); 1H-NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.61 (d, J = 7.4 
Hz, 2H), 7.44 – 7.27 (m, 9H), 6.20 (s, 1H), 6.02 (d, J = 8.1 Hz, 1H), 5.16 (s, 2H), 4.50 (dt, J = 8.1, 4.2 
Hz, 1H), 4.36 (m, 2H), 4.22 (t, J = 7.1 Hz, 1H), 4.07 (d, J = 5.1 Hz, 2H), 2.96 (dd, J = 15.8, 4.3 Hz, 1H), 
2.79 (dd, J = 15.8, 4.3 Hz, 1H), 1.47 (s, 9H). 13C-NMR (101 MHz, CDCl3) δ 170.1, 170.0, 169.7, 156.3, 
144.1, 141.4, 135.2, 128.81 128.8, 128.6, 127.8, 127.2, 125.4, 120.1, 82.7, 67.5, 67.3, 51.4, 47.3, 41.5, 
38.1, 28.0. MS (ESI) m/z calcd. for [C32H34N2NaO7]+: 581.6; found: 581.4 [M+Na]+. 
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H-isoAsp(OtBu)-Gly-OBn (62) 
 
To a solution of 61 (1.3 g, 2.33 mmol, 1.0 eq) in DMF (47 mL), at 0 °C under nitrogen atmosphere, 
piperidine (1.15 mL, 11.16 mmol, 5.0 eq) was added and the reaction mixture was stirred at 0 °C for 10 
min and at room temperature for 3 h. The mixture was diluted with AcOEt (400 mL) and washed with 
H2O (4 × 100 mL). The organic phase was dried over Na2SO4 and volatiles were removed under reduced 
pressure. The residue was purified using a Grace Reveleris system (column: Reveleris Silica 40 g; liquid 
load; flow rate: 33 mL/min; gradient: CH2Cl2/MeOH 98:2 to 8:2 in 35 min) affording the desired product 
62 as a white foam (613 mg, 78%). 
Rf = 0.35 (CH2Cl2/MeOH 95:5); 1H-NMR (400 MHz, CDCl3) δ 7.92 (bs, 1H), 7.38 – 7.27 (m, 5H), 5.13 
(s, 2H), 4.04 (qd, J = 18.2, 5.4 Hz, 2H), 3.67 (dd, J = 9.1, 3.2 Hz, 1H), 2.66 (dd, J = 15.5, 3.2 Hz, 1H), 
2.44 (dd, J = 15.5, 9.1 Hz, 1H), 2.12 (bs, 2H), 1.42 (s, 9H). MS (ESI) m/z calcd. for [C17H24N2NaO5]+: 
359.4; found: 359.1 [M+Na]+. 
BocHN-DKP3(CH2NHMtr)-COOAllyl (68) 
 
To a solution of azide 57 (1.00 g, 1.67 mmol, 1.0 eq) in THF (28 mL), at -20 °C and under nitrogen 
atmosphere, PMe3 (4.2 mL of 1 M solution in THF, 4.18 mmol, 2.5 eq) and 2-(t-
butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON, 1.03 g, 4.18 mmol, 2.5 eq) were added: the 
reaction was stirred at room temperature for 5 h.The mixture was diluted with CH2Cl2 (270 mL) and 
washed with H2O (4 × 100 mL) and brine (1 × 100 mL). The organic phase was dried over Na2SO4 and 
volatiles were removed under reduced pressure. The residue was purified by flash chromatography on 
silica gel (100% CH2Cl2 to CH2Cl2/MeOH 9:1) affording the desired product 68 as a white foam (790 
mg, 70%). 
Rf = 0.23 (Hexane/AcOEt 3:7); 1H-NMR (400 MHz, CDCl3) δ 7.22 – 7.11 (m, 4H), 6.80 (s, 1H), 6.59 
(s, 1H), 5.90 (ddt, J = 16.3, 10.5, 5.8 Hz, 1H), 5.41 (d, J = 15.2 Hz, 1H), 5.37 – 5.30 (m, 1H), 5.29 – 
5.24 (m, 1H), 5.02 – 4.93 (m, 1H), 4.63 (d, J = 5.8 Hz, 2H), 4.44 (dd, J = 9.3, 3.2 Hz, 1H), 4.04 (s, 2H), 
3.86 (s, 3H), 3.77 – 3.66 (m, 2H), 3.50 (d, J = 12.7 Hz, 1H), 3.29 (dd, J = 17.6, 3.2 Hz, 1H), 2.76 (dd, J 
= 17.6, 9.3 Hz, 1H), 2.68 (s, 3H), 2.56 (s, 3H), 2.14 (s, 3H), 1.43 (s, 9H). MS (ESI) m/z calcd for 
[C33H45N4O9S]+: 673.3; found: 673.3 [M+H]+. 
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Cbz-Arg(Mtr)-DKP3(CH2NHMtr)-COOAllyl (70) 
 
Cbz-Arg(Mtr)-OH (850 mg, 1.63 mmol, 1.2 eq) was dissolved in DMF (12 mL) under nitrogen 
atmosphere. HATU (621 mg, 1.63 mmol, 1.2 eq), HOAt (222 mg, 1.63 mmol, 1.2 eq) and iPr2NEt (711 
µL, 4.08 mmol, 3.0 eq) were added at 0 °C: the mixture was stirred at 0 °C for 30 minutes. BocHN-
DKP3(CH2NHMtr)-COOAllyl (68) was deprotected according to GP5. The corresponding 
trifluoroacetate 69 (931 mg, 1.36 mmol, 1.0 eq) was dissolved in DMF (15 mL) and iPr2NEt (237 µL, 
1.36 mmol, 1.0 eq) was added: this mixture was added to the previous solution of Cbz-Arg(Mtr)-OH in 
DMF and the reaction mixture was stirred at 0 °C for 1 h, then at room temperature overnight. The 
mixture was diluted with AcOEt (270 mL) and washed with KHSO4 1 M (3 × 90 mL), saturated aqueous 
NaHCO3 (3 × 90 mL) and brine (1 × 100 mL). The organic phase was dried over Na2SO4 and the volatiles 
were removed under reduced pressure. The residue was purified using a Grace Reveleris system 
(column: Reveleris Silica 12 g; dry load; flow rate: 27 mL/min; gradient: CH2Cl2/MeOH 98:2 to 9:1 in 
35 min) affording the desired product 70 as a white foam (1.28 g, 90%). 
Rf = 0.5 (CH2Cl2/MeOH 9:1); 1H-NMR (400 MHz, CD3OD) δ 7.37 – 7.25 (m, 5H), 7.13 (dd, J = 33.7, 
8.1 Hz, 4H), 6.67 (s, 1H), 6.63 (s, 1H), 5.96 – 5.84 (m, 1H), 5.34 – 5.27 (m, 2H), 5.22 – 5.17 (m, 1H), 
5.07 (dd, J = 12.5 Hz, 2H), 4.64 – 4.50 (m, 3H), 4.13 – 4.07 (m, 1H), 4.05 – 3.98 (m, 3H), 3.90 – 3.82 
(m, 4H), 3.81 (s, 3H), 3.78 – 3.74 (m, 1H), 3.60 (dd, J = 12.0 Hz, 1H), 3.21 (bs, 1H), 3.15 – 3.10 (m, 
1H), 3.06 (dd, J = 17.5, 4.5 Hz, 1H), 2.88 (dd, J = 17.5, 4.5 Hz, 1H), 2.66 (s, 3H), 2.60 (s, 6H), 2.48 (s, 
3H), 2.10 (s, 3H), 2.07 (s, 3H), 1.83 – 1.64 (m, 1H), 1.79 – 1.66 (m, 1H), 1.62 – 1.47 (m, 3H). 13C-NMR 
(101 MHz, CD3OD) δ 171.3, 168.8, 168.2, 160.7, 159.9, 158.2, 139.9, 139.5, 138.6, 137.9, 136.0, 134.8, 
133.5, 131.0, 129.5, 129.4, 129.2, 129.1, 128.9, 126.1, 125.7, 118.6, 113.2, 112.8, 67.8, 66.5, 60.4, 56.2, 
56.0, 52.0, 47.8, 46.9, 40.1, 37.0, 30.2, 24.4, 24.3, 18.8, 18.2, 12.1. MS (ESI) m/z calcd. for 
[C52H66N8NaO13S2]+: 1097.4; found: 1097.4 [M+Na]+. 
Cbz-Arg(Mtr)-DKP3(CH2NHMtr)-COOH (71) 
 
To a solution of 70 (1.26 g, 1.17 mmol, 1.0 eq) under nitrogen atmosphere at 0 °C, [Pd(PPh3)4] (392 mg, 
0.35 mmol, 0.3 eq) and N-methylaniline (106 µL, 0.98 mmol, 1.2 eq) were added. The reaction mixture 
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was stirred 5 min at 0 °C and 2 h at room temperature. The mixture was diluted with CH2Cl2 (150 mL) 
and washed with KHSO4 1 M (4 × 50 mL). The organic phase was dried over Na2SO4 and volatiles were 
removed under reduced pressure. The residue was purified using a Grace Reveleris system (column: 
Reveleris HP Silica 40 g; liquid load; flow rate: 33 mL/min; gradient: CH2Cl2/MeOH 98:2 to 8:2 in 1 h) 
affording the desired product 71 as a pale yellow foam (1 g, 82%). 
Rf = 0.2 (CH2Cl2/MeOH 95:5). 1H-NMR (400 MHz, CD3OD) δ 7.37 – 7.24 (m, 8H), 7.20 – 7.06 (m, 
4H), 6.67 (s, 1H), 6.63 (s, 1H), 5.32 (d, J = 15.3 Hz, 1H), 5.14 – 5.00 (m, 2H), 4.83 (s, 6H), 4.51 – 4.45 
(m, 1H), 4.13 – 4.07 (m, 1H), 4.06 – 3.98 (m, 3H), 3.91 – 3.82 (m, 4H), 3.81 (s, 3H), 3.78 – 3.73 (m, 
1H), 3.58 (dd, J = 13.5 Hz, 1H), 3.26 – 3.07 (m, 2H), 2.96 (dd, J = 17.5, 4.7 Hz, 1H), 2.85 (dd, J = 17.5, 
4.7 Hz, 1H), 2.66 (s, 3H), 2.60 (s, 6H), 2.48 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H), 1.78 – 1.67 (m, 1H), 1.62 
– 1.44 (m, 3H). MS (ESI) m/z calcd. for [C49H61N8Na2O13S2]+: 1080.2; found: 1080.3 [M+Na]+. 
Cbz-Arg(Mtr)-DKP3(CH2NHMtr)-isoAsp(OtBu)-Gly-OBn (65) 
 
To a solution of 71 (1.00 g, 0.97 mmol, 1.0 eq) in DMF (10 mL) under nitrogen atmosphere at 0 °C, 
HATU (443 mg, 1.16 mmol, 1.2 eq), HOAt (158 mg, 1.16 mmol, 1.2 eq) and iPr2NEt (507 µL, 2.91 
mmol, 3.0 eq) were added: the reaction mixture was stirred at 0 °C for 30 min. 62 (392 mg, 1.16 mmol, 
1.2 eq) was dissolved in DMF (9.5 mL) and added to the previous solution: the reaction mixture was 
stirred at 0 °C for 1 h, then at room temperature overnight. The mixture was diluted with CH2Cl2 (50 
mL) and washed with KHSO4 1 M (4 × 80 mL), saturated aqueous NaHCO3 (4 × 80 mL) and brine (1 × 
100 mL). The organic phase was dried over Na2SO4 and volatiles were removed under reduced pressure. 
The residue was purified using a Grace Reveleris system (column: Reveleris Silica 40 g; dry load; flow 
rate: 30 mL/min; gradient: 100% CH2Cl2 to CH2Cl2/MeOH 8:2 in 45 min) affording the desired product 
65 as a white foam (715 mg, 54%). 
Rf = 0.4 (CH2Cl2/MeOH 9:1); 1H-NMR (400 MHz, Acetone-d6) δ 7.79 (s, 1H), 7.67 (t, J = 5.7 Hz, 1H), 
7.62 (d, J = 8.3 Hz, 1H), 7.48 (s, 1H), 7.40 – 7.27 (m, 10H), 7.24 – 7.14 (m, 4H), 6.76 (s, 1H), 6.70 – 
6.68 (m, 1H), 6.66 (s, 1H), 6.57 (s, 1H), 6.53 – 6.45 (m, 1H), 5.29 (d, J = 15.1 Hz, 1H), 5.14 (s, 2H), 
5.12 – 5.01 (m, 2H), 4.73 (dt, J = 8.3, 5.5 Hz, 1H), 4.67 – 4.61 (m, 1H), 4.29 – 4.21 (m, 1H), 4.12 – 4.00 
(m, 4H), 3.95 (dd, J = 18.5, 5.7 Hz, 2H), 3.88 (s, 3H), 3.82 (s, 3H), 3.81 – 3.77 (m, 1H), 3.55 – 3.47 (m, 
1H), 3.36 – 3.25 (m, 1H), 3.20 – 3.08 (m, 1H), 3.05 (dd, J = 15.4, 5.3 Hz, 1H), 2.80 – 2.75 (m, 2H), 2.73 
(d, J = 5.3 Hz, 1H), 2.68 (s, 3H), 2.64 (s, 3H), 2.62 (s, 3H), 2.55 (s, 3H), 2.12 – 2.08 (m, 6H), 1.89 – 
1.77 (m, 1H), 1.68 – 1.53 (m, 3H), 1.44 (s, 9H). 13C-NMR (101 MHz, Acetone-d6) δ 174.1, 171.1, 171.0, 
170.7, 167.6, 160.2, 159.1, 157.8, 139.7, 139.5, 139.3, 138.4, 138.3, 137.3, 137.2, 136.5, 136.1, 131.4, 
129.5, 129.4, 129.2, 129.2, 129.0, 128.8, 125.7, 125.0, 113.2, 112.7, 82.4, 67.4, 67.2, 60.3, 56.3, 56.1, 
55.6, 52.5, 51.2, 47.6, 47.0, 42.0, 40.4, 40.0, 39.5, 38.3, 30.7, 28.3, 26.6, 24.6, 24.5, 18.9, 18.3, 12.3, 
12.3. MS (ESI) m/z calcd. for [C66H84N10NaO17S2]+: 1375.5; found: 1375.4 [M+Na]+. 
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H-Arg(Mtr)-DKP3(CH2NHMtr)-isoAsp(OtBu)-Gly-OH (66) 
 
To a solution of 65 (410 mg, 0.30 mmol, 1.0 eq) in THF/H2O 1:1 (30 mL), Pd/C 10% (32 mg, 0.03 
mmol, 0.1 eq) was added: the hydrogenolythic cleavage was carried out as described in GP6. The desired 
compound 66 was obtained as a white solid (328 mg, 96%) and used without further purification. 
MS (ESI) m/z calcd. for [C51H72N10Na2O15S2]2+: 1174.44; found: 1174.62 [M+2Na]2+. 
Cyclo[DKP3-isoAsp(OtBu)-Gly-Arg(Mtr)]-CH2NHMtr (67) 
 
The macrolactamization reaction was carried out on 66 (328 mg, 0.29 mmol, 1.0 eq) according to GP7 
(Procedure B). The mixture was concentrated affording an orange oil, which was diluted with AcOEt 
(350 mL) and washed with KHSO4 1 M (4 × 90 mL). The organic phase was dried over Na2SO4 and 
volatiles were removed under reduced pressure. The residue was purified using a Grace Reveleris system 
(column: Reveleris HP Silica 12 g; dry load; flow rate: 24 mL/min; gradient: 100% CH2Cl2 to 
CH2Cl2/MeOH 7:3 in 25 min) affording the desired product 67 as a white solid (255 mg, 79%). 
Rf = 0.4 (CH2Cl2/MeOH 9:1); 1H-NMR (400 MHz, DMSO-d6) δ 8.60 (d, J = 9.0 Hz, 1H), 8.30 (t, J = 
6.1 Hz, 1H), 8.16 (d, J = 7.3 Hz, 1H), 7.87 (t, J = 6.3 Hz, 1H), 7.64 (dd, J = 7.1, 3.8 Hz, 1H), 7.51 (s, 
1H), 7.17 – 7.07 (m, 4H), 6.75 (s, 1H), 6.68 (s, 1H), 6.39 (s, 1H), 5.20 (d, J = 15.2 Hz, 1H), 4.80 – 4.69 
(m, 1H), 4.35 (dd, J = 11.8, 2.3 Hz, 1H), 4.17 (dd, J = 16.9, 7.3 Hz, 1H), 4.10 – 3.99 (m, 1H), 3.92 (d, 
J = 6.2 Hz, 2H), 3.89 – 3.80 (m, 4H), 3.79 (s, 3H), 3.65 – 3.56 (m, 2H), 3.54 – 3.43 (m, 3H), 3.10 – 2.97 
(m, 3H), 2.62 – 2.51 (m, 11H), 2.43 (s, 3H), 2.16 – 2.07 (m, 1H), 2.06 (s, 3H), 2.04 (s, 3H), 1.65 – 1.54 
(m, 1H), 1.49 – 1.29 (m, 12H). 13C-NMR (101 MHz, DMSO-d6) δ 172.8, 170.7, 169.9, 168.9, 168.7, 
166.1, 165.8, 158.5, 157.5, 156.2, 138.2, 137.8, 137.6, 137.2, 135.6, 135.2, 130.0, 127.9, 127.6, 124.0, 
123.6, 112.2, 111.7, 81.4, 58.8, 55.7, 55.5, 53.0, 50.0, 49.6, 45.5, 45.1, 41.3, 38.4, 37.8, 36.4, 28.8, 27.6, 
25.5, 23.9, 23.7, 18.1, 17.7, 11.8, 11.8. MS (ESI) m/z calcd. for [C51H70N10NaO14S2]+: 1133.44 ; found: 
1133.40 [M+Na]+. 
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Cyclo[DKP3-isoDGR)]-CH2NH2 (56) 
 
67 (220 mg, 0.20 mmol) was deprotected according to GP 8 (Procedure B). The crude compound was 
purified by RP-HPLC (gradient: 100% H2O + 0.1% TFA for 2 min, then from 100% H2O + 0.1% TFA 
to 77% H2O + 0.1% TFA / 23% CH3CN + 0.1% TFA in 9 min, tR (product) = 9.9 min). The purified 
product was freeze-dried from water to give 56 (as trifluoroacetate salt) as a white solid (80 mg, 47%). 
1H-NMR (400 MHz, D2O) δ 7.47 – 7.34 (m, 4H), 5.26 (d, J = 15.7 Hz, 1H), 4.87 (dd, J = 11.8, 3.9 Hz, 
1H), 4.47 – 4.41 (m, 1H), 4.28 (d, J = 17.3 Hz, 1H), 4.25 – 4.19 (m, 2H), 4.18 (s, 2H), 4.16 – 4.13 (m, 
1H), 4.02 (dd, J = 15.0, 4.7 Hz, 1H), 3.80 (d, J = 17.3 Hz, 1H), 3.68 (dd, J = 15.0, 1.5 Hz, 1H), 3.21 (t, 
J = 6.8 Hz, 2H), 3.15 (dd, J = 13.7, 3.0 Hz, 1H), 3.02 (dd, J = 15.1, 3.9 Hz, 1H), 2.69 (dd, J = 15.1, 11.8 
Hz, 1H), 2.37 (dd, J = 13.7, 11.9 Hz, 1H), 1.90 – 1.81 (m, 1H), 1.79 – 1.57 (m, 2H). 13C-NMR (101 
MHz, D2O) δ 176.0, 175.8, 172.8, 172.0, 171.4, 168.0, 167.2, 156.9, 136.2, 132.4, 129.5, 129.5, 128.3, 
128.2, 59.7, 54.2, 51.3, 50.5, 47.5, 42.8, 41.6, 40.5, 39.3, 38.3, 38.2, 28.1, 24.6. MS (ESI) m/z calcd. for 
[C27H39N10O8]+: 631.29; found: 631.21 [M+H]+. 
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SYNTHESIS OF CYCLO[DKP3-ISODGR]-VAL-ALA-PTX CONJUGATE 55 
Dipeptide linker 72 was synthesized according to literature procedure and its analytical data were in 
agreement with those already published.25a 
 
Reagents and conditions: a) NHS, EDC·HCl, DMF, 0 °C to r.t., overnight; b) 56, PBS/CH3CN, pH 7.5, 0 °C to r.t., overnight; 
c) TFA, CH2Cl2, r.t., 1 h, 55% over three steps; d) 4-nitrophenylchloroformate, pyridine, CH2Cl2, -50 °C to -20 °C, 4 h, 84% 
based on recovered starting material; e) 83, iPr2NEt, DMF, 0 °C to r.t., overnight, 52%. 
N-Hydroxysuccinimidyl ester of 72 (80) 
 
NHS (9.6 mg, 0.084 mmol, 1.3 eq) and EDC·HCl (16 mg, 0.084 mmol, 1.3 eq) were added under 
nitrogen atmosphere at 0 °C to a solution of 72 (40 mg, 0.064 mmol, 1.0 eq) in DMF (2 mL): the mixture 
was stirred at 0 °C for 5 min, then at room temperature overnight. The mixture was diluted with AcOEt 
(100 mL) and washed with H2O (3 × 20 mL). The organic phase was dried over Na2SO4 and concentrated 
under reduced pressure affording the desired product 80 as white solid (46 mg). The product was used 
without further purification. 
Rf = 0.5 (CH2Cl2/MeOH 9:1 + 0.1% CH3COOH). 
Cyclo[DKP-isoDGR]-Val-Ala-PAB-OC(O)N(Me)-CH2CH2-N(Me)Boc (81) 
 
A solution of 56 (28 mg, 0.032 mmol, 1.0 eq) in phosphate buffer (1.5 mL, pH 7.5) was added to a 
solution of 80 (46 mg, 0.064 mmol, 2.0 eq) in CH3CN (1.5 mL) under nitrogen atmosphere at 0 °C, 
adjusting the pH at 7.3-7.6 with aqueous NaOH (0.2 M) during the first 5 h. The resulting solution was 
stirred at room temperature overnight. The reaction mixture was concentrated and the residue was 
centrifuged with MeOH/Et2O affording the desired product 73 as a white solid (40 mg), which was used 
without further purification. 
MS (ESI) m/z calcd. for [C57H84N15O16]+: 1234.62; found: 1234.64 [M+H]+.  
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Cyclo[DKP-isoDGR]-Val-Ala-PAB-OC(O)N(Me)-CH2CH2-NHMe (82) 
 
81 (40 mg, 0.032 mmol) was deprotected according to GP5. The crude residue was purified by RP-
HPLC (gradient: 100% H2O + 0.1% TFA for 2 min, then from 90% H2O + 0.1% TFA / 10% CH3CN + 
0.1% TFA to 50% H2O + 0.1% TFA / 50% CH3CN + 0.1% TFA in 12 min, tR (product) = 9.0 min). The 
purified product was freeze-dried from glacial acetic acid to give 82 (as trifluoroacetate salt) as a white 
solid (24 mg, 55% over three steps). 
1H-NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 8.34 – 8.28 (m, 1H), 8.26 (t, J = 5.6 Hz, 1H), 8.21 – 8.15 
(m, 1H), 8.17 – 8.11 (m, 1H), 7.93 (s, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 9.1 Hz, 1H), 7.59 (d, J 
= 8.4 Hz, 2H), 7.54 (d, J = 8.5 Hz, 1H), 7.49 – 7.44 (m, 1H), 7.31 (d, J = 8.4 Hz, 2H), 7.25 – 7.17 (m, 
4H), 5.23 (d, J = 15.3 Hz, 1H), 5.00 (s, 2H), 4.62 – 4.54 (m, 1H), 4.44 – 4.34 (m, 2H), 4.26 – 4.20 (m, 
2H), 4.20 – 4.10 (m, 3H), 3.90 (d, J = 15.3 Hz, 1H), 3.68 – 3.53 (m, 4H, overlapped with solvent signal), 
3.52 – 3.45 (m, 2H, overlapped with solvent signal), 3.06 (d, J = 11.3 Hz, 4H, overlapped with solvent 
signal), 2.86 (s, 2H), 2.57 (d, J = 17.9 Hz, 2H), 2.23 – 2.16 (m, 2H), 2.16 – 2.09 (m, 1H), 2.03 – 1.95 
(m, 1H), 1.90 (s, 6H), 1.80 – 1.70 (m, 2H), 1.69 – 1.62 (m, 1H), 1.56 – 1.39 (m, 3H), 1.30 (d, J = 7.0 
Hz, 3H), 1.26 – 1.21 (m, 2H), 0.86 (m, 6H).13C-NMR (101 MHz, DMSO-d6) δ 172.5, 172.5, 172.2, 
171.9, 171.7, 171.1, 169.1, 166.1, 166.0, 163.6, 156.8, 151.2, 138.9, 138.6, 134.9, 133.6, 131.4, 128.4, 
127.7, 127.5, 126.8, 119.0, 118.9, 109.5, 74.8, 66.3, 62.6, 59.0, 57.7, 56.1, 52.7, 52.1, 49.0, 49.0, 45.6, 
41.7, 41.6, 41.4, 37.8, 36.3, 34.7, 32.8, 30.2, 28.9, 28.4, 25.1, 21.6, 21.0, 19.1, 18.1, 17.8, 14.1. MS 
(ESI) m/z calcd. for [C52H76N15O14]+: 1134.57; found: 1134.77 [M+H]+. 
2’-(4-Nitrophenoxycarbonyl)paclitaxel (83) 
 
Paclitaxel (27, 500 mg, 0.586 mmol, 1.0 eq) was dissolved in dry CH2Cl2 (6 mL) under nitrogen 
atmosphere. Pyridine (142 µL, 1.76 mmol, 3.0 eq) was added dropwise and the mixture was cooled to 
-50 °C. A solution of 4-nitrophenylchloroformate (177 mg, 0.878 mmol, 1.5 eq) in dry CH2Cl2 (2.5 mL) 
was added under nitrogen atmosphere: the mixture was stirred at -20 °C for 4 h. The mixture was diluted 
with AcOEt (200 mL) and washed with KHSO4 1 M (2 × 30 mL) and brine (1 × 30 mL). The organic 
phase was dried over Na2SO4 and concentrated under reduced pressure. The crude residue was purified 
using a Grace Reveleris system (column: Reveleris Silica 12 g; dry load; flow rate: 36 mL/min; gradient: 
100% Hexane to 100% AcOEt in 19 min) affording the desired product 83 as a white solid (300 mg, 
84% based on recovered starting material). 
Rf = 0.3 (Hexane/AcOEt 4:6). 
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Cyclo[DKP3-isoDGR]-Val-Ala-PTX (55) 
82 (12 mg, 0.009 mmol, 1.0 eq) was dissolved in dry DMF (100 µL) under nitrogen atmosphere and 
cooled to 0 °C. A solution of 83 (27 mg, 0.026 mmol, 3.0 eq) in dry DMF (900 µL) and iPr2NEt (8 µL, 
0.045 mmol, 5.0 eq). were subsequently added to the previous solution: the mixture was stirred at room 
temperature overnight. The solvent was removed under vacuum; the crude residue was centrifuged 
(H2O/CH3CN) and purified by RP-HPLC (gradient: 90% H2O + 0.1% TFA / 10% CH3CN + 0.1% TFA 
for 2 min, then from 90% H2O + 0.1% TFA / 10% CH3CN + 0.1% TFA to 32% H2O + 0.1% TFA / 68% 
CH3CN + 0.1% TFA in 13 min, tR (product) = 13.2 min). The purified product was freeze-dried from 
H2O affording the desired product 55 (as trifluoroacetate salt) as a white solid (10 mg, 52%). 
1H-NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 9.18 (d, J = 8.6 Hz, 1H), 8.57 (d, J = 9.1 Hz, 1H), 8.30 
– 8.23 (m, 2H), 8.18 – 8.11 (m, 2H), 8.02 – 7.96 (m, 2H), 7.87 – 7.79 (m, 4H), 7.76 – 7.70 (m, 1H), 7.70 
– 7.40 (m, 12H), 7.29 – 7.16 (m, 6H), 6.30 (s, 1H), 5.84 (s, 1H), 5.70 – 5.54 (m, 1H), 5.42 (d, J = 6.8 
Hz, 1H), 5.22 (d, J = 15.0 Hz, 1H), 4.99 – 4.74 (m, 4H), 4.64 – 4.54 (m, 1H), 4.44 – 4.38 (m, 1H), 4.37 
– 4.31 (m, 1H), 4.26 – 4.07 (m, 6H), 4.06 – 3.98 (m, 2H), 3.90 (d, J = 15.0 Hz, 1H), 3.74 – 3.64 (m, 
1H), 3.63 – 3.46 (m, 5H), 3.13 – 2.99 (m, 3H), 2.91 – 2.66 (m, 4H), 2.63 – 2.53 (m, 2H), 2.36 – 2.03 
(m, 10H), 2.02 – 1.92 (m, 1H), 1.82 (s, 3H), 1.79 – 1.70 (m, 2H), 1.69 – 1.59 (m, 2H), 1.52 (s, 6H), 1.30 
(d, J = 7.0 Hz, 3H), 1.24 (s, 4H), 1.06 – 0.98 (m, 6H), 0.91 – 0.80 (m, 6H). 13C-NMR (101 MHz, DMSO-
d6) δ 201.6, 172.5, 172.1, 171.7, 170.9, 170.6, 169.5, 168.9, 168.6, 166.0, 165.2, 158.3, 156.6, 138.9, 
134.8, 129.9, 129.5, 128.6, 128.2, 127.7, 127.5, 127.3, 119.0, 109.4, 83.6, 74.7, 70.5, 69.3, 66.0, 58.9, 
57.5, 52.8, 50.4, 48.8, 46.3, 41.7, 41.3, 38.9, 34.8, 34.4, 30.3, 28.9, 28.5, 28.5, 28.2, 26.3, 22.4, 21.6, 
21.4, 19.1, 18.1, 17.9, 13.8, 9.7. MS (MALDI-TOF) m/z calcd. for [C100H124N16O29]+: 2015.2; found: 
2016.1 [M+H]+ (HCCA matrix). 
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SYNTHESIS OF CYCLO[GISODGRF] 84 
The synthesis of cyclo[GisodGRf] (84) was accomplished as described in EP.11 GENERAL PROCEDURES 
FOR SOLID-PHASE SYNTHESIS on SASRIN™ Resin (400 mg, 0.404 mmol). 
 
Reagents and Conditions: a) Fmoc-Asp(OH)-OtBu, HATU, HOAt, iPr2NEt, DMF, M.W., 90%; b) 1. 25% piperidine in DMF; 
2. Fmoc-AA-OH, HATU, HOAt, iPr2NEt, DMF, M.W.; c) 1. 25% piperidine in DMF; 2. Cbz-Gly-OH, HATU, HOAt, iPr2NEt, 
DMF, M.W.; d) 1% TFA in CH2Cl2, r.t., 3 min × 24 times, 73%; e) H2, 10% Pd/C, THF/H2O 2:1, overnight, r.t., quant.; 
f) HATU, HOAt, iPr2NEt, DMF/CH2Cl2 1:1 (1.4 mM), overnight, r.t., 39%; g) TFA/thioanisole/EDT/anisole 90:5:3:2, 2 h, r.t., 
49%. 
Loading of Fmoc-Asp(OH)-OtBu on SASRIN™ Resin 
 
The loading of Fmoc-L-Asp(OH)-OtBu (500 mg, 1.22 mmol) on SASRIN™ Resin was carried out 
according to EP.11 GENERAL PROCEDURES FOR SOLID-PHASE SYNTHESIS, swelling the beads with 
DMF. The amino acid was activated as described in GP2 (Procedure B) and added to the resin: a double 
coupling performed, then the solid support was washed thoroughly with dichloromethane and methanol. 
After drying under vacuum, the beads were weighted and the yield of the loading calculated. 
𝑦% =  
(𝑚𝑇𝑂𝑇  −  𝑚𝑅𝐸𝑆𝐼𝑁)
(𝑀. 𝑊.𝐴𝐴 −  𝑀. 𝑊.𝑊𝐴𝑇𝐸𝑅 ) 𝑛𝑅𝐸𝑆𝐼𝑁
% =  
(544 −  400) 𝑚𝑔
(411.46 −  18.02) 𝑚𝑔/𝑚𝑚𝑜𝑙 ×  0.404 𝑚𝑚𝑜𝑙
% = 90% 
The amounts of reagents for the next steps were calculated consequently and are reported in TABLE 13. 
TABLE 13. Amounts of amino acids used in the SPPS of compound 84. 
Fmoc-AA-OH Molecular Weight (g/mol) Amount (mg) 
Fmoc-Gly-OH 297.31 
324 
324 
Fmoc-D-Phe-OH 387.43 
423 
423 
Fmoc-Arg(Pbf)-OH 648.78 
707 
707 
Cbz-Gly-OH 209.2 
229 
229 
Double coupling reactions were performed for all the amino acid residues.  
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Cbz-Gly-Arg(Mtr)-D-Phe-Gly-Asp(OH)-OtBu (85) 
 
The peptide cleavage from the resin was performed according to GP4. The desired product 85 was 
obtained as white foam (293 mg, 73%). 
Rf = 0.50 (CH2Cl2/MeOH 9:1, CH3COOH drops); 1H-NMR (400 MHz, CD3OD) δ 7.42 – 7.09 (m, 10H), 
5.09 (s, 2H), 4.73 – 4.61 (m, 2H), 4.34 – 4.25 (m, 1H), 3.96 – 3.75 (m, 4H), 3.31 (bs, 2H, overlapped 
with solvent signal), 3.03 – 2.89 (m, 4H), 2.70 (bs, 2H), 2.60 (s, 3H), 2.54 (s, 3H), 2.08 (s, 3H), 1.61 – 
1.47 (m, 2H), 1.43 (s, 6H), 1.42 (s, 9H), 1.20 (s, 2H). 13C-NMR (101 MHz, CD3OD) δ 174.3, 174.3, 
172.5, 172.5, 171.6, 171.4, 171.4, 159.9, 158.2, 158.2, 139.5, 139.5, 138.7, 138.7, 133.6, 133.6, 130.4, 
130.4, 130.2, 130.2, 129.6, 129.6, 129.5, 129.5, 129.4, 129.4, 129.1, 129.1, 128.9, 128.9, 127.8, 127.8, 
126.1, 126.1, 118.5, 87.7, 87.7, 83.3, 83.3, 68.0, 68.0, 56.5, 54.5, 51.4, 44.9, 44.0, 44.0, 43.8, 43.8, 38.0, 
38.0, 29.4, 28.7, 28.7, 28.2, 28.2, 26.3, 19.7, 19.7, 18.5, 12.5, 12.5. MS (ESI) m/z calcd. for 
[C48H64N8NaO13S]+: 1015.4; found: 1015.4 [M+Na]+. 
H-Gly-Arg(Mtr)-D-Phe-Gly-Asp(OH)-OtBu (86) 
 
The Cbz-removal from compound 85 was carried out according to GP6. The desired product 86 was 
obtained as white foam (260 mg, quantitative). 
MS (ESI) m/z calcd. for [C40H58N8NaO11S]+: 881.38; found: 881.49 [M+Na]+. 
Cyclo[Gly-Asp(OtBu)-Gly-Arg(Mtr)-D-Phe] (87) 
 
The macrolactamization reaction on 86 was performed according to GP7 (Procedure B). The crude 
compound was dissolved with AcOEt (300 mL) and washed with KHSO4 1 M (4 × 100 mL) and brine 
(2 × 50 mL). The organic layer was dried over Na2SO4 and volatiles were removed under reduced 
pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2 100% to 
CH2Cl2/MeOH 9:1, solid load) affording the desired product 87 as a white foam (95 mg, 39%). 
Rf = 0.50 (CH2Cl2/MeOH 9:1); 1H-NMR (600 MHz, CD3OD) δ 7.27 – 7.17 (m, 4H), 7.17 – 7.09 (m, 
1H), 4.71 (dd, J = 5.9, 4.7 Hz, 1H), 4.64 (dd, J = 11.3, 4.4 Hz, 1H), 4.10 (d, J = 16.6 Hz, 1H), 4.01 (t, J 
= 6.3 Hz, 1H), 3.85 (d, J = 15.8 Hz, 1H), 3.76 (d, J = 16.6 Hz, 1H), 3.61 (d, J = 15.8 Hz, 1H), 3.38 (dd, 
J = 14.1, 4.4 Hz, 1H), 3.03 – 2.97 (m, 4H), 2.84 – 2.76 (m, 3H), 2.72 (dd, J = 14.7, 4.7 Hz, 1H), 2.59 (s, 
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4H), 2.53 (s, 4H), 2.09 (s, 3H), 1.48 (s, 8H), 1.44 (d, J = 3.1 Hz, 9H), 1.20 – 1.12 (m, 3H), 0.99 – 0.88 
(m, 2H). 13C-NMR (151 MHz, CD3OD) δ 173.8, 172.9, 172.3, 171.1, 170.9, 159.9, 139.4, 138.9, 134.4, 
133.5, 130.1, 129.6, 127.8, 126.1, 118.5, 87.7, 83.5, 56.6, 55.7, 51.4, 44.1, 44.0, 43.5, 38.1, 37.7, 28.7, 
28.2, 26.3, 26.3, 26.3, 19.6, 18.4, 12.5. [Due to technical problems, compound 87 was characterized 
using a spectrometer operating at 600 MHz]. MS (ESI) m/z calcd. for [C40H56N8NaO10S]+: 863.37; 
found: 863.38 [M+Na]+. 
Cyclo[GisodGRf] (84) 
 
The final deprotection on compound 87 was carried out as described in GP8 (Procedure A). The residue 
was purified by RP-HPLC (gradient: from 90% H2O + 0.1% TFA / 10% CH3CN + 0.1% TFA to 60% 
H2O + 0.1% TFA / 40% CH3CN + 0.1% TFA in 8 min, tR (product) = 4.4 min). The purified product 
was freeze-dried from water to give 84 (as trifluoroacetate salt) as a white solid (35 mg, 49%). 
1H-NMR (400 MHz, CD3OD) δ 7.12 – 6.97 (m, 5H), 4.62 (dd, J = 6.4, 4.5 Hz, 1H), 4.44 (dd, J = 10.7, 
4.8 Hz, 1H), 3.83 (t, J = 7.5 Hz, 1H), 3.77 (d, J = 16.5 Hz, 1H), 3.69 – 3.60 (m, 2H), 3.45 (d, J = 15.8 
Hz, 1H), 3.16 (dd, J = 14.0, 4.8 Hz, 1H), 2.88 – 2.76 (m, 2H), 2.71 – 2.54 (m, 3H), 1.47 – 1.29 (m, 2H), 
1.20 – 1.05 (m, 1H), 0.90 – 0.77 (m, 1H). [Compound 84 was fully characterized by Cristina Paissoni 
(R10582)]. MS (ESI) m/z calcd. for [C23H33N8O7]+: 533.25; found: 533.24 [M+H]+. 
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SYNTHESIS OF CYCLO[DKP3-RAD] 88A AND 88B 
N3-DKP3-COOAllyl 44, BocHN-DKP3-COOAllyl 93 and BocHN-DKP3-COOH 94 were synthesized 
according to literature procedure and their analytical data were in agreement with those already 
published.27 
 
Reagents and conditions. a) HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 84%; b) TFA, CH2Cl2, r.t., 2 h; c) PMe3 in 
toluene, Boc-ON, THF, -20 °C to r.t., 5 h, 78%; d) [Pd(PPh3)4], pyrrolidine, PPh3, CH2Cl2, 0 °C, 1 h, quant.; e) 94, HATU, 
HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 65%; f) TFA, CH2Cl2, r.t., 2 h; g) Cbz-L-Asp(OtBu)-OH, HATU, HOAt, iPr2NEt, 
DMF, 0 °C to r.t., overnight, 83%; h) H2, 10% Pd/C, THF/H2O 1:1, overnight, r.t., quant.; i) HATU, HOAt, iPr2NEt, 
DMF/CH2Cl2 1:1 (1.4 mM), 0 °C to r.t., overnight, 82%; j) TFA/thioanisole/EDT/anisole 90:5:3:2, 2 h, rt, 30%. The synthesis 
was performed according to ref. 27. 
BocHN-Arg(Mtr)-Ala-OBn (91) 
 
To a solution of BocHN-Arg(Mtr)-OH 89 (290 mg, 0.60 mmol, 1.0 eq) in DMF (9.0 mL), at 0 °C and 
under nitrogen atmosphere, HATU (250 mg, 0.66 mmol, 1.1 eq), HOAt (90 mg, 0.66 mmol, 1.1 eq) and 
iPr2NEt (315 µL, 1.8 mmol, 3.0 eq) were added: the reaction was stirred at 0 °C for 30 min. A solution 
of L-Ala-OBn∙HCl (140 mg, 0.66 mmol, 1.1 eq) in DMF (3.0 mL) and iPr2NEt (209 µL, 1.2 mmol, 2.0 
eq) was added dropwise to the previous solution: the reaction mixture was stirred at 0 °C for 1 h and at 
room temperature overnight. The mixture was diluted with AcOEt (50 mL) and washed with KHSO4 1 
M (4 × 50 mL), saturated aqueous NaHCO3 (4 × 50 mL) and brine (2 × 50 mL). The organic phase was 
dried over Na2SO4 and volatiles were removed under reduced pressure. The residue was purified by 
flash chromatography on silica gel (Hexane/AcOEt 3:7, solid load) affording the desired product 91 as 
a white foam (332 mg, 84%). 
Rf = 0.13 (Hexane/AcOEt 3:7); 1H-NMR (400 MHz, CDCl3) δ 7.41 (d, J = 6.9 Hz, 1H), 7.37 – 7.26 (m, 
5H), 6.52 (s, 1H), 6.31 (bs, 2H), 5.52 (d, J = 7.5 Hz, 1H), 5.12 (d, J = 12.4 Hz, 2H), 4.61 – 4.46 (m, 1H), 
4.27 (bs, 1H), 3.81 (s, 3H), 3.19 (bs, 2H), 2.68 (s, 3H), 2.61 (s, 3H), 2.12 (s, 4H), 1.88 – 1.76 (m, 1H), 
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1.67 – 1.52 (m, 3H), 1.40 (s, 12H). 13C-NMR (101 MHz, CDCl3) δ 173.0, 172.4, 158.7, 156.4, 156.1, 
138.8, 136.9, 135.5, 128.7, 128.5, 128.2, 125.0, 111.9, 80.1, 67.3, 55.6, 53.4, 48.5, 40.7, 30.6, 28.5, 25.2, 
24.3, 18.5, 17.4, 12.1. MS (ESI) m/z calcd. for [C31H45N5NaO8S]+: 670.29; found: 670.09 [M+Na]+. 
BocHN-DKP3-Arg(Mtr)-Ala-OBn (95) 
 
To a solution of BocHN-DKP3-COOH 94 (160 mg, 0.41 mmol, 1.0 eq), prepared as described in ref. 
27, in DMF (4.1 mL), under nitrogen atmosphere and at 0 ºC, HATU (186 mg, 0.49 mmol, 1.2 eq), 
HOAt (67 mg, 0.49 mmol, 1.2 eq) and iPr2NEt (271 μL, 1.64 mmol, 4.0 eq.) were added successively. 
After 30 min, a solution of the TFA salt 92 (324 mg, 0.49 mmol, 1.2 eq), obtained treating 91 according 
to GP5, in DMF (4.1 mL) was added and the reaction mixture was stirred at 0 ºC for 1 h and at r.t. 
overnight. The mixture was afterwards diluted with AcOEt (50 mL) and washed with KHSO4 1 M (3 × 
90 mL), saturated aqueous NaHCO3 (3 × 90 mL) and brine (2 × 90 mL). The organic phase was dried 
over Na2SO4 and volatiles were removed under reduced pressure. The residue was purified by flash 
chromatography on silica gel (from CH2Cl2/MeOH 96:4 to CH2Cl2/MeOH 9:1, solid load) affording the 
desired product 95 as a white foam (246 mg, 65%). 
Rf = 0.29 (CH2Cl2/MeOH 95:5); 1H-NMR (400 MHz, CD2Cl2) δ 7.92 (bs, 1H), 7.79 – 7.41 (m, 2H), 7.37 
– 7.15 (m, 10H), 6.54 (s, 1H), 6.25 (bs, 2H), 5.65 (bs, 1H), 5.43 – 5.34 (m, 1H), 5.09 (q, J = 12.3 Hz, 
2H), 4.60 (bs, 1H), 4.54 – 4.34 (m, 2H), 4.08 (d, J = 15.0 Hz, 1H), 3.92 – 3.68 (m, 3H), 3.70 – 3.36 (m, 
2H), 3.24 – 2.78 (m, 4H), 2.64 (s, 3H), 2.57 (s, 3H), 2.09 (s, 3H), 1.78 (bs, 1H), 1.60 (bs, 1H), 1.56 – 
1.45 (m, 2H), 1.36 (s, 12H). 13C-NMR (101 MHz, CD2Cl2) δ 173.0, 172.4, 170.5, 168.1, 166.8, 158.9, 
157.0, 156.5, 138.9, 136.9, 136.2, 136.0, 133.9, 129.2, 128.9, 128.7, 128.4, 125.2, 112.1, 80.2, 67.4, 
60.3, 55.8, 53.0, 51.8, 48.9, 47.7, 41.2, 40.9, 38.3, 30.3, 28.5, 25.4, 24.3, 18.6, 17.4, 12.1. MS (ESI) m/z 
calcd. for [C45H60N8NaO11S]+: 943.40; found: 943.61 [M+Na]+. 
CbzHN-Asp(OtBu)-DKP3-Arg(Mtr)-Ala-OBn (97) 
 
To a solution of Cbz-L-Asp(OtBu)-OH (136 mg, 0.42 mmol, 1.5 eq.) in DMF (2.6 mL), under nitrogen 
atmosphere and at 0 ºC, HATU (160 mg, 0.42 mmol, 1.5 eq), HOAt (57 mg, 0.42 mmol, 1.5 eq) and 
iPr2NEt (195 μL, 1.12 mmol, 4.0 eq.) were added successively. Compound 95 (255 mg, 0.28 mmol, 1.0 
eq) was deprotected according to GP5 and the corresponding trifluoroacetate salt 96 was dissolved in 
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DMF (3.0 mL) and added to the previous solution after 30 min. The reaction mixture was stirred at 0 ºC 
for 1 h and at r.t. overnight. The mixture was afterwards diluted with AcOEt (45 mL) and washed with 
KHSO4 1 M (3 × 40 mL), saturated aqueous NaHCO3 (3 × 40 mL) and brine (1 × 40 mL). The organic 
phase was dried over Na2SO4 and volatiles were removed under reduced pressure. The residue was 
purified by flash chromatography on silica gel (CH2Cl2/MeOH 95:5, solid load) affording the desired 
product 97 as a white foam (263 mg, 83%). 
Rf = 0.27 (CH2Cl2/MeOH 95:5); 1H-NMR (400 MHz, CD2Cl2) δ 7.72 (bs, 1H), 7.59 (bs, 2H), 7.39 – 
7.16 (m, 15H), 6.53 (s, 1H), 6.25 (bs, 2H), 6.17 (d, J = 7.5 Hz, 1H), 5.23 (d, J = 15.2 Hz, 1H), 5.16 – 
5.01 (m, 3H), 4.88 (d, J = 12.0 Hz, 1H), 4.63 – 4.51 (m, 2H), 4.50 – 4.39 (m, 3H), 4.15 (d, J = 15.2 Hz, 
1H), 3.86 – 3.81 (m, 2H), 3.79 (s, 3H), 3.63 – 3.51 (m, 1H), 3.17 – 3.04 (m, 2H), 2.99 (d, J = 14.0 Hz, 
1H), 2.81 (d, J = 14.0 Hz, 1H), 2.77 – 2.68 (m, 1H), 2.64 (s, 3H), 2.57 (s, 3H), 2.09 (s, 3H), 1.86 – 1.74 
(m, 1H), 1.67 – 1.56 (m, 1H), 1.51 (s, 2H), 1.34 (s, 12H). 13C-NMR (101 MHz, CD2Cl2) δ 173.1, 172.3, 
172.1, 170.9, 170.7, 168.0, 166.8, 158.8, 156.9, 156.8, 138.8, 136.9, 136.6, 136.3, 136.0, 134.0, 129.2, 
128.9, 128.7, 128.5, 128.4, 128.2, 125.1, 112.1, 82.0, 67.6, 67.4, 59.9, 55.8, 53.0, 52.1, 51.7, 48.9, 47.9, 
40.9, 40.0, 38.5, 37.5, 30.3, 30.1, 28.1, 25.3, 24.3, 18.6, 17.4, 12.1. MS (ESI) m/z calcd. for 
[C56H71N9NaO14S]+: 1148.47; found: 1148.58 [M+Na]+. 
CbzHN-Asp(OtBu)-DKP3-Arg(Mtr)-Ala-OBn (98) 
 
Cbz-carbamate and benzyl ester protecting groups were removed by hydrogenolysis of compound 97 as 
described in GP6. The desired product was obtained as white foam (185 mg, quantitative). 
MS (ESI) m/z calcd. for [C41H59N9NaO12S]+: 924.39; found: 924.61 [M+Na]+. 
Cyclo[DKP3-Arg(Mtr)-Ala-Asp(OtBu)] (99A + 99B) 
 
The macrolactamization reaction on 98 was performed according to GP7 (Procedure A). The crude 
compound was dissolved with AcOEt (150 mL) and washed with KHSO4 1 M (3 × 100 mL). The organic 
layer was dried over Na2SO4 and volatiles were removed under reduced pressure. The residue was 
purified by flash chromatography on silica gel (from CH2Cl2/MeOH 96:4 to CH2Cl2/MeOH 92:8, solid 
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load) affording the desired product as mixture of two inseparable isomers 99A and 99B as a white foam 
(150 mg, 81%). 
Rf = 0.60, 0.52 (CH2Cl2/MeOH 9:1); 1H-NMR (400 MHz, CD3OD) δ 7.39 – 7.21 (m, 5HA + 5HB), 6.66 
(s, 1HA), 6.65 (s, 1HB), 5.51 (d, J = 17.8 Hz, 1HA), 5.29 – 5.12 (m, 1HB), 4.74 (d, J = 6.4 Hz, 1HB), 4.60 
(bs, 2HA), 4.58 – 4.49 (m, 1HB), 4.45 – 4.34 (m, 1HA), 4.20 – 4.03 (m, 1HA + 3HB), 4.03 – 3.89 (m, 2HA 
+ 1HB), 3.89 – 3.79 (m, 4HA + 4HB), 3.64 (bs, 1HA), 3.61 – 3.50 (m, 1HB), 3.41 (dd, J = 14.0, 5.0 Hz, 
1HB), 3.28 – 3.12 (m, 1HA + 2HB), 3.12 – 3.03 (m, 2HA), 3.02 – 2.70 (m, 3HA+ 2HB), 2.68 (s, 3HA), 2.67 
(s, 3HB), 2.61 (s, 3HA), 2.60 (s, 3HB), 2.52 – 2.38 (m, 1HB), 2.36 – 2.20 (m, 1HB), 2.13 (s, 3HA), 2.10 (s, 
3HB), 1.95 – 1.75 (m, 1HA + 2HB), 1.75 – 1.52 (m, 3HA + 2HB), 1.52 – 1.36 (m, 12HA + 12HB). 13C-
NMR (101 MHz, CD3OD) δ 175.0, 174.1, 173.5, 172.3, 171.5, 170.7, 169.4, 168.6, 159.9, 158.1, 139.5, 
137.9, 137.3, 136.6, 134.9, 130.7, 130.0, 129.9, 129.4, 129.1, 128.9, 125.7, 113.2, 112.8, 82.7, 82.5, 
60.5, 60.2, 56.0, 53.2, 53.0, 47.8, 41.4, 40.5, 40.2, 39.6, 38.6, 37.1, 36.7, 30.7, 28.4, 28.3, 27.8, 24.4, 
18.8, 18.2, 16.8, 12.2. MS (ESI) m/z calcd. for [C41H57N9NaO11S]+: 906.38; found: 906.56 [M+Na]+. 
Cyclo[DKP3-RAD] Peptidomimetics 88A and 88B 
 
The final deprotection on the mixture 99A + 99B was carried out as described in GP8 (Procedure A). 
The residue was purified by RP-HPLC (gradient: from 90% H2O + 0.1% TFA / 10% CH3CN + 0.1% 
TFA to 72% H2O + 0.1% TFA / 28% CH3CN + 0.1% TFA in 12 min, tR (product 88A) = 9.2 min, tR 
(product 88B) = 11.0 min). The purified products were freeze-dried from water to give 88A (6.5 mg) 
and 88B (5.7 mg) trifluoroacetate salts as a white solids (30%). 
Compound 88A: 1H-NMR (400 MHz, D2O) δ 7.56 – 7.35 (m, 5H), 5.14 (d, J = 15.7 Hz, 1H), 4.80 – 
4.72 (m, 1H, overlapped with solvent signal), 4.65 (t, J = 6.8 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 4.25 – 
4.14 (m, 3H), 3.54 (dd, J = 14.9, 4.8 Hz, 1H), 3.30 (t, J = 6.8 Hz, 2H), 3.10 (dd, J = 14.2, 5.7 Hz, 1H), 
2.99 (d, J = 6.9 Hz, 2H), 2.70 (dd, J = 14.2, 6.0 Hz, 1H), 1.94 (dd, J = 14.9, 6.9 Hz, 2H), 1.85 – 1.63 
(m, 2H), 1.50 (d, J = 7.2 Hz, 3H). 13C-NMR (101 MHz, D2O) δ 174.4, 173.6, 173.2, 172.8, 169.3, 168.0, 
156.8, 135.3, 129.1, 128.2, 127.6, 60.3, 55.7, 52.3, 51.0, 49.9, 48.1, 40.5, 39.5, 38.2, 34.7, 26.6, 24.6, 
16.0. MS (ESI) m/z calcd. for [C27H38N9O8]+: 616.28; found: 616.30 [M+H]+. 
Compound 88B: 1H-NMR (400 MHz, D2O) δ 7.51 – 7.30 (m, 5H), 5.39 (d, J = 15.6 Hz, 1H), 4.61 (t, J 
= 4.2 Hz, 1H), 4.54 (t, J = 6.1 Hz, 1H), 4.49 (dd, J = 8.5, 4.5 Hz, 1H), 4.17 (d, J = 15.6 Hz, 1H), 4.12 – 
4.02 (m, 2H), 4.02 – 3.74 (m, 2H), 3.17 (dd, J = 15.3, 4.2 Hz, 1H), 3.09 (dt, J = 11.2, 5.5 Hz, 2H), 3.04 
– 2.90 (m, 2H), 2.84 (dd, J = 15.3, 4.9 Hz, 1H), 1.93 – 1.60 (m, 2H), 1.62 – 1.46 (m, 2H), 1.41 (d, J = 
7.2 Hz, 3H). 13C-NMR (101 MHz, D2O) δ 175.0, 174.4, 173.9, 173.1, 170.7, 168.0, 167.4, 156.6, 135.0, 
129.2, 129.0, 128.1, 127.5, 59.3, 52.4, 51.6, 51.1, 50.8, 47.3, 40.7, 39.6, 37.6, 34.5, 29.9, 24.5, 15.9. MS 
(ESI) m/z calcd. for [C27H38N9O8]+: 616.28; found: 616.32 [M+H]+.  
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SYNTHESIS OF VEGF-C DERIVED PEPTIDES 113-118 
The synthesis of VEGF-C derived peptide sequences (113-118, FIGURE 56) was accomplished as 
described in EP.11 GENERAL PROCEDURES FOR SOLID-PHASE SYNTHESIS on Rink Amide MHBA Resin 
(200 mg, 0.100 mmol). 
 
FIGURE 56. VEGF-C derived peptides 113-118. 
 
 
 
Reagents and conditions: a) SPPS: 1. 25% piperidine in DMF; 2. Fmoc-AA-OH (4.0 eq), DIC, HOAt, iPr2NEt, DMF; 3. 25% 
Ac2O in DMF; b) TFA/thioanisole/EDT/anisole 90:5:3:2 v/v/v/v, r.t., 3 h, 7-30%. 
The exact amounts of the amino acids used for each peptide sequence are reported in the corresponding 
TABLE. 
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Natural VEGF-C fragment Ac-Ile-Asp-Asn-Glu-Trp-Arg-Lys-Thr-Ile-amide (113) 
 
TABLE 14. Amounts of amino acids used in the SPPS of compound 113. 
Fmoc-AA-OH Molecular Weight (g/mol) Amount (mg) 
Fmoc-Gln(Trt)-OH 610.70 244 
Fmoc-Thr(tBu)-OH 397.46 159 
Fmoc-Lys(Boc)-OH 468.54 187 
Fmoc-Arg(Pbf)-OH 648.78 260 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-Glu(OtBu)-OH 425.47 170 
Fmoc-Asn(Trt)-OH 596.69 239 
Fmoc-Asp(OtBu)-OH 411.46 165 
Fmoc-Ile-OH 353.41 141 
The supported peptide (0.100 mmol) was deprotected as described in GP4 and purified by RP-HPLC 
(gradient: 80% H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH for 5 min, then from 80% 
H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH to 37% H2O + 0.1% CH3COOH / 63% 
CH3CN+ 0.1% CH3COOH in 10 min; tR (product) = 7.9 min). 
The desired peptide 113 was freeze-dried from glacial acetic acid, obtaining the corresponding salt as 
white solid (6 mg, 12%). 
MS (MALDI-TOF) m/z calcd. for [C53H84N17O17]+: 1231.6; found:1231.2 [M+H]+ (SIN matrix). 
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Peptide Ac-Trp-Asp-Asn-Glu-Trp-Arg-Lys-Thr-Trp-amide (114) 
 
TABLE 15. Amounts of amino acids used in the SPPS of compound 114. 
Fmoc-AA-OH Molecular Weight (g/mol) Amount (mg) 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-Thr(tBu)-OH 397.46 159 
Fmoc-Lys(Boc)-OH 468.54 187 
Fmoc-Arg(Pbf)-OH 648.78 260 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-Glu(OtBu)-OH 425.47 170 
Fmoc-Asn(Trt)-OH 596.69 239 
Fmoc-Asp(OtBu)-OH 411.46 165 
Fmoc-Trp(Boc)-OH 526.58 211 
The supported peptide (0.100 mmol) was deprotected as described in GP4 and purified by RP-HPLC 
(gradient: 80% H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH for 5 min, then from 80% 
H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH to 37% H2O + 0.1% CH3COOH / 63% 
CH3CN+ 0.1% CH3COOH in 10 min; tR (product) = 11.2 min). 
The desired peptide 114 was freeze-dried from glacial acetic acid, obtaining the corresponding salt as 
white solid (22 mg, 16%). 
MS (MALDI-TOF) m/z calcd. for [C64H85N18O16]+: 1361.6; found: 1361.6 [M+H]+ (HCCA matrix). 
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Peptide Ac-Aib-Ile-Asp-Asn-Aib-Trp-Arg-Lys-Aib-Ile-amide (115) 
 
TABLE 16. Amounts of amino acids used in the SPPS of compound 115. 
Fmoc-AA-OH Molecular Weight (g/mol) Amount (mg) 
Fmoc-Gln(Trt)-OH 610.70 244 
Fmoc-2-Aminoisobutyric acid-OH* 325.36 
130 
130 
Fmoc-Lys(Boc)-OH 468.54 187 
Fmoc-Arg(Pbf)-OH 648.78 260 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-2-Aminoisobutyric acid-OH* 325.36 
130 
130 
Fmoc-Asn(Trt)-OH 596.69 239 
Fmoc-Asp(OtBu)-OH 411.46 165 
Fmoc-Ile-OH 353.41 141 
Fmoc-2-Aminoisobutyric acid-OH* 325.36 
130 
130 
*A double coupling was performed. 
The supported peptide (0.100 mmol) was deprotected as described in GP4 and purified by RP-HPLC 
(gradient: 80% H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH for 5 min, then from 80% 
H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH to 37% H2O + 0.1% CH3COOH / 63% 
CH3CN+ 0.1% CH3COOH in 10 min; tR (product) = 10.6 min). 
The desired peptide 115 was freeze-dried from glacial acetic acid, obtaining the corresponding salt as 
white solid (25 mg, 20%). 
MS (MALDI-TOF) m/z calcd. for [C56H91N18O15]+: 1256.5; found: 1256.4 [M+H]+ (SIN matrix). 
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Peptide Ac-Aib-Trp-Asp-Asn-Aib-Trp-Arg-Lys-Aib-Trp-amide (116) 
 
TABLE 17. Amounts of amino acids used in the SPPS of compound 116. 
Fmoc-AA-OH Molecular Weight (g/mol) Amount (mg) 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-2-Aminoisobutyric acid-OH* 325.36 
130 
130 
Fmoc-Lys(Boc)-OH 468.54 187 
Fmoc-Arg(Pbf)-OH 648.78 260 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-2-Aminoisobutyric acid-OH* 325.36 
130 
130 
Fmoc-Asn(Trt)-OH 596.69 239 
Fmoc-Asp(OtBu)-OH 411.46 165 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-2-Aminoisobutyric acid-OH* 325.36 
130 
130 
*A double coupling was performed. 
The supported peptide (0.100 mmol) was deprotected as described in GP4 and purified by RP-HPLC 
(gradient: 80% H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH for 5 min, then from 80% 
H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH to 37% H2O + 0.1% TFA / 63% CH3CN+ 
0.1% CH3COOH in 10 min; tR (product) = 12.6 min). 
The desired peptide 116 was freeze-dried from glacial acetic acid, obtaining the corresponding acetate 
salt as white solid (41 mg, 30%). 
MS (MALDI-TOF) m/z calcd. for [C67H92N19O14]+: 1387.6; found: 1387.3 [M+H]+ (SIN matrix). 
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Peptide Ac-Trp-(αMe)Asp-Asn-(αMe)Asp-Trp-Arg-Api-Thr-Trp-amide (117) 
 
TABLE 18. Amounts of amino acids used in the SPPS of compound 117. 
Fmoc-AA-OH M.W. (g/mol) Amount (mg) 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-Thr(tBu)-OH 397.46 159 
Fmoc-Api(Boc)-OH* 466.53 
187 
187 
Fmoc-Arg(Pbf)-OH* 648.78 
260 
260 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-(αMe)Asp(OtBu)-OH* 425.47 
170 
170 
Fmoc-Asn(Trt)-OH* 596.69 
239 
239 
Fmoc-(αMe)Asp(OtBu)-OH* 425.47 
170 
170 
Fmoc-Trp(Boc)-OH* 526.58 
211 
211 
*A double coupling was performed. 
The supported peptide (0.100 mmol) was deprotected as described in GP4 and purified by RP-HPLC 
(gradient: 80% H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH for 5 min, then from 80% 
H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH to 37% H2O + 0.1% CH3COOH / 63% 
CH3CN+ 0.1% CH3COOH in 10 min; tR (product) = 13.1 min). 
The desired peptide 117 was freeze-dried from glacial acetic acid, obtaining the corresponding salt as 
white solid (18 mg, 13%). 
MS (MALDI-TOF) m/z calcd. for [C65H85N18O16]+: 1373.6; found: 1373.8 [M+H]+ (HCCA matrix). 
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Peptide Ac-Api-Trp-Asp-Asn-(αMe)Asp-Trp-Arg-Api-Thr-Trp-amide (118) 
 
TABLE 19. Amounts of amino acids used in the SPPS of compound 118. 
Fmoc-AA-OH M.W. (g/mol) Amount (mg) 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-Thr(tBu)-OH 397.46 159 
Fmoc-Api(Boc)-OH* 466.53 
187 
187 
Fmoc-Arg(Pbf)-OH 648.78 260 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-(αMe)Asp(OtBu)-OH* 425.47 
170 
170 
Fmoc-Asn(Trt)-OH 596.69 239 
Fmoc-Asp(OtBu)-OH 411.46 165 
Fmoc-Trp(Boc)-OH 526.58 211 
Fmoc-Api(Boc)-OH* 466.53 
187 
187 
*A double coupling was performed. 
The supported peptide (0.100 mmol) was deprotected as described in GP4 and purified by RP-HPLC 
(gradient: 80% H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH for 5 min, then from 80% 
H2O + 0.1% CH3COOH / 20% CH3CN + 0.1% CH3COOH to 37% H2O + 0.1% CH3COOH / 63% 
CH3CN+ 0.1% CH3COOH in 10 min; tR (product)= 11.7 min). 
The desired peptide 118 was freeze-dried from glacial acetic acid, obtaining the corresponding acetate 
salt as white solid (11 mg, 7%). 
MS (MALDI-TOF) m/z calcd. for [C70H93N20O17]+: 1485.7; found: 1485.7 [M+H]+ (HCCA matrix).  
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HPLC TRACES OF THE FINAL PRODUCTS 
Cyclo[DKP5-isoDGR] (39) 
 
Purity: >99% 
 
 
Cyclo[DKP7-isoDGR] (40) 
 
Purity: 94% 
  
 EXPERIMENTAL PART 97 
 
 
Cyclo[DKP3-isoDGR)]-CH2NH2 (56) 
 
Purity: >99% 
 
 
Cyclo[DKP3-isoDGR]-Val-Ala-PTX (55) 
 
Purity: 95% 
  
98 EXPERIMENTAL PART  
 
 
Cyclo[GisodGRf] (84) 
 
Purity: >99% 
 
 
Cyclo[DKP3-RAD] isomer A (88A) 
 
Purity: >99% 
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Cyclo[DKP3-RAD] isomer B (88B) 
 
Purity: >99% 
 
 
Ac-Ile-Asp-Asn-Glu-Trp-Arg-Lys-Thr-Ile-amide (113) 
 
Purity: >99% 
  
100 EXPERIMENTAL PART  
 
 
Ac-Trp-Asp-Asn-Glu-Trp-Arg-Lys-Thr-Trp-amide (114) 
 
Purity: 97% 
 
 
Ac-Aib-Ile-Asp-Asn-Aib-Trp-Arg-Lys-Aib-Ile-amide (115) 
 
Purity: >99% 
  
 EXPERIMENTAL PART 101 
 
 
Ac-Aib-Trp-Asp-Asn-Aib-Trp-Arg-Lys-Aib-Trp-amide (116) 
 
Purity: 99% 
 
 
Ac-Trp-(αMe)Asp-Asn-(αMe)Asp-Trp-Arg-Api-Thr-Trp-amide (117) 
 
Purity: >99% 
  
102 EXPERIMENTAL PART  
 
 
Ac-Api-Trp-Asp-Asn-(αMe)Asp-Trp-Arg-Api-Thr-Trp-amide (118) 
 
Purity: >99% 
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SYNTHESIS OF SCAFFOLDS N3-DKP5-COOH 41 AND N3-DKP5-COOH 42 
 
Reagents and conditions: a) KHMDS, BnBr, THF/DMF, -70 to -40 °C, 5 h, 66%; b) [Pd(PPh3)4], N-methylaniline, CH2Cl2, 
0 °C, 1 h, 70%. 
SYNTHESIS OF CYCLO[DKP5-ISODGR] 39 AND CYCLO[DKP7-ISODGR] 40 
 
Reagents and conditions: a) Fmoc-Gly-OH, DIC, DMAP (cat.), DMF; b) 2% piperidine and 2% DBU in DMF; c) Fmoc-
Asp(OH)-OtBu, DIC, HOAt, DMF; d) 2% piperidine and 2% DBU in DMF; e) 41-42, DIC, HOAt, DMF; f) PMe3, 
dioxane/water 4:1, 20 min × 3 times; g) Cbz-Arg(Mtr)-OH, DIC, HOAt, DMF; h) 1% TFA in CH2Cl2, r.t., 5 min × 10 times, 
71-81%; i) H2, 10% Pd/C, THF/H2O 1:1, 98%-quant.; j) HATU, HOAt, iPr2NEt, DMF (1.4 mM), 32%; k) 
TFA/thioanisole/EDT/anisole 90:5:3:2, 25-37%. 
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Compound 53 and compound 54 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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Compound 41 and compound 42 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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Compound 45 
1H-NMR (400 MHz, CD3OD) 
 
13C-NMR (101 MHz, CD3OD) 
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Compound 46 
1H-NMR (400 MHz, CD3OD) 
 
13C-NMR (101 MHz, CD3OD) 
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Compound 47 
1H-NMR (400 MHz, CD3OD) 
 
13C-NMR (101 MHz, CD3OD) 
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Compound 49 
1H-NMR (400 MHz, CD3OD) 
 
13C-NMR (101 MHz, CD3OD) 
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Compound 39 
1H-NMR (400 MHz, D2O) 
 
13C-NMR (101 MHz, D2O) 
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Compound 40 
1H-NMR (400 MHz, D2O) 
 
13C-NMR (101 MHz, D2O) 
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SYNTHESIS OF CYCLO[DKP3-ISODGR]-CH2NH2 PEPTIDOMIMETIC 56 
 
Reagents and conditions: a) TFA, CH2Cl2, r.t., 2 h; b) Cbz-Arg(Mtr)-OH, HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 
94% over 2 steps; c) HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 86%; d) piperidine, DMF, 2 h, r.t., 67%; 
e) [Pd(PPh3)4], N-Methylaniline, CH2Cl2, 0 °C, 1 h, 88%; f) 62, HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 95%; 
g) H2, 10% Pd/C, THF/H2O 1:1, overnight, r.t., 95%; h) HATU, HOAt, iPr2NEt, DMF/CH2Cl2 1:1 (1.4 mM), 0 °C to r.t., 
overnight, 79%; i) TFA/TMSBr/thioanisole/EDT/phenol 70:14:10:5:1, 2 h, r.t., 47%. 
SYNTHESIS OF CYCLO[DKP3-ISODGR]-VAL-ALA-PTX CONJUGATE 55 
 
Reagents and conditions: a) NHS, EDC·HCl, DMF, 0 °C to r.t., overnight; b) 56 PBS/CH3CN, pH 7.5, 0 °C to r.t., overnight; 
c) TFA, CH2Cl2, r.t., 1 h, 55% over three steps; d) 4-nitrophenylchloroformate, pyridine, CH2Cl2, -50 °C to -20 °C, 4 h, 84% 
based on recovered starting material; e) 83, iPr2NEt, DMF, 0 °C to r.t., overnight, 52%. 
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Compound 61 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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Compound 62 
1H-NMR (400 MHz, CDCl3) 
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Compound 68 
1H-NMR (400 MHz, CDCl3) 
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Compound 70 
1H-NMR (400 MHz, CD3OD) 
 
13C-NMR (101 MHz, CD3OD) 
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Compound 71 
1H-NMR (400 MHz, CD3OD) 
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Compound 65 
1H-NMR (400 MHz, Acetone-d6) 
 
13C-NMR (101 MHz, Acetone-d6) 
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Compound 67 
1H-NMR (400 MHz, DMSO-d6) 
 
13C-NMR (101 MHz, DMSO-d6) 
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Compound 56 
1H-NMR (400 MHz, D2O) 
 
13C-NMR (101 MHz, D2O) 
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Compound 82 
1H-NMR (400 MHz, DMSO-d6) 
 
13C-NMR (101 MHz, DMSO-d6) 
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Compound 55 
1H-NMR (400 MHz, DMSO-d6) 
 
13C-NMR (101 MHz, DMSO-d6) 
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SYNTHESIS OF CYCLO[GISODGRF] 84 
 
Reagents and Conditions: a) Fmoc-Asp(OH)-OtBu, HATU, HOAt, iPr2NEt, DMF, M.W., 90%; b) 1. 25% piperidine in DMF; 
2. Fmoc-AA-OH, HATU, HOAt, iPr2NEt, DMF, M.W.; c) 1. 25% piperidine in DMF; 2. Cbz-Gly-OH, HATU, HOAt, iPr2NEt, 
DMF, M.W.; d) 1% TFA in CH2Cl2, r.t., 3 min x 24 times, 73%; e) H2, 10% Pd/C, THF/H2O 2:1, overnight, r.t., quant.; 
f) HATU, HOAt, iPr2NEt, DMF/CH2Cl2 1:1 (1.4 mM), overnight, r.t., 39%; g) TFA/thioanisole/EDT/anisole 90:5:3:2, 2 h, r.t., 
49%. 
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Compound 85 
1H-NMR (400 MHz, CD3OD) 
 
13C-NMR (101 MHz, CD3OD) 
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Compound 87 
1H-NMR (600 MHz, CD3OD) 
 
13C-NMR (151 MHz, CD3OD) 
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Compound 84 
1H-NMR (400 MHz, D2O) 
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SYNTHESIS OF CYCLO[DKP3-RAD] 88A AND 88B 
 
Reagents and conditions. a) HATU, HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 84%; b) TFA, CH2Cl2, r.t., 2 h; c) PMe3 in 
toluene, Boc-ON, THF, -20 °C to r.t., 5 h, 78%; d) [Pd(PPh3)4], pyrrolidine, PPh3, CH2Cl2, 0 °C, 1 h, quant.; e) 94, HATU, 
HOAt, iPr2NEt, DMF, 0 °C to r.t., overnight, 65%; f) TFA, CH2Cl2, r.t., 2 h; g) Cbz-L-Asp(OtBu)-OH, HATU, HOAt, iPr2NEt, 
DMF, 0 °C to r.t., overnight, 83%; h) H2, 10% Pd/C, THF/H2O 1:1, overnight, r.t., quant.; i) HATU, HOAt, iPr2NEt, 
DMF/CH2Cl2 1:1 (1.4 mM), 0 °C to r.t., overnight, 82%; j) TFA/thioanisole/EDT/anisole 90:5:3:2, 2 h, rt, 30%. 
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Compound 91 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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Compound 95 
1H-NMR (400 MHz, CD2Cl2) 
 
13C-NMR (101 MHz, CD2Cl2) 
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Compound 97 
1H-NMR (400 MHz, CD2Cl2) 
 
13C-NMR (101 MHz, CD2Cl2) 
  
 APPENDIX OF NMR SPECTRA 133 
 
Compound mixture 99A + 99B 
1H-NMR (400 MHz, CD3OD) 
 
13C-NMR (101 MHz, CD3OD) 
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Compound 88A 
1H-NMR (400 MHz, D2O) 
 
13C-NMR (101 MHz, D2O) 
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Compound 88B 
1H-NMR (400 MHz, D2O) 
 
13C-NMR (101 MHz, D2O) 
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